

1 **A literature survey of all volatiles from healthy human breath and**
2 **bodily fluids: the human volatilome**

3

4 **Natalia Drabińska¹, Cheryl Flynn², Norman Ratcliffe², *, Ilaria Belluomo³, Antonis**
5 **Myridakis³, Oliver Gould², Matteo Fois², Amy Smart², Terry Devine², Ben de Lacy**
6 **Costello²**

7 ¹ Department of Chemistry and Biodynamics of Food, Institute of Animal Reproduction
8 and Food Research of Polish Academy of Sciences, Tuwima 10, 10-747 Olsztyn, Poland

9 ² Centre of Research in Biosciences, University of the West of England, Frenchay Campus,
10 Coldharbour Lane, Bristol, BS16 1QY

11 ³ Department of Surgery and Cancer, Imperial College London, St. Mary's campus, QEQM
12 building, W2 1NY, London UK

13

14 *corresponding author: Norman Ratcliffe; Norman.Ratcliffe@uwe.ac.uk

15

16 **ORCID Numbers:**

17 Natalia Drabińska: 0000-0001-5324-5982

18 Cheryl Flynn:

19 Norman Ratcliffe: 0000-0003-4704-3123

20 Ben de Lacy Costello: 0000-0003-2999-6801

21 Ilaria Belluomo: 0000-0002-8637-0285

22 Antonis Myridakis: 0000-0003-1690-6651

23 Matteo Fois: 0000-0003-3903-9730

24 Terry Devine: 0000-0002-8968-3914

25 Amy Smart: 0000-0002-2191-5643

26 Oliver Gould: 0000-0003-0389-9966

27

28

29 **Abstract**

30 This paper comprises an updated version of the 2014 review which reported 1846
31 volatile organic compounds (VOCs) identified from healthy humans. In total over 900
32 additional VOCs have been reported since the 2014 review and the VOCs from Semen
33 have been added. The numbers of VOCs found in breath and the other bodily fluids are:
34 blood 379, breath 1488, faeces 443, milk 290, saliva 549, semen 196, skin 623 and
35 urine 444. Compounds were assigned CAS registry numbers and named according to a
36 common convention where possible. The compounds have been included in a single table
37 with the source reference(s) for each VOC, an update on our 2014 paper. VOCs have also
38 been grouped into tables according to their chemical class or functionality to permit easy
39 comparison.

40 Careful use of the database is needed especially as a number of the identified VOCs only
41 have level 2 - putative assignment and only a small fraction of the reported VOCs have
42 been validated by standards. Some clear differences are observed, for instance, a lack of
43 esters in urine with a high number in faeces and breath. However, the lack of compounds
44 from matrices such as semen and milk compared to the breath for example could be due
45 to the techniques used or reflect the intensity of effort e.g. there are few publications on
46 VOCs from milk and semen compared to a large number for breath. The large number of
47 volatiles reported from skin is partly due to the methodologies used, e.g. by collecting
48 skin sebum (with dissolved VOCs and semi VOCs) onto glass beads or cotton pads and
49 then heating to a high temperature to desorb VOCs.

50 All compounds have been included as reported (unless there was a clear discrepancy
51 between name and chemical structure), but there may be some mistaken assignments
52 arising from the original publications, particularly for isomers. It is the authors' intention
53 that this work will not only be a useful database of VOCs listed in the literature but will
54 stimulate further study of VOCs from healthy individuals. For example although this work
55 lists VOCs reported in the literature more work is required to confirm the identification
56 of these VOCs adhering to the principles outlined in the metabolomics standards
57 initiative. Establishing a list of volatiles emanating from healthy individuals and increased
58 understanding of VOC metabolic pathways is an important step for differentiating
59 between diseases using VOCs.

60

61 **Keywords**

62 Volatile organic compounds; breath; urine; saliva; blood; milk; skin; faeces; semen.

63

64 **1. Introduction**

65 Until 2014 there had been no central compendium of volatile organic compounds (VOCs)
66 reported from the human body, this was addressed with a review by de Lacy Costello et
67 al [1]. This review thoroughly updates that compendium and encompasses VOCs from
68 breath, saliva, blood, milk, skin secretions (sweat and follicle fluids), urine, faeces and is
69 extended by the addition of VOCs from semen. In total 906 additional compounds are
70 reported and this opens the question how many more VOCs are yet to be identified? This
71 is very different from other *in vivo* biomolecules e.g. amino acids where it is likely there
72 are no more amino acids to be found. Improving on the 2014 review we include the
73 references that identify each VOC within the table. Therefore, it can now be observed if a
74 particular compound is reported multiple times, which gives more credence to its
75 presence. There is also greater range of sub-tables, based upon the chemical class of the
76 identified VOCs

77 Only 14 VOCs were found to be reported from all matrices with a further 28 VOCs being
78 common to 7 of the 8 matrices, this is perhaps fewer than anticipated given the large
79 number of total VOCs identified.

80 The total number of compounds reported has risen since the 2014 review for several
81 reasons. There has been a tendency for larger sample numbers and consequently larger
82 numbers of controls highlighting differences between healthy individuals. There have
83 also been further advances in high throughput devices, automation and pre-
84 concentration methods. This coupled with more sensitive instruments and larger mass
85 spectral databases has further increased the number of “new” VOCs being identified.

86 To prevent this review from becoming too large and unmanageable general comments
87 will be made about the sources of some compounds, without going into significant detail.
88 The purpose of this review remains to bring together all the reported VOCs from the
89 healthy human body and provide the interested reader with references to the original
90 studies.

91

92 **2. Compound naming and identification**

93

94 There is a huge variation in naming conventions used within the source publications.
95 We have kept the compound names as they appear in the original references, so
96 ethanoate and acetate etc. are both used. Frequently, this will be the name as it appears

97 in the NIST spectral library, but this is not always the case and both common and
98 systematic names appear in the tables. Where different nomenclature has been used
99 between references, the alternatives have been listed. Sometimes structural and
100 positional isomers are not specified in a particular paper, but they are still included as a
101 separate entry, with a comment to this effect. Stereoisomers have generally been
102 grouped together under a single entry, particularly as it is unclear how the specified
103 stereoisomers were identified.

104 Chemical nomenclature can be challenging to the non-chemist, hence the utility of using
105 CAS numbers, which are intended to aid identification where different naming
106 conventions are used in the original publications. CAS numbers are not infallible though
107 e.g. the mixed (+/-) camphor has a different CAS number from (-) camphor, when they
108 refer to almost identical compounds.

109 To further aid comparisons subtables have been created based on chemical class. Where
110 a compound contains two different functional groups, it will appear in both of the
111 relevant subtables.

112 Most of the VOCs reported here were identified using gas chromatography mass
113 spectrometry (GC-MS), with library matching to aid tentative identification of the VOCs.
114 In some earlier studies gas chromatography flame ionisation detection (GC-FID) was
115 undertaken with standards, for measuring breath volatiles of ethanol, methanol [2],
116 isoprene [3], and acetone.

117 The identification of compounds by GC-MS is often a difficult task. The VOCs reported
118 within this manuscript have often been assigned an identity by spectral library match
119 only, which can sometimes be misleading, particularly for isomers, especially
120 hydrocarbon isomers. More recent work though often incorporates the use of retention
121 indices to increase confidence in the library identification. However, the use of standards
122 to confirm identification remains the gold standard for validating the identity of VOC
123 metabolites.

124 Improved equipment, for instance two-dimensional gas chromatography combined with
125 high resolution time of flight mass spectrometry (GCxGC-TOF-MS) is able to detect an
126 impressive number of compounds compared to a standard quadrupole GC-MS. It brings
127 in to question the likelihood of co-elution and the possibility of misidentification. Some
128 compounds may not be in the NIST library or other libraries and this can be another
129 reason for misidentification. Other compounds might be from artefacts, such as

130 contamination, degradation/oxidation, which can result from collection, storage, sample
131 treatment, or measurement.

132

133 **3. A comparison of the VOC compounds found in breath, saliva, blood, milk,** 134 **skin secretions, urine, faeces and semen**

135 Table 1 describes 2746 VOCs which have been identified from the healthy human body.
136 This compares to 1840 VOCs identified in a previous 2014 review (de Lacy Costello et al.
137 2014). The numbers of VOCs found in each bodily fluid and breath are: blood 379
138 (additional 225 compounds vs 2014), breath 1488 (additional 616 compounds vs 2014),
139 faeces 443 (additional 61 compounds vs 2014), milk 290 (additional 34 compounds vs
140 2014), saliva 549 (additional 190 compounds vs 2014), semen 196 (not previously
141 included in 2014), skin 623 (additional 91 compounds Vs 2014) and urine 444
142 (additional 165 compounds vs 2014). Therefore, there have been increased numbers of
143 VOCS reported for all the sources of VOCs included in the original 2014 review, with
144 marked increases in breath, blood, saliva and urine. We should re-emphasise that these
145 increases probably just reflect the recent research effort in these areas. Likewise, the
146 small number of compounds in semen is likely because, their source is just one
147 publication. The data in Table 1 has been sub-categorised into 12 classes, which were
148 then further sub-divided to help the observation of inter relationships between
149 compounds.

150 There must be transfer of VOCs throughout the body, from the original source(s) to the
151 final bodily fluid destination. As to whether sufficient chemical transfer occurs for
152 detection, or whether the VOC survives the journey, through the human body is the
153 question. Almost certainly the gut microbiome is the source for many chemicals, and
154 sometimes there is a change of chemistry on route from the gut to e.g. the bladder.
155 Benzoic acid for instance (which naturally occurs in most berries) found in the gut, is
156 derivatised in the liver and excreted as the less volatile hippuric acid
157 (benzoylaminoethanoic acid), the liver can oxidise many compounds e.g. hydrocarbons.
158 Furthermore, esters can be biosynthesised by fatty acid ethyl ester synthases in the liver
159 and pancreas, [4] and there are esterases in the lung etc.

160 Analysis of the 2014 review table showed there were only 12 compounds found in all the
161 matrices. Three of these benzene, toluene and styrene [5] are common pollutants in the
162 environment and are in cigarette smoke [6]. It should be mentioned that 25-40% of

163 absorbed toluene is exhaled and the remaining amount is metabolised and excreted, by
164 oxidation to benzyl alcohol, which is then metabolised to benzaldehyde [7]. With the
165 increase in numbers of compounds, for this review (and the addition of semen), there
166 are still only 14 chemicals in common: ethyl ethanoate, ethanol, 1-butanol, acetone, 2-
167 butanone, 2-pentanone, 2-heptanone, benzaldehyde, ethanal, hexanal, 3-methylbutanal,
168 ethanoic acid, hexanoic acid and limonene. Ethyl ethanoate and ethanal are the two
169 compounds that were not reported in the previous review. Limonene is likely to originate
170 from the environment, it is a commonly used product in household materials, and is in
171 food stuffs, e.g. potatoes. Benzaldehyde can originate from oxidation of toluene in the
172 human body, toluene, is a common atmospheric pollutant. Ethanol may come from
173 drinking alcohol; however, the gut is also capable of ethanol production, and given the
174 significant amount of ethanoic acid in the gut, this can explain the origins of ethyl
175 ethanoate. Hexanoic acid is likely to have its origins in the gut, although it's not clear why
176 this particular short-chain fatty acid (SCFA) is so prevalent. 2-Ketones are certainly found
177 in the gut [8] e.g. 2-butanone was shown to be in all the faecal samples in one study [9].
178 Short chain aldehydes such as hexanal can arise from peroxidation of unsaturated fatty
179 acids [10](potentially in many parts of the body including adipose tissue), and also from
180 oxidation of the respective alcohol.

181

182 **4. Listing of all compounds, with CAS numbers, formulae and origins (Table 1)**

183 Table 1 is an exhaustive table containing every VOC found in the healthy human body to
184 date, across all the different bodily samples (breath, blood, faeces, urine, milk, skin, saliva
185 and semen). Compounds are listed in alphabetical order, and appear with their CAS
186 number assigned by the original authors, where appropriate, and chemical formula. The
187 table rows indicate which particular sample(s) each compound has been found in, and
188 the paper(s) which identified each volatile in each fluid are also noted using reference
189 numbers.

190 While Table 1 lists all the compounds, Tables 2-12 describe VOCs according to their
191 chemical classes, and they are further split into sub-tables where appropriate. Within the
192 tables, the compounds are described in increasing carbon number. A brief discussion is
193 given for the compounds included in these tables.

194

195 **4.1. Nitrogen containing VOCs found in the human body (Table 2a-2c)**

196 There are significantly more nitrogen compounds here than in the 2014 review, these
197 compounds have been split into three sub tables: nitrogen-containing (non-heterocyclics,
198 Table 2a), nitrogen-heterocycles (Table 2b) and nitrogen and sulfur containing
199 compounds Table 2c). These 3 sub tables were then further divided into subgroups as
200 follows:

201 *Nitrogen-containing (non-heterocyclics)*: sundry nitrogen compounds (ammonia, nitric
202 oxide, hydroxylamine, nitric acid), aliphatic monoamine (non-cyclic nitrogen), aliphatic
203 di-, tri, or tetra-amines (non-cyclic nitrogen), anilines, amino acids, amines with
204 carboxylic or sulfonic acids, amines plus other functional groups, hydrazines, azides, azo,
205 nitriles, isonitriles, imines, isocyanates, amides, amide with other functional group,
206 carbamates & carboxamide, ureas, carbamimidate, hydroxylamines, nitroso, oximes and
207 amine oxides.

208 *Nitrogen-heterocycles*: azirine/ aziridine [C₂N ring] azete / azetidine [C₃N ring],
209 pyrrolidines, pyrroline/dihydropyrroles [C₄N ring, pyrrole [C₄N ring], pyrazoles and
210 imadazoles and other diazoles [C₃N₂ ring], pyrazoles and imadazoles and other diazoles
211 [C₃N₂ ring], triazoles [C₂N₃ rings], tetraazoles [C₁N₄ rings], piperidines [C₅N ring],
212 pyridines [C₅N ring], piperazines [C₄N₂ ring], diazines (pyrazines and pyrimidenes) [C₄N₂
213 rings aromatic], indoles, quinolene and hydroquinolines, other multicyclic CN
214 heterocyclics, cyclic amide / lactam, oxazoles, (& oxaline, oxazolidine, isoxazole,
215 isoxazline, isoxazolidine) [C₃NO], other CNO heterocyclics.

216 *Nitrogen and sulfur containing compounds*: At least 8 compound groupings containing
217 both sulfur and nitrogen in the functional group were split into thiocyanate and
218 isothiocyanate, thiazole [C₃NS ring], benzothiazoles, thiazolidines [C₃NS ring], thioamide,
219 thiocarbamate & thiourea and others.

220 Nitrogen-containing (non-heterocyclic) compounds like ammonia, the simplest amine is
221 well known to be linked to breath particularly with high protein intake. Nitric oxide has
222 been found in breath and blood. Human paranasal sinuses and diet can affect production
223 [11]. Hydroxylamine can be synthesised by oxidation of ammonia enzymatically e.g. by
224 ammonia monooxygenase [12]. Interestingly nitric acid has now been reported in breath,
225 it might be considered curious that this strong mineral acid, along with hydrochloric and
226 sulphuric acids can be made by the human body. It is likely that the nitric acid could arise
227 from inhalation of nitrogen dioxide atmospheric pollution, or the oxidation of nitric oxide
228 which can lead to nitric acid synthesis.

229 The largest molecular weight (MW) nitrogen VOC compound detected so far is N, N-
230 dimethyl-1-octadecanamine/ N, N-dimethyl-1-octadecylamine (20 carbons).

231 Many amino acids, particularly in breath have now been reported, e.g. glycine, proline,
232 ornithine, arginine, leucine and valine.

233 Seven hydrazine based compounds have been reported. Hydrazine is a known rocket fuel,
234 however there are rare pointers in the literature for hydrazine synthase enzymes,
235 suggesting conversion from ammonia to hydrazine by bacteria can happen [13]. There
236 are 39 nitrile (cyanide) compounds, the origin of these for instance, alkyl nitrile
237 compounds could arise from diet by ingesting cyanogenic glycosides albeit in small
238 quantities [14]. It has been stated that certain bacteria can make hydrogen cyanide, again
239 confirming that bacteria may be a biosynthetic route.

240 There are a range of primary, secondary and tertiary amines, presumably at some stage
241 they have been synthesised by alkylation of ammonia, it is beyond the scope of this
242 review to attempt to assess the origins of so many diverse compounds.

243 There are rarely 3 and 4 membered ring cyclic nitrogen compounds, in contrast to the 21
244 pyrrole (5-membered) and 18 pyrazines (6-membered di-nitrogen compounds and
245 pyridine), many of which are alkylated. Volatile pyrazines and pyridines can contribute
246 to food flavours [15] and diet is therefore a potential source.

247 There are 37 nitrogen sulfur compounds, mainly found in breath. Many are thiocyanates
248 being the hydrolysis products of glucosinolates, secondary metabolites characteristic for
249 the family *Brassicaceae* e.g. broccoli. For instance, allyl isothiocyanate is responsible for
250 a significant smell of cooked cauliflower. Moreover, methyl thiocyanate, butyl
251 isothiocyanate, 2-methylbutyl isothiocyanate and other sulphides have been found
252 in Brassica vegetables [16,17].

253

254 **4.2. Sulfur containing VOCs found in the human body (Table 3)**

255 There were 113 sulfur compounds reported (Table 3), further divided into 13 sub
256 sections: elemental sulfur, thiols, sulphides, sulfoxides, sulfonic acid esters, sulfate esters,
257 thioesters, thietane[C₃S], thiophene, thiolane [C₄S], thiane [C₅S], dithiane [C₄S₂], oxathole
258 [C₃OS] and oxadithiane [C₃OS₂].

259 For thiocyanates, thiocarbamates, thioureas, sulfonamides and amino thio acids see
260 Nitrogen Table 2c, also for sulfur containing heterocyclics possessing nitrogen atoms.

261 Many of these compounds probably arise from food and metabolic changes occurring in
262 the body, such as de novo synthesis of glutathione and antioxidative processes in the liver.

263

264 **4.3. Alcohol containing VOCs found in the human body (Table 4)**

265 The alcohol compounds were divided into 12 sub-groups: straight chain alcohols,
266 branched alcohols, unsaturated alcohols, cycloalkyl alkanols, phenyl alkanols,
267 cyclohexanols, other cycloalkanols, multi-cyclic alkanols, diols, triols, pentols and
268 phenols.

269 The straight chain primary alcohols were present as a homologous series (present with
270 some gaps). From methanol to 1-eicosanol (20 carbons), there were only 2 gaps, 1-
271 heptadecanol and 1-nonadecanol, comparing all the bodily fluids and breath. It is likely
272 that many of the gaps would be filled by undertaking future studies, for instance 1-
273 heptanol and 1-octanol has not yet been found in breath, but they have been identified in
274 other bodily fluids such as faeces.

275 Certainly, alcohols can be made in the gut e.g. via the reduction of the respective acid [9],
276 or by carbohydrate fermentation or fermentation of nitrogenous compounds [18].
277 Moreover, the liver is capable of alcohol synthesis.

278 Alcohols, from methanol to octanol were derived by oxidation of unsaturated fatty acids,
279 $\text{CH}_3(\text{CH}_2)_n\text{OH}$ from $n=0-7$ except for propanol ($n=2$) omitted in the homologous series
280 [10]. This is a likely source of saturated alcohols in all bodily fluids and breath.

281

282 **4.4. Acid containing VOCs found in the human body (Table 5)**

283 The acids (175 compounds) were divided into 8 sub-groups: aliphatic acids-saturated
284 straight chain, aliphatic acids-branched /cyclic, aliphatic acids-unsaturated, aromatic
285 acids, aliphatic dioc/trioic, acids which also contain an alcohol group, hydroxybenzoic
286 acids, acids containing an aldehyde or ketone group and, acids contacting another
287 unspecified group. Amino acids are given in the nitrogen compound table. Phenols,
288 although very weak acids, have not been included in this group and are tabulated with
289 alcohols.

290 Of the straight chain carboxylic acids, all the acids from methanoic acid to docosanoic acid
291 have now been detected in one or more of the fluids and breath from the human body.

292 The complete homologous series of acids from ethanoic to docosanoic acid have been
293 found in saliva, apart from decanoic and undecanoic acid and from methanoic to

294 docosanoic acid in skin secretions, apart from pentanoic acid. The highest MW acid,
295 docosanoic acid possesses 22 carbons. In all the studies, there is a threshold of around
296 16-22 carbon length for the VOCs reported. As to whether there are real biochemical
297 reasons or it is a limitation of the analytical method, is an open question

298 As a general comment, SCFAs from methanoic to hexanoic acids have been reported as
299 the most abundant and significant end products of fermentation in the gut. The ratio of
300 compounds found may be dependent on individuals, which have different
301 gastrointestinal transit times (GITT). For instance, a long GITT can have a significant
302 effect on bacteria metabolism, more protein is broken down into amino acids which are
303 in turn broken down into small fatty acids. Branched SCFAs arise from breakdown of
304 branched amino acids, as opposed to straight chain SCFAs which can arise from
305 carbohydrate metabolism (as well as other routes) [19]. A study has also shown that
306 blood in faeces will also affect the ratio of short chain fatty acids due to the breakdown of
307 haemoglobin [20]. Also, carbohydrate availability can affect acid type production in the
308 gut and therefore VOCs in the faeces. Carbon limited fermentation produces more formic
309 acid [21]. Acetic acid the main SCFA produced in the gut is readily absorbed through the
310 colon wall and is transferred to the liver, where it is used to e.g. synthesise cholesterol
311 [22]. It does not appear to have been detected in blood, although it must be present. Other
312 SCFAs are rapidly absorbed into the blood stream, it is considered that only 5-10 % are
313 excreted [22]. It must be noted that butanoic acid and to a lesser extent other SCFAs are
314 used as an important energy source by the gut wall and the amount of these acids
315 reaching the blood stream maybe low.

316 Acids can also be biosynthesised in the human body from aldehydes. Aldehyde oxidase
317 (AO) is very concentrated in the liver, where it oxidizes multiple aldehydes [23]. AO
318 activity has been indicated as occurring in the epithelial and alveolar cells of the lungs.
319 There have also been indications of AO activity occurring in the kidneys and
320 gastrointestinal tract (both small and large intestine). It should be pointed out that
321 catalysts are not essential, air oxidation can oxidise aliphatic aldehydes into carboxylic
322 acids [24]. A recent report, showed significant, almost 9-fold difference in nonanoic acid
323 abundance between a lung cancer group and control group [25]. Its origins may be due
324 to oxidative stress due to oxidation of unsaturated aldehydes [10].

325 Of the 32 branched acids found in total, more were found in skin secretions [18]. A
326 commonly found acid in faeces, urine, breath, and skin secretions was 2-ethylhexanoic

327 acid, a common contaminant derived from plasticisers e.g. plastic tubing, containers for
328 bodily fluids etc.

329 More unsaturated fatty acids were found in skin than other bodily fluids and breath. The
330 largest chain size was for docosahexaenoic acid (20 carbons), found in breath. Oxidation
331 of unsaturated fatty acids can produce smaller chain unsaturated fatty acids, a list of
332 predicted mono alkene acids expected to be enhanced by oxidative stress is reported in
333 a recent review. The origin of compounds such as 9-decenoic and 10-undecenoic acids
334 (which have been reported from skin) can be satisfactorily explained by such a route [10].
335 The number of very long chain fatty acids (C-20 plus) found will undoubtedly increase in
336 the future with increased sensitivity of analytical methods. They are present in the human
337 body and have been linked to Refsum's disease and maybe adrenoleukodystrophy.
338 Nervonic acid (C-24) is found in brain tissues, and higher amounts have been correlated
339 to schizophrenia. A note of caution however, as identifying long chain fatty acids
340 accurately can be problematic due their susceptibility to breakdown (particularly in the
341 heat of a GC inlet port). Thus, derivatization or alternate analytical methods might be
342 required for absolute compound identification.

343

344 **4.5. Ether containing VOCs found in the human body (Table 6a and 6b)**

345 The ethers were split into two sub-tables: non-cyclic ethers (Table 6a) and cyclic ethers
346 (6b).

347 The non-cyclic ethers were further divided into five sub-classes as follows: (for ethers
348 that contain additional non-hydrocarbon or hydroxyl functional groups see the specific
349 table for that functional group), mono- (34) di- (11), tri- (2) and tetra-ethers (1), non-
350 cyclic hydroxy ethers (27) and peroxides (2).

351 The cyclic ethers were divided into oxiranes (16), furans (21), benzofurans (3),
352 hydrofurans (13), hydrobenzofurans (1), furanones (see listing under lactones in ester
353 table), furans with other functional groups (22), dioxolanes [C₃O₂] (8), dioxolane with
354 other functional groups (1), pyrans, hydropyrans (4), benzopyrans with other functional
355 groups (for pyranones, see the ester table) (10), dioxanes (1), oxepines and oxepanes (4),
356 cyclooxaoctane/enes (11), crown ethers (1) and multicyclic cyclic ethers (13).

357 Some ethers are used in cosmetics (212), and some food additives (16). Peroxidation of
358 certain polyunsaturated fatty acids, enhanced with oxidative stress, can lead to furan
359 generation [10]. However the confirmation of the ether origins requires more studies.

360

361 **4.6. Aldehyde containing VOCs found in the human body (Table 7)**

362 The total number of volatile aldehydes found in all bodily fluids and breath was 159,
363 (Table 7), an increase of 56 compounds since 2014 [1]. Aldehydes were further divided
364 into: aliphatic (16), branched aliphatics (13), 2-unsaturated (23), other unsaturated
365 linear compounds (17), unsaturated branched (16), aliphatic cyclic (7), benzaldehyde,
366 phenylalkyl aldehydes (23), aliphatic dialdehydes (2), hydroxyl aldehydes (22), ketone
367 aldehydes (2), ether aldehydes (7), carboxylic acid aldehydes (9) and aldehydes with
368 other various functional groups (7).

369 A complete homologous series of aliphatic aldehydes was observed, particularly for
370 faeces, from methanal to octadecanal, with the omission of heptadecanal. Perhaps future
371 work will report heptadecanal, or there is no biochemical route to this compound. A
372 recent review of products of oxidative stress (oxidation of unsaturated fatty acids)
373 summarises the origins of straight chain aldehydes from ethanal to decanal, $\text{CH}_3(\text{CH}_2$
374 $)_n\text{CHO}$ from $n=0-8$, although there are other potential origins [10].

375 Of the branched aliphatic aldehydes, five 2-methyl aldehydes were reported, from 2-
376 methylpropanal to 2-methylpentanal, then a gap until 2-methylundecanal and then 2-
377 methylhexadecanal.

378 A complete homologous series of 2-unsaturated aldehydes was found between 2-
379 propenal and 2-hexadecenal, from one or more of the bodily fluids. This is in contrast to
380 the 2014 review, where the series only reached 2-decenal [1]. As is the case for some of
381 the other chemical classes, more recent papers have filled in some of the previous gaps
382 identified in the homologous series. For example, recently, 2-dodecenal has been
383 reported in breath condensate [26].

384 The reported aldehydes have a cut off in molecular size around 16-18 carbons:
385 octadecanal (18 carbons), 2-methylhexadecanal (17carbons), 2-hexadecenal (16
386 carbons), 4-hydroxy-2,6- hexadecadienal (16 carbons) and 4-hydroxy-2-hexadecenal (16
387 carbons). There are two main reasons for a lack of detection of aldehydes with higher
388 carbon numbers namely a lack of biochemical routes, or the low vapour pressure of these
389 compounds.

390 Lipid oxidation of monounsaturated and polyunsaturated fatty acids are known to
391 produce 2-alkenals, as well as dienals, such as 2,4-heptadienal, which has been found e.g.

392 in milk [27]. It has been reported that 23 different aldehydes in milk can be produced by
393 oxidative degradation of oleic, linoleic and linolenic acids [27].

394 With regard to branched chain saturated aldehydes, a 2020 study of Ratcliffe, *et al* [10]
395 predicted six compounds originating from the oxidation of unsaturated fatty acids: 3-
396 methylbutanal, 3-methylpentanal, 4-methylhexanal, 4-methylpentanal, 5-
397 methylheptanal and 5-methylhexanal, but none were reported in the 2014 review [1].
398 However, 3-methylbutanal and 3-methylpentanal, have now been reported in the current
399 manuscript. It does suggest that other hypothesised compounds will be found in future
400 studies [10] and does highlight the importance of identifying plausible metabolic routes.
401 for VOCs. It should be observed that 5-methylheptanal is not in the NIST library, so its
402 identification is currently unlikely. This does highlight a potential issue with the
403 identification of compounds which heavily relies on putative identification via current
404 mass spectral library entries. Modern mass spectral libraries contain many thousands of
405 compounds and are constantly updated but still contain only a fraction of the possible
406 organic molecules which could be potential metabolites.

407 For mono-unsaturated hydroxyl aldehydes, a homologous series of nine 4 hydroxy-2-
408 enals have been detected, whereas conversely in 2014 none had been reported. The
409 lowest MW compound is 4-hydroxy-2-hexenal, then the 4-hydroxy-2-heptenal is
410 “missing”, with the last compound being 4-hydroxy-2-hexadecenal. This again provides a
411 potential target for future analytical studies as do all the “gaps” in the homologous series
412 within these tables. Alternatively it might highlight the need for better mechanistic
413 metabolic studies to understand why certain VOCs may be missing. 4-hydroxynonenal in
414 particular has been extensively reported in association with oxidative stress and lipid
415 oxidative breakdown, especially from *n*-6 PUFAs, mainly arachidonic and linoleic acids
416 [26,28]. To further add to the series, 4-hydroxy-2-pentenal has been found in smoker’s
417 breath using secondary electrospray ionisation- mass spectrometry (SESI-MS) [29].

418 The origins of a series of volatile hydroxyl, alkene aldehydes have been listed [10].

419 A whole series of nine 4 hydroxy-2,6-dienals has now been shown starting from 4-
420 hydroxy-2,6-octadienal to 4-hydroxy-2,6- hexadecadienal.

421 With regard to aldehyde oxo-acids, a series of 6-oxohexanoic acid, 7-oxo-heptanoic acid,
422 8-oxooctanoic acid, 9-oxononanoic acid, 10-oxocaproic acid / 10-oxodecanoic acid, 11-
423 oxoundecanoic acid and 12-oxododecanoic acid have been reported herein, four of which
424 have been linked to smoking [29].

425 As a general comment, aldehydes are capable of oxidation to acids, by oxygen, even
426 without the mediation of a catalyst and these aldehydes could contribute to an increase
427 of concentration of carboxylic acids, and a concomitant decrease in aldehyde
428 concentration.

429

430 **4.7. Hydrocarbon containing VOCs found in the human body (Table 8a- 8e)**

431 The hydrocarbons were split into five major classes: cyclic hydrocarbons (Table 8a),
432 aromatic compounds (Table 8b), branched chain alkanes (Table 8c), alkenes (Table 8d),
433 and n-alkanes (Table 8e).

434 The alkenes were split into mono alkenes and non- cyclic, branched alkenes, dienes, tri-
435 enes, tetra-enes, penta-enes and hexa-enes and alkynes.

436 The cyclic hydrocarbons were split into cyclopropanes, cyclobutane and cyclobutenes,
437 cyclopentane, cyclopentenenes, cyclopentadienes, cyclohexanes and cyclohexenes,
438 cyclohexadienes, cyclo- heptane/ heptane/ heptadiene/ heptatriene, cyclo-octane/
439 octadienes/ octateraenes, cyclic C10, C11, C12, C14, C16, hydronaphthalenes,
440 hydroazulenes, other bicyclo, and other tricycle compounds.

441 The aromatic compounds were split into several sections: benzyl, phenyl, biphenyl,
442 indane/indene, 1,2,3,4-tetrahydronaphthalenes/ dihydronaphthalenes, 1,2,3,4-
443 tetrahydronaphthalenes, naphthalenes, azulenes, anthracene, and acenaphthalenes.

444 There is an impressive complete homologous series from methane to tetratriacontane
445 (34 carbons) when taking into account all the bodily fluids and breath. Breath contains
446 the majority of these compounds with the exception of docosane, tricosane, pentacosane,
447 hexacosane and nonacosane.

448 Alkanes, from methane to octane (at least) can be considered to arise from oxidation of
449 unsaturated fatty acids [10]. It is interesting that many researchers consider that the
450 source of methane in breath is from the gut as 1 in 3 subjects possess gut methanogens
451 [30]. However, lipid oxidation is clearly another potential source. The authors are
452 unaware of any studies undertaken to assess methane lipid origins, in breath, although
453 methane, ethane, propane, butane and pentane have been well described as autoxidation
454 products e.g. from linoleic acid [31]. Straight chain aliphatic hydrocarbons have been
455 considered as non-invasive markers of free-radical induced lipid peroxidation in liver
456 damage, especially breath ethane and pentane, which appear to be better correlated with
457 alcohol induced hepatic injury than to other aetiologies [25].

458 There were more hydrocarbons reported than any other class of VOCs, 853 in total. The
459 origins have not been extensively considered. As a general consideration, GC-MS spectra
460 of diesel and to a lesser extent petrol, shows the huge numbers of potential compounds
461 present. It is possible that we are observing the human volatilome being significantly
462 affected by the industrial world we live in (the exposome).

463 The human body in combination with its bacterial hosts are likely to be capable of
464 biotransformations of hydrocarbons to a lesser or greater extent thus producing more
465 VOCs to potentially confuse VOC biomarker discovery. There are also naturally occurring
466 hydrocarbons in food which add to the impressive list here.

467 Alkenes, from ethene, and propene to decene in a homologous series and their 2-isomers,
468 2-pentene, 2-hexene, and 2-octene would be expected to occur by oxidation of
469 unsaturated fatty acids [10]. As examples in the literature, ethene has been shown in the
470 volatilome of humans and can be formulated from oxidation of omega-3 acids e.g.
471 linolenic acid, by disproportion of ethyl radicals [32] and 1-pentene has been reported to
472 be generated by decomposition of omega-6 unsaturated fatty acid hydroperoxides e.g.
473 from linoleic and arachidonic acid [33].

474

475 **4.8. Ester-containing VOCs found in the human body (Table 9)**

476 In total 305 esters have been reported. The esters were arranged into sub groups:
477 methanoates, ethanoates, propanoates, butanoates and pentanoates, 2-
478 methylbutanoates, 3-methylbutanoates, hexanoates, heptanoates, hexanoates, nonoates,
479 decanoates, undecanoates, dodecanoates, tridecanoates, tetradecanoates,
480 pentadecanoates, hexadecanoate/heptadecanoate/octadecanoate / docosanoates and
481 tetracosanoates, ene-oates, other-oates, cyclic HC oates and benzoates, salicylates (inc.
482 substituted benzoic acid esters), hydroxy acid esters (except hydroxybenzoic), other
483 mono esters, lactones, delta, pyranones (benzopyranone and dioxanedione), others /
484 uncertain cyclic esters, diesters and triesters (phthalates listed separately) and finally
485 phthalates, carbonates and anhydrides.

486 Acetate (ethanoate) esters were by far the most abundant esters. This is probably
487 reflected by the fact that acetic acid is the most common gut acid. Acetates found in
488 breath were the major contributor to the overall total. There were many esters reported
489 in breath which were not present in other bodily fluids. Therefore, it is not easy to say
490 that breath ester VOCs arose from other bodily fluids.

491 Esters are represented from the whole homologous series from methanoate to
492 octadecanoate, when all the bodily fluids and breath are considered. Then there is a big
493 gap in the series to tetracosanoic acid, methyl ester. The largest ester reported, is behenyl
494 behenate (44 carbons), which is likely to originate from its uses in cosmetics.

495 Bacteria present in faeces have been shown to be capable of ester synthesis [34], and it is
496 very likely that the reaction of alcohols with the respective acid produces many esters in
497 the gut which can then enter the blood stream and circulate throughout the body.
498 Unfortunately for this theory, very few esters have been found in blood, but this is most
499 likely due to the paucity of studies undertaken on VOCs in blood. There are also a variety
500 of esters found in breath which are not found in the gut, this again could be because these
501 esters have not yet been detected in faeces due to analytical imitations or a relative lack
502 of studies. However, it could be that lung based esterases aid ester synthesis and explain
503 in part why more esters have been identified in breath.

504 The phthalates (phthalate esters) are exclusively endogenous and probably arose from
505 plasticiser exposure, and subsequent metabolism. There is a whole range of long chain
506 fatty acid esters and aromatic esters found in skin, which are mainly missing from other
507 bodily fluids and breath. This could be due to the analytical methodologies used.

508 If one considers that all the acids and alcohols reported here can undergo esterification
509 it is possible to rationalise the origins of many of the esters described here. One of many
510 interesting observations, is the lack of esters in urine, apart from lactones. Esters have
511 low solubility in water which could explain the lack of esters in urine.

512

513 **4.9. Ketone containing VOCs found in the human body (Table 10a, 10b)**

514 The ketone table (Table 10a) was divided into a range of sub groups: aliphatic, straight
515 chain ketones, straight chain alkene ketones, aliphatic diones, branched aliphatic ketones,
516 alkyl phenyl ketones, alkyl cyclohexyl ketones, other aliphatic and aromatic ketones,
517 hydroxy ketones, phenol ketones, acid ketones, and ketones with other functional groups.
518 Table 10b presents cycloketones.

519 A homologous series of 2-ketones from acetone (propan-2-one) to 2-nonadecyl ketone
520 (19 carbons) was reported herein. In contrast, the 2014 review described a homologous
521 series which went from acetone to nona-2-one [1].

522 Acetone was found to be one of the most reported volatiles from the human body and is
523 well known to be produced by fatty acid breakdown whereas 2-butanone derives from

524 carbohydrate metabolism. Methyl ketones are produced by many species of bacteria and
525 can also be produced by fungi.

526 The carbonyl group in ketones was found in different positions, in 2, 3, 4, 6 and 8. This is
527 quite selective when compared with the options available. Substitution in the 2 position
528 was by far the most common class of ketone.

529

530 ***4.10. Halogenated containing VOCs found in the human body (Table 11)***

531 All the halogenated compounds were separated into 6 sub-sections: fluorinated
532 compounds (16), chlorinated compounds (35), alkenyl & benzyl chloro-compounds (19),
533 bromo-compounds (8), iodinated compounds (6), mixed halogen and halogen plus other
534 hetero compounds (17), chlorinated biphenyls and chlorinated and brominated phenol
535 compounds (43).

536 Most of the fluorinated compounds were discovered in breath. Sevoflurane was listed:
537 this is a sweet-smelling, non-flammable, highly-fluorinated methyl isopropyl ether is
538 used as an inhalational anaesthetic, and its occurrence in breath of healthy humans is
539 presumably because of the clinical environment where the breath was collected. 1,1,2-
540 trichloro-1,2,2-trifluoroethane / Freon 113 is used as an electrical cleaning agent and is
541 likely to have come from the environment.

542 With regard to chlorinated compounds, some are solvents. Vinyl chloride originates from
543 PVC and some can arise from chlorinating water.

544 Dibromomethane occurs naturally in small amounts in the ocean where it is formed, most
545 likely by algae and kelp. This and similar brominated compounds can enter the food chain
546 and hence reach humans via the diet. It may also still be used for the fumigation of stored
547 grains, fruits, and vegetables [35].

548 Volatile iodine compounds, such as methyl iodide, ethyl iodide, chloriodomethane,
549 diiodomethane (CH_2I_2) and bromiodomethane are widely detected over oceans, where
550 the biogenic activity of phytoplankton and macroalgae are likely to be an important
551 source of these VOCs. Presumably, these types of compounds can also enter the human
552 food chain [36].

553 Many chlorinated fluorinated compounds (CFCs) have been used, especially in the past
554 as refrigerants, propellants in aerosols and solvents. As these are being phased out in
555 consumer products, they and their degradation products must be originating from the

556 environment. Dibromochloromethane and bromodichloromethane also have
557 environmental origins [37].

558 A large number of chlorinated biphenyls and chlorinated and brominated phenol
559 compounds were found such as 4-hydroxy-2,2',3,4',5'-pentachlorobiphenyl which was
560 found in blood and no other bodily fluid.

561

562 **4.11. VOCs found in the human body not categorised previously (Table 12)**

563 Table 12 shows compounds not categorised in Tables 2 to 11, encompassing carbon
564 dioxide, carbon monoxide, hydrogen, hydrogen peroxide dimethylselenide and
565 tetramethyl-germane all reported in breath.

566

567 **5. DISCUSSION**

568 Discussion of the VOCs reported in breath, saliva, blood, milk, skin secretions (sweat and
569 follicle fluids), urine, faeces and semen.

570

571 **5.1. Volatile organic compounds in breath**

572 Exhaled breath contains many different volatile compounds. It has been stated
573 previously that a total of more than 1000 VOCs can be observed, even though they are not
574 present in each person studied [38]. Our literature search revealed 1488 named volatile
575 compounds as being related to exhaled breath. More than half of the screened papers
576 used gas chromatography mass spectrometry (GC-MS) to quantify VOCs in breath,
577 confirming this instrument as the gold standard technique for the analysis of this
578 biological matrix. In most of the papers, GC-MS is typically used in combination with
579 thermal desorption (TD) sorbent tubes to collect and analyse breath.

580 The most used direct sampling techniques are proton transfer reaction mass
581 spectrometry (PTR-MS) and selected ion flow tube mass spectrometry (SIFT-MS) used in
582 25 % of the screened papers. The absence of chromatographic separation in direct
583 sampling techniques however can only tentatively identify the VOC molecular structure,
584 and generally those assignments are confirmed with GC-MS [39] or in the case of breath
585 condensate, with UPLC-MS [40–43].

586 However, in the last five years, a new direct sampling technology, named secondary
587 electrospray ionization (SESI) has been increasingly applied in breath research and is
588 opening new avenues in the field. Since it is based on electrospray ionization of the VOCs,

589 it is able to ionise previously difficult to detect compounds, by covering higher molecular
590 weight, less volatile and more polar species which are not easily analysed with GC
591 approaches [29,41,42,44–47]. While it lacks chromatographic separation and often forms
592 ion adducts (e.g. $M+Na^+$) due to the electrospray ionization, the use of high resolution
593 mass spectrometers with multi-stage (MS^n) capabilities partially counterbalances the
594 aforementioned limitations [48].

595 Many of the volatile compounds related to exhaled breath are not endogenously
596 produced, and some compounds appeared only in a few individuals. The list reported in
597 our table of VOCs is considered as a list for discussion, and we do not consider it
598 comprehensive.

599 Water, oxygen, nitrogen, argon and other rare gases are not listed in this table. For many
600 of these compounds it is unknown if they are produced endogenously. Among the
601 compounds which are listed as appearing in exhaled breath (Table 1), many are related
602 to smoking e.g. 29 dienes, 27 alkenes and 3 alkynes are mentioned as smoking-related
603 [1]. If you smoke it has been stated that your breath contains 2,5-dimethylfuran. A team
604 of Catalan researchers have proved that the presence of this chemical compound
605 indicates that a person has smoked in the last three days and they state that this
606 substance does not appear in the breath of non-smokers, unless they have been in direct
607 contact with tobacco smoke for a long time [49].

608 More recent work of exhaled breath from healthy volunteers, divided into three groups
609 (non-smokers, ex-smokers and smokers) showed that nonanal concentration was
610 dependent on smoking, but was independent of the amount of tobacco consumed, age
611 and gender [50]. A targeted analyses studying healthy smokers showed that acetonitrile
612 is readily detected by SIFT-MS in the breath and urinary headspace of smokers at levels
613 dependent on the cigarette consumption, but is practically absent from the breath and
614 urine headspace of non-smokers, see some further references re breath and smoking
615 [51–57], which also describe various furans. This is not to say that these compounds arise
616 only in smokers, but that they show higher concentrations in them.

617 Quite a number of volatile compounds may be related to food consumption, medication
618 (or effects of) or professional exposure [58–61]. Some of the compounds in breath are
619 produced by bacteria in the mouth [62] and by bacteria in the gut, such as hydrogen [63]
620 and methane [64] and undoubtedly many more. It could very well be the case that

621 volatiles from oral anaerobes in the mouth confound breath biomarker discovery and this
622 has been studied [9].

623 The most prominent volatile compounds in breath are isoprene [65–68] and acetone [68–
624 70]. Isoprene, identified and quantified in more than half of the papers analysed for this
625 review, is a by-product of the mevalonate pathway, but also produced (or at least stored)
626 in the periphery of the human body [71,72]. Acetone can be formed from acetoacetate by
627 acetoacetate-decarboxylase. Isoprene is ‘the’ paradigmatic example for a compound
628 whose concentration in exhaled breath changes enormously during exertion of an effort
629 [71,73–75]. If, for example, a volunteer starts to pedal on a stationary bicycle with 75W,
630 the isoprene concentration increases by a factor 3–4 in end tidal breath. Originally, it was
631 thought that this increase is just due to an increase of cardiac output [76]. But the
632 pioneering work of King *et al* [71–73,75] demonstrated that the increase in cardiac
633 output alone would not be able to lead to the observed pronounced increase in isoprene.
634 For the isoprene concentration in exhaled breath to increase, it is not even necessary to
635 exert an effort. A few leg contractions or arm contractions suffice to increase the isoprene
636 concentration in exhaled breath [71–75]. Apart from isoprene, also other compounds
637 increase during exertion. Among these compounds are methyl acetate, dimethylsulfide
638 and 2-pentanone [74]. This is in contrast to the prediction of Farhi’s equation [77], which
639 would predict a decrease in concentration during effort. An example of a compound
640 which follows Farhi’s equation is butane [74].

641 The big advantage of exhaled breath, in comparison to blood, is the fact that it can be
642 sampled as often as is desirable. Breath can even be sampled and analysed in real time,
643 down to breath-to-breath resolution. Breath analysis during sleep illustrates this most
644 convincingly [78]. In measurements during sleep, isoprene and acetone display very
645 different concentration characteristics. Both show (often) increasing concentrations
646 during the night. The isoprene concentration displays a very pronounced peak structure,
647 which is due to movements of the body or changes in sleep stage. Acetone does not show
648 such a peak structure but just a smooth increase.

649 In contrast to GC-MS and SESI-MS, a more limited number of volatile compounds in
650 exhaled breath have been investigated with PTR-MS [79-83] and SIFT-MS [84-86]. These
651 techniques are inherently quantitative, without the need of external calibration which
652 greatly expands their real-time measurement capabilities. More recently they have been
653 coupled with thermal desorption units, to enable sample collection and later analysis for

654 large-scale studies [87]. In the future, real-time measurements should be performed for
655 all VOCs, giving rise to the possibility of modelling their production and metabolism
656 within the human body. Also their connection to food consumption, smoking habits or
657 medication would be very interesting. A particular interest is in therapeutic monitoring
658 of drugs and their metabolites. As an example, consider valproate which is administered
659 to avoid seizures in epileptic patients or in persons suffering from propionic acidemia
660 [58] and is metabolized to 3-heptanone which can be observed in exhaled breath [58].
661 Since the concentration of 3-heptanone in normal healthy volunteers is <1 ppb, virtually
662 all the 3-heptanone in exhaled breath can be attributed to metabolized valproate. Such
663 metabolic changes inducing the release of specific VOCs may allow therapeutic
664 monitoring of different drugs in the future.

665 Many of VOCs in breath may have exogenous sources [88–92], be produced through
666 medication [58,93] or be released by bacteria in the airways [94,95], the oral cavity
667 [93,96–101] or in the gut [30,63]. The concentrations of volatile compounds in exhaled
668 breath may depend on the sampling method [102–105] and on the specific Henry's
669 constant between blood and breath [106–108] which depends on haematocrit (blood cell
670 volume) and other parameters.

671

672 **5.2. Volatile organic compounds found in saliva**

673 The profile of VOCs in saliva can give information about the oral health and oral
674 microbiome. Saliva has many advantages over breath in terms of sampling, shipping and
675 storage of samples. Moreover, saliva is considered as an equivalent of blood which does
676 not require invasive collection, because there is an equilibrium of the dissolved
677 metabolites between the blood capillaries and the membranes of the salivary glands
678 [109]. On the other hand, the problem with saliva is the possibility of contamination
679 during sampling and the problem with optimal sampling time, with some people being
680 less capable of saliva production.

681 The most comprehensive profile of VOCs in saliva was provided by al Kateb *et al.* in 2013
682 [110] and this has not changed since the previously published review [1]. After 2014, the
683 biggest contribution to the saliva volatilome was made by Monedeiro *et al.* [111] who
684 reported the presence of 162 VOCs in healthy subjects using headspace solid phase
685 microextraction (HS-SPME)-GC-MS methodology. The total number of VOCs reported in
686 saliva in this review is 549, which represents an increase of 96 compounds since 2014.

687 These additional VOCs were sourced from papers studying differences between diseased
688 subjects and controls (which were hopefully healthy [111–118]). All of these compounds
689 had previously been identified in other body fluids [1]. Most of the studies used SPME
690 fibres with different modifications as a sampling technique. As SPME is based on
691 absorption, the number of compounds detected is limited by the sorption properties of
692 the coating material. Improvements to the SPME method, using materials with larger
693 surface of absorption like coupons, blades and thin-films can significantly improve the
694 absorption capabilities, resulting in the detection of less abundant compounds,
695 impossible to detect with conventional SPME fibres.

696 The application of other, non-absorptive techniques, such as solvent extraction [119] may
697 allow for the extraction of a wider range of metabolites, and the detection of a higher
698 number of salivary metabolites in the future.

699 According to the recent database (Table1), the dominant chemical class in saliva is
700 alcohols, comprising approx. 16 % of all VOCs, followed by ketones (14 %) and cyclic
701 hydrocarbons (12 %). Taking into account all the types of hydrocarbons, they make up
702 34 % of all VOCs in saliva. The difference between the percentage composition of saliva
703 reported previously [1] is mainly due to the work of Monedeiro *et al.* [111] who reported
704 that alcohols and ketones are the dominant groups in saliva.

705 Aside from the studies aimed at profiling bodily fluids, some articles reported attempts
706 to apply saliva characterization for diagnostic purposes. The VOCs in subjects with oral
707 diseases of a possible bacterial origin, such as submandibular abscesses and halitosis
708 were compared to the saliva profiles of healthy individuals [111]. The authors reported
709 the presence of 23 and 41 VOCs specific for halitosis and submandibular abscess,
710 respectively. Halitosis resulted in a larger number of sulfur compounds, while
711 submandibular abscesses, which is an inflammatory disease, was characterized by a
712 greater abundance of inflammation-associated alcohols, aldehydes, and hydrocarbons.
713 The comparison of saliva VOCs between healthy children and children with celiac disease
714 showed that the abundance of some VOCs, such as ethyl acetate, nonanal, and 2-hexanone
715 is different in children with celiac disease treated with a gluten-free diet, compared to
716 healthy children [113].

717 Moreover, saliva analysis has raised interest in the forensic science area. The SPME-GC-
718 MS analysis of different bodily fluids showed that despite the similarities within a fluid,
719 there is a large number of quantitative differences in each specimen, characteristic for

720 the individual person, with a low occurrence of matching errors [112]. It was found that
721 saliva and hand odour were the most efficient for differentiation of subjects, providing
722 sufficient stability and variability for differentiation.

723 SPME in thin-film geometry (TF-SPME) was used for the retrospective analysis of the
724 intake of 49 prohibited substances and steroids by measuring their metabolites in saliva
725 [114]. As the authors underlined, saliva is a good specimen for doping control as it
726 contains mostly non-conjugated, biologically active forms of drugs. GC-MS analysis
727 allowed for the detection of 26 VOCs in saliva, without derivatisation.

728

729 **5.3. Volatile organic compounds in blood**

730 Blood directly reflects the internal environment of the body, including nutritional,
731 metabolic, and immune status [120]. Thus, the analysis of plasma-derived VOCs in blood
732 has been an active area of research. However, obtaining blood samples is not trivial
733 requiring trained phlebotomists. It is not well tolerated by patients in comparison to
734 producing a breath or urine sample, and blood samples usually require pre-treatment
735 which is costly and time consuming.

736 379 VOCs have been identified from blood, which is relatively few compared to the
737 number found in breath [106]. However, this is a large increase compared to the previous
738 review in 2014 where only 154 VOCs were reported. There certainly is not a lack of
739 studies reporting the analysis of volatile compounds in blood. However, these studies
740 tend to be focused on the monitoring of exposure to environmental pollutants [121], the
741 quantification of blood alcohol [122] and other inhalants derived from solvents [123],
742 and storage and aging of blood for forensic applications [124–127].

743 However, there have been relatively few studies which compared the volatile profiles
744 above blood in healthy volunteers versus a diseased group. Zlatkis *et al* [128] studied the
745 sera of seemingly healthy individuals versus virus infected patients using capillary GC.
746 Although example chromatograms were presented showing a large number of peaks for
747 both groups, the identification of compounds was limited. It was found that virally
748 infected patients had a wider range of VOCs associated with their samples [129]. Recently
749 there have been two studies which measured the blood volatiles of patients with liver
750 [130] and lung cancer [131] versus healthy individuals. Horvath *et al* [132] described the
751 results of a study where trained dogs could discriminate between blood samples from
752 ovarian cancer patients and blood samples taken from patients with other gynaecological

753 cancers or from healthy control subjects. A paper by Wang *et al* [133] used SPME-GC-MS
754 to differentiate blood samples of 20 healthy volunteers from colorectal cancer patients.
755 Only the few compounds which were significantly higher in the healthy group were
756 reported.

757 A few papers exist looking solely at the VOC profiles of healthy volunteer blood without
758 a disease group for comparison [106,118,134]. Mochalski *et al* [106] and Ross *et al* [134]
759 compared the volatiles appearing in blood to those found in breath, and Kusano *et al* used
760 hand odour, oral fluid, breath, blood, and urine to differentiate between individuals.

761 Much of the work relating to environmental exposure to pollutants centres around the
762 National Health and Nutrition Examination Surveys (NHANES) which have been
763 undertaken in the US [135]. These studies have aimed to quantify a range of common
764 environmental pollutants in the blood of over 1000 volunteers. There have been a
765 number of publications relating to the methods used and the results of these studies
766 [136–139]. The studies tended to use purge and trap analysis combined with GC-MS
767 [137] but more recently they have adopted SPME based methods coupled to GC-MS [136].
768 The data from NHANES is used to set expected limits for a range of VOCs in blood (usually
769 in the ppb/ppt range) for non-occupationally exposed individuals [135]. Most recently
770 this data has been used comparatively in measuring the blood VOC levels of people living
771 on the gulf coastline of the US who have been exposed to VOCs derived from the
772 Deepwater Horizon oil spill [140]. There are commercial tests available which give a
773 measure of the volatile solvent profile in blood versus the NHANES data [135].

774 The high level of alcohol consumption in the US and Europe means that blood alcohol
775 analysis is one of the most common clinical analyses performed. Headspace GC is
776 commonly used to determine blood alcohol levels. This method is convenient as it can be
777 automated and biological products that can cause interference are not directly injected
778 into the GC. A dedicated range of columns have been developed specifically for blood
779 alcohol analysis and the analysis can be completed in 2 min [141]. Blood gas analysis
780 usually involves the measurement of methanol, ethanol, isopropyl alcohol, 1-propanol,
781 acetaldehyde, and acetone. The analysis usually includes the use of an internal standard
782 for example t-butyl alcohol (internal standard for the European blood alcohol analysis).
783 However, many forensic laboratories are also interested in the measurement and
784 quantification of an extended number of VOCs which may be derived from inhaling and
785 ingesting dangerous and controlled substances [123]. Volatiles such as diethyl ether,

786 butane, ethyl acetate, hexane, toluene, xylene, and some halogenated hydrocarbons are
787 common VOCs with the potential for abuse via sniffing [142]. It may be particularly
788 important to measure these compounds in blood samples taken at autopsy, if the death
789 is suspicious [143]. These additional VOCs also have the potential to interfere with the
790 blood alcohol analysis, so their separation and measurement is important [141].

791 The measurement of ammonia in blood is also an established clinical test [144]. Many of
792 the procedures for ammonia determination involve two general steps: the release of
793 ammonia gas or capture of ammonium ions from the sample and the quantitation of the
794 liberated gas or captured ions [145]. Detection is typically via colourimetric/fluorimetric
795 methods [146], gas sensitive electrode [147] or enzymatic methods [148,149]. Elevated
796 levels of ammonia in blood is considered a strong indicator of an abnormality in nitrogen
797 homeostasis, the most common reason is related to liver dysfunction. Hyperammonemia
798 arises from excessive production by colonic bacteria and the small intestine. At high
799 levels ammonia is a potent toxin of the central nervous system and has been linked to
800 hepatic encephalopathy (HE). However, breath ammonia determination is not currently
801 accepted as a reliable marker of HE, although a large amount of data supports the role of
802 hyperammonaemia in the direct and indirect alterations of brain function underlying HE.
803 A relatively recent paper [150] describes the measurement of capillary blood (an
804 equivalent to arterial blood) following an oral glutamine challenge. This method was
805 more successful at identifying minimal HE than the use of capillary blood measurements
806 alone.

807 Since our previous 2014 review [1], there have been a handful of forensic science papers
808 on how storage and aging of blood impacts its VOC profile [124–127], as this has
809 implications for sniffer dog training. Dubois *et al.* used variable energy electron impact
810 ionization TD-GC-GC-TOF-MS and found it was able to monitor subtle changes in blood
811 VOCs within the first week of aging. Whilst these publications have yielded a great deal
812 of data, and found new compounds previously unidentified in blood, only the data from
813 fresh blood which hasn't aged or decomposed could be included in this review.

814

815 **5.4. Volatile organic compounds in milk**

816 This review has identified 290 compounds in human milk. This represents only a small
817 increase vs the 2014 review where 256 compounds had been identified. There are many
818 papers on the nutritional composition of human milk (as an example see the review by

819 Jenness [151] and also on the presence of environmental chemicals (as an example see
820 the review by LaKind [152]), but there is relatively little specifically relating to the
821 volatile components. Most GC-MS analytical studies appear to be directed at identifying
822 the presence of a specific pollutant, medicinal substance, or group of environmental
823 compounds, to support research on chemical exposure to the nursing infant or using milk
824 as a geographical pollutant indicator. A literature search revealed numerous papers on
825 organochlorine pesticides, brominated diphenyl ethers, dioxins, polychlorinated
826 biphenyls, parabens, triclosan, polycyclic musk fragrances, flavonoids, and many others.
827 However, not all these compounds can be considered as volatiles at body temperatures.
828 Others studies looked for compounds transferring to breast milk from mothers taking
829 specific dietary supplements, such as the search for odorous components from fish oil
830 [153] or 1,8-cineole metabolites after taking 1,8-cineole capsules [154]. Studies looking
831 for specific compounds after exposure to environmental contamination, medication, or
832 dietary supplementation have not been included in the tables. The most extensive list of
833 likely volatiles was given by Pellazari *et al* [155] who identified 156 'purgeable'
834 compounds from maternal milk, in a study to evaluate the utility of using milk in pollutant
835 studies. A wide range of classes of compounds was identified by GC-MS from passing
836 helium gas through warm milk and trapping vapours on a Tenax cartridge. Similar classes
837 of compounds were reported by Shimoda *et al* [156] using a diethyl ether distillation-
838 extraction. Other studies have looked for specific organic compounds in the headspace
839 above milk using SPME with GC-MS (four VOCs [157], monocyclic aromatic amines [158],
840 phthalate esters [159], benzene and alkylbenzenes [5,160]). A broader study, also using
841 the SPME method, attempted to quantify 36 different VOCs [161] and identified 10
842 compounds whose median concentration across 12 samples was above the 'lowest
843 recordable level'. Buettner *et al* has analysed the volatiles from milk and in one study
844 identified 45 odour-active constituents, using olfactory GC in combination with GC-MS
845 [162].

846 A study from 2009 [163] made a comparison between mother milk and formulas,
847 underling in these, the presence of different volatiles related to the heat treatment of milk,
848 such as methional, 2-furfural, and sulphides. On the other hand, the GC-MS analyses
849 revealed a higher variation in the volatiles from milk compositions for the mother's milk,
850 exposing the infant to more diverse flavour, including a higher variety of terpenes
851 probably originating from the maternal diet. Another study regarding the quality of

852 breast milk has been published in 2010 [164], using high-resolution gas
853 chromatography–olfactometry (HRGC-O) to investigate the reasons behind the formation
854 of the typical fish-like and metallic off odour during the storage of human milk, not to be
855 found in the cow milk under the same conditions. In this case, the studies underlined the
856 presence of oxidation products from long-chain (poly)unsaturated fatty acids such as (Z)-
857 1,5-octadien-3-one, trans-4,5-epoxy-(E)-2-decenal, 1-octen-3-one and (Z)-3-hexenal.
858 Fatty acid degradation products have also been found to be responsible for changes in
859 milk flavour [165,166] using two-dimensional high-resolution gas chromatography-mass
860 spectrometry (TD-HRGC-MS) and GC-MS analyses. These studies investigated the
861 modifications occurring in the metabolite profile when breast milk is subjected to
862 different treatments. Analogously, Garrido *et al* [167], showed how high-pressure
863 thermal (HPT) treatments can modify the volatile profile, increasing the abundance of
864 different chemical groups (aldehydes, ketones, furan, pyrans, alcohols), and decreasing,
865 on the other hand, the content of aliphatic hydrocarbons present in the non-treated
866 human milk samples. Also in these cases, the changes in the VOC profile can be attributed
867 to the negative odours sometimes attributed to human milk. As much as the storage and
868 ambient conditions, also the mother’s diet, both in the phases of pregnancy and nursing,
869 was found to have a direct connection with the breast milk volatiles profile [168]. On the
870 same issue, Ramsons (a plant with garlic like odour) consumption was found to affect
871 milk aroma, as pointed out by Scheffler *et al* [169], who identified volatile ramson-
872 derived metabolites in human milk, applying gas chromatography-mass
873 spectrometry/olfactometry (GC-MS/O). An analogous study was also conducted
874 regarding garlic consumption [170].

875 Hartmann *et al* [171] employed GC-MS to investigate the presence of 5- α -androst-16-en-
876 3-one in human breast milk, underling the issues and the procedures needed when it is
877 necessary to underline a specific compound in the milk matrix. Another research group
878 also focused on a specific compound [154,172], 1,8-cineole, again investigated by GC-MS.
879 These studies also point out how the analysis of the volatiles in human milk are promising
880 for health monitoring since metabolite profiles in milk might be substantially different
881 from those in the commonly analysed body fluids of blood and urine, due to the high lipid
882 content.

883

884 **5.5. Volatile organic compounds from skin secretions**

885 The number of different compounds identified from human skin secretions is very large.
886 Our literature search revealed 623 named VOCs analysed from skin secretions (an
887 increase compared to the 532 found in the previous version in 2014 [1]. Odour can be
888 particular to an individual and distinguishable both by people and by canines [173]. Also
889 skin is not homogeneous and the distribution of the different types of glands and
890 microbiota across the body can be expected to lead to different VOC profiles. Even the
891 odours of a single individual varies; with diet, emotional state, menstrual cycle, age, and
892 many others factors [174,175]. Studies of the secretions from the skin are particularly
893 susceptible to interference from personal care products. Although experimental
894 procedures attempt to minimize the presence of exogeneous compounds by asking
895 subjects to refrain from use of such products apart from a designated soap for a time
896 period before testing, some identified compounds are highly likely to come from
897 exogeneous sources [176,177]. Bernier *et al* [178] reported hundreds of compounds
898 spanning a wide range of classes, in a study attempting to identify candidate mosquito
899 attracting compounds. Samples were collected from the hands using glass beads and
900 analysed by GC-MS. Many of the compounds were relatively high MW species and it could
901 be argued that some would be expected to have limited volatility at body temperature.
902 The papers of Zeng *et al* [179,180] list a number of C-6 to C-11 acids and in particular E-
903 3-methylhex-2-enoic acid, as responsible for characteristic axillary (armpit) odours along
904 with a large n-dodecanoic acid peak, lactones and alcohols found in solvent extraction of
905 worn absorbant pads. Other studies also look specifically for odiferous axillary
906 compounds. Kuhn and Natsch found a genetic contribution to odorant carboxylic acids
907 [177] and Hasegawa *et al* [181] found a difference between 'spicy' and 'sour' axillary
908 odour and identified sulfanyl alcohols. Another study analysed compounds on the
909 forearm [176] by using ethanol and hexane extraction. However, relatively few
910 compounds are common to these or other papers.

911 The difficulty of identifying a set of VOCs characteristic of human sweat is exemplified in
912 the paper of Penn *et al* [182] looking at 'fingerprints' in human odour. They used
913 polydimethylsiloxane coated stirrer bars to collect axillary samples from 194 individuals
914 over 10 weeks; 4941 separate GC-MS peaks were found of which only 373 were
915 consistent over time within an individual (118 were chemically identified). They report
916 very few of the peaks as common to all samples. Only 38 compounds were found to be
917 present in at least half the samples. There are a few studies that attempt to collect the

918 compounds that are volatile at body temperatures rather than by volatilization of
919 collected skin secretions. Gallagher *et al* [176] lists a set of volatile compounds from the
920 forearm, when collected using SPME fibres held above the arm compared with solvent
921 extraction. Haze *et al* [183] identified straight chain hydrocarbons, alcohols, acids and
922 aldehydes from headspace analysis of cloth worn on the back and found a link with 2-
923 nonenal and ageing. Zhang *et al* [184] identified 35 compounds predominantly alcohols,
924 alkanes and aldehydes using SPME fibres to collect volatiles from the hand and forearm
925 and found differences between the hot humid spring and cold dry winter.

926 SPME-GC-MS has also been used to study axillary odour [185] para-axillary and areola
927 volatile compounds for possible mother–infant recognition chemicals [186,187] report
928 aldehydes (e.g. 3-methyl-2-butenal, benzaldehyde, octanal, nonanal, decanal) and
929 ketones (e.g. 6-methyl-5-en-2-one). In these papers, there are very few named
930 compounds that are common between studies. As an example, nonanal occurs in twelve
931 of the publications under examination, decanal (11 times), octanal and 6-methyl-5-
932 epten-2-one (10 times each) and finally octanoic acid and acetic acid (7 times each). This
933 was also observed by Prada *et al* [188], using SPME-GC-MS. Dormont *et al* [189] pointed
934 out the great importance of sampling when the sample collection occurs outdoors. The
935 authors compared four methods for sampling skin odours: solvent extraction, headspace
936 SPME, and two new techniques not previously used for the study of mammal volatiles,
937 contact SPME and dynamic headspace with a chromatoprobe design (miniaturized
938 trapping tubes that are directly inserted into the GC injector for thermal desorption). The
939 same study underlined the prevalence of aldehydes in the volatile profile, in particular
940 nonanal and decanal. The same research group in 2013 [190] pointed out the complexity,
941 in terms of the number of compounds, featuring in the chemical profile of skin volatiles.
942 This work underlined, that the compounds found in human skin vary widely depending
943 on the part of the body where the samples are collected and the sampling methods
944 employed. For example, the axillae region is characterised by apocrine, eccrine and
945 sebaceous glands, which in addition to the microbiota bring about a specific volatile
946 profile. This profile features mostly alkane and C₆-C₁₁ carboxylic acids. Different VOCs
947 were found in the hand, primarily aldehydes and ketones (nonanal, decanal, undecanal,
948 6-methyl-5-hepten-2-on and geranylacetone). This was also confirmed by Mochalski in
949 2018 [191], where the use of ion mobility spectrometer coupled with gas
950 chromatography (GC-IMS) was found to present considerable potential for the detection

951 of VOCs. At the same time it presented some drawbacks, like the fact that some interesting
952 classes of VOCs such as alkanes cannot be measured using that IMS instrument. The
953 ionisation source determines the range of compounds that may be detected, e.g. a beta
954 emitter such as nickel 63 does not detect alkanes, while a photo ionisation source in
955 conjunction with an IMS detects alkanes sensitively.

956 An IMS coupled with a short multi-capillary column (MCC) was instead employed by
957 Ruzsanyi et al [187] for near real-time monitoring of human skin emissions, who pointed
958 out that octanal, nonanal and decanal may originate from the skin. Curran *et al* [192]
959 presented 24 different compounds employing SPME-GC-MS to measure human scent, and
960 utilize it to identify and distinguish between individuals.

961 Another interesting avenue for VOCs from the skin is finding a correlation between them
962 and the compounds found in blood. From the study of the literature, families of VOCs have
963 been found to be present in both blood and skin. Namely: aromatic compounds (16
964 compounds in common), aldehydes (15), acyclic alkanes, alcohols (14), ketones (13),
965 nitrogen-containing compounds (8), esters (7), acyclic alkenes, acids (6) non-aromatic
966 cyclic hydrocarbon, sulfur-containing compounds and ethers (3 each) and halogenated
967 compounds.

968

969 **5.6. Volatile organic compounds from urine**

970 The recent review revealed 444 VOCs associated with urine [196–198] compared to 279
971 reported in the previous version. The largest number of compounds identified in urine
972 belong to the ketone group. Ketones in urine are likely to at least partially arise from
973 bacterial action in the gut, maybe by decarboxylation from the corresponding oxo-acids,
974 since ketones were found at much lower concentrations in the urine of ‘germ free’ rats
975 [193]. Levels of the key ketone bodies, propanone (acetone) and acetoacetate have been
976 found to vary between 1.16–14 mol L⁻¹ and 1.3–15 mmol L⁻¹ respectively in urine [199].
977 The ketone bodies (acetoacetate, hydroxybutyrate and propanone) are produced in the
978 liver during periods of rapid fat oxidation, when the rate of fat breakdown exceeds the
979 capacity of the Krebs cycle to process the resulting acetyl CoA [200,201].

980 Several significant studies of VOCs in urine have been undertaken e.g. [193], [194]. Nine
981 compounds were present in all studies: propanone, 2-butanone, 2-pentanone, 2-
982 heptanone, 3-hexanone, 4-heptanone, 2, 5-dimethylfuran, 2-ethyl-5-methylfuran and
983 toluene, so can be present with a very high degree of certainty. A study [195] of 4-

984 heptanone in urine strongly suggest its presence originates at least in part from *in vivo*
985 oxidation of the plasticizer component, 2-ethylhexanoic acid.

986 Propanone, 2-butanone, 2-pentanone and 2-heptanone were also found ubiquitously in
987 the headspace of faecal samples from healthy individuals [9]. Propanone can be produced
988 by the non-enzymatic decarboxylation of acetoacetate and may sometimes be smelt on
989 the urine and breath in acute diabetes.

990 In summary, the VOCs in urine cover a range of chemical classes: e.g. acids, alcohols,
991 ketones, aldehydes, amines, N-heterocycles, O-heterocycles, sulfur compounds and
992 hydrocarbons (Table 1). When comparing the VOCs from urine and faeces a notable
993 difference is the number of esters. The relative levels have not altered since 2014 with
994 additional esters identified in faeces (10) and urine (7). However, there were no new
995 straight chain hydrocarbons identified in urine thus a notable difference remains, making
996 alkanes the smallest group for urine volatiles. Although previously identified, Cozzolino
997 *et al* [202] again detected hexane in their study of healthy children using SPME-GC-MS.
998 Cozzolino *et al* [196] pre-treated samples under both acidic and alkaline conditions,
999 followed by analysis with SPME GC-MS, identifying a total of 162 urine compounds, 42 of
1000 which were previously undetected. The combination of salting, pH change and solvent
1001 extraction by Cozzolino *et al* has shown many hundreds of compounds can be readily
1002 detected by a typical benchtop quadruple GC-MS..

1003 A large number of terpenes are described and are considered to be derived from food
1004 [193]. Little data exists on quantitative measurements of VOCs in urine. Concentrations
1005 of phenol (typically 10 mg day⁻¹ excreted in urine) and p-cresol (typically 52 mg day⁻¹
1006 excreted in urine) have been reported to increase in urine with increasing protein intake.
1007 Their formation is considered to be due to gut microbiota acting on tyrosine; anaerobic
1008 bacteria in the left colon producing phenol and aerobic bacteria in the ileum/cecum
1009 producing p-cresol. The relationship is complicated by fibre intake. High fibre intake with
1010 high protein resulted in a smaller increase in concentration due to decreased transit time
1011 [203]. This study was motivated by phenols being implicated in bladder and colon cancer,
1012 which no longer is considered to be the case.

1013 Normal alcohol emission ranges reported are 0-46 mg/24 h for ethanol, 0-300 µg/24 h
1014 for n-propanol and 0-18 µg/24 h for n-butanol; these levels approximately mirror blood
1015 serum levels [183]. Trimethylamine and 4-heptanone, were quantified as 0.5 -20 µg ml⁻¹
1016 and 40-800 ng ml⁻¹ respectively in urine [204].

1017 It has been suggested that methylamine and other short chain aliphatic amines may play
1018 a significant role in central nervous system disturbances observed during hepatic and
1019 renal disease [205]. To this end a quantitative method was developed for methylamine
1020 determination in the gas phase from urine. The average output was 11 mg day⁻¹ with a
1021 range of 1.7– 62 mg day⁻¹, with diet having a small effect. The source was considered to
1022 be mainly endogenous. Gut bacteria are likely to be implicated in the production of
1023 methylamine (probably from creatinine) as rats with no gut bacteria produced less than
1024 half the output [205]. The average daily output for dimethylamine was about 17 mg with
1025 values for the majority of the population lying within the 0.68–35.72 mg range [206].
1026 Healthy young adults excrete about 1 mg of trimethylamine and 40 mg of trimethylamine
1027 N-oxide daily, although these levels are markedly influenced by diet, particularly when it
1028 contains marine fish. When marine fish is a dietary component, several hundred mg of
1029 trimethylamine N-oxide may be excreted [207].

1030 New, alternative, and combined approaches have been employed to enhance how urine
1031 volatiles are detected. The volatiles in urine have recently been evaluated by combined
1032 odour and GC-MS chemical analysis. For the first time a comprehensive description of the
1033 smell of the individual components has been described [208]. This work also involved
1034 enzymatic (glucuronidase) pre-treatment followed by solvent extraction. Recently, Zou
1035 *et al* [197] developed a novel ultrasonic nebulization extraction proton transfer reaction
1036 mass spectrometry (UNE-PTR-MS) technique to rapidly detect selected compounds
1037 within a urine sample. Encouragingly, only 0.66 mL of urine is required for a full scan,
1038 which delivers a response in 34 s. The authors state this method overcomes lengthy pre-
1039 concentration processes, extended sampling procedures, and prevents alteration to the
1040 urine whilst in storage. Although no new urine compounds were detected, the technique
1041 showed promising results for common urine VOCs: methanol, acetaldehyde, and acetone,
1042 yielding relative recoveries of between 88.39 % and 94.54 %. However, the results stem
1043 from just one urine sample, therefore, further analysis would be needed to determine
1044 whether this new method is sufficient in detecting larger numbers and more specific
1045 VOCs in urine, perhaps identifying new compounds that may aid in disease diagnosis as
1046 suggested by the authors.

1047 Benign prostatic hypertrophy (BPH), the medical term for an enlarged prostate, is so
1048 common in older men, it could be considered normal. About half of all men between ages

1049 51 and 60 have BPH and up to 90% of men over age 80 have it. This could affect urine
1050 volatiles but has not been investigated in any detail.

1051

1052 **5.7. Volatile organic compounds from faeces**

1053 The first report of gas analysis from faeces was in 1861 when Rüge reported that human
1054 rectal gas contained hydrogen, carbon dioxide, and methane, in addition to other
1055 unidentified gases [209]. Flatus is considered to be a mixture of hydrogen (0–50 %),
1056 nitrogen (5–90 %), oxygen (0–10 %), carbon dioxide (10–30 %), and methane (0–10 %).
1057 Methane production occurs in about 50 % of the healthy population, some members
1058 producing higher levels than others; methane production is correlated with
1059 methanogenic bacteria. Similarly, sulfate-reducing bacteria are responsible for the
1060 generation of pungent sulfides [210]. In the original compendium 381 compounds were
1061 reported in faeces, since then a further 62 compounds not stated in the original
1062 compendium have been found. Of these, 24 compounds had been reported from other
1063 fluids and have now been identified in faecal samples (Table 1). This now means that in
1064 total 443 compounds have been assigned an identity from faecal samples. These
1065 additional 62 compounds came from just 5 papers; this is indicative that while
1066 compounds have been added to the compendium it is very likely that there are more to
1067 be found. The 443 compound value still falls far short of the number of compounds found
1068 in breath, which is likely to be a function of a smaller number of studies carrying out
1069 qualitative analysis on faecal samples when compared to breath.

1070 Significant concentrations of a range of volatile fatty acids [211], indoles [212] and
1071 phenols [213] have been observed in faeces. Fermentation of carbohydrates in the gut
1072 produces ethanoic, propionic, butanoic, pentanoic, and hexanoic acids, particularly
1073 by *Bacteroides* [214]. *In vitro* studies [215] have provided evidence that proteinacious
1074 foods also produce SCFAs via the action of bacteria such as *Clostridia spp.*; BCFAs, such as
1075 2-methylbutanoic acid and methylpropionic acids, are principally produced by gut
1076 microbial action on proteins via the respective branched amino acid.

1077 Gould *et al* [216], conducted a study in which ¹³C labelled compounds were used as
1078 internal standards in faecal samples to quantify 15 compounds. This study is unique as it
1079 is the only work, we have identified in which many compounds were quantified based on
1080 what is in the faeces and not just the headspace. This work also turned the faeces alkaline
1081 by the addition of sodium hydroxide to quantify trimethylamine, which is the first-time

1082 this has been reported from faeces [216]. This paper contributed 12 new compounds to
1083 the previous compendium [1], including 4-isopropyl benzaldehyde (cuminaldehyde), and
1084 2,4-dithiapentane which are associated with cumin and truffle fungus, respectively. Long
1085 chain fatty acids (LCFAs) were quantified in work by Song *et al* [217]. Nine of these
1086 compounds were previously reported as being found in skin and/or saliva (Table 11).
1087 Both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are compounds that
1088 were not found in the original compendium. EPA and DHA are omega 3 fatty acids found
1089 in cold water fish, these compounds are also used as dietary supplements as they are the
1090 fatty acids that form cellular walls in the brain and eyes [218]. A recent mechanistic study
1091 in how unsaturated long chain fatty acids are oxidized in the body to form many smaller
1092 metabolites is described [10].

1093 Volatiles such as methanethiol and ammonia are considered to be derivable from
1094 methionine by the action of bacteria such as *Clostridium sporogenes* [219]. Hydrogen
1095 sulfide and methanethiol can be damaging to the large intestinal epithelium and are also
1096 generated from sulfur-containing substances in the diet [220]. Similarly, fermentation of
1097 tyrosine and tryptophan in faeces has been shown to produce the VOCs phenol and
1098 indole, respectively [219]. Phenol and *p*-cresol are considered to be produced by aerobic
1099 intestinal microbiota acting on tyrosine and the latter by anaerobic organisms [211].

1100 Of the 58 compounds new to faecal samples 13 of those were previously found in saliva.
1101 There is newly emerging evidence that the oral microbiome might have an impact on the
1102 gut microbiome [221]. Olsen and Yamazaki present work in which patients with chronic
1103 periodontitis the bacteria *Prophyromonas gingivalis* creates dysbiosis which in turn cause
1104 dysregulation of the gut microbiota [221].

1105 Two earlier studies stated that a total of 297 and 135 different VOCs have been identified
1106 respectively by Garner *et al* [9] and De Preter *et al* [222] in the headspace of faeces from
1107 healthy individuals on an *ad libitum* diet. These two studies showed that typically, for
1108 each donor the number of VOCs ranged from 78 to 125 (median = 101). Interestingly, 44
1109 compounds were stated to be common to 80 % of the cohort samples [9].
1110 Dixon *et al* [223] hypothesized that the varied functionality of the metabolites in the
1111 headspace of faeces, dictated the use of several diverse SPME fibre coatings for more
1112 comprehensive metabolomic coverage. They evaluated eight different commercially
1113 available SPME fibres in combination with GC-FID and GC-MS. This approach appears
1114 very promising; 267 peaks were found with GC-FID though the authors have yet to

1115 identify all the compounds. SPME can suffer from competitive absorption, the length of
1116 equilibration time of the sample, and length of time the SPME fibre is exposed can all
1117 effect what compounds are absorbed onto the fibre. This means that not all the
1118 compounds from a matrix, particularly one as complex as faeces, are absorbed.

1119 Alcohols were thought uncommon in adult faeces [224]. However, the studies reported
1120 in this review reported 52 different alcohols to be present. Ethanol is very commonly
1121 observed. It is likely that gut bacteria can reduce acids to alcohols. Esters were found to
1122 represent the largest group of compounds identified. An interesting readily observed
1123 feature of the esters in stool is the similarity of the higher MW compounds, they either
1124 possess a long-chain acid and short-chain alcohol or a short-chain acid and long-chain
1125 alcohol. This suggests that the number of esters identified is not a true picture of what is
1126 present in the faeces but a limit on the method i.e. the volatility of the esters. It is very
1127 likely that a more sensitive method or better pre-concentration will significantly increase
1128 the compounds observed.

1129 A diverse range of aromatic compounds (Table 1) including mono-, di-, tri- and tetra-
1130 substituted benzenoids, mono- and di-substituted furans, and nitrogen containing
1131 derivatives of pyridine, pyrrole, and indole have been reported. Most of these have only
1132 been recently reported in faeces, although it has been established that phenolic and
1133 indole compounds arise from the metabolism of aromatic amino acids by gut bacteria
1134 [215]. There are many publications which have observed that alkyl furans are produced
1135 by fungi. In contrast there is a paucity of publications relating to furan biosynthesis by
1136 bacteria. Fungi are well known to be commensal organisms in the gut, which could
1137 explain the origins of furans, possibly from the metabolism of fructose. Furans are now
1138 considered to be also synthesisable from the oxidation of polyunsaturated fatty acids *in*
1139 *vivo* [10]. Some benzenoid compounds such as dimethylbenzenes, ethylbenzene, and
1140 toluene (constituents of petrol) probably arise from air pollution.

1141 A range of aldehydes have been reported [9] in the faeces of individuals. A complete
1142 homologous series has been reported from ethanal to octadecanal. Ethanal is of particular
1143 interest due to its abundance and is considered to promote mutagenesis [225–227] and
1144 be associated with bowel cancer. The toxic effects of higher aldehydes have received
1145 much less attention. The origins of some aldehydes may be dietary. For instance, 2-
1146 methylpropanal, 3-methylpropanal, hexanal, nonanal, decanal, and benzaldehyde are
1147 found in potato tubers and hexanal in carrots. However, it is doubtful that these

1148 compounds would remain unchanged through the digestive system and biosynthesis by
1149 microorganisms in the gut and oxidation of unsaturated fatty acids appears more likely.
1150 Acetone and butan-2-one were reported in 100 % of faecal samples from a longitudinal
1151 cohort study [9], which probably arise from fatty acid and carbohydrate metabolism
1152 [228]. Methylketones can be produced by many species of bacteria and can also be
1153 produced by fungi from the respective alkanolic acid and undoubtedly other ketonic
1154 compounds can also be synthesized by bacteria. The universal presence of 2,3-
1155 butanedione is interesting in faeces [9] since it may have health implications by impacting
1156 on the growth of some bacteria and yeasts [229]. This group of compounds, and indeed
1157 other groups, are not normally the end products of metabolism by microorganisms
1158 therefore their concentrations would be expected to be continually changing in the gut.
1159 Methane is a product of bacterial reduction of carbon dioxide, or from acetic acid, and
1160 potentially from oxidation of some unsaturated fatty acids *in vivo*.
1161 Numerous hydrocarbons have now been discovered in faeces although the longer chain
1162 species have been found in small numbers [9]. Isoprene has been extracted from faeces
1163 [230]. Isoprene in the gut may be the result of cholesterol biosynthesis [231] and it is
1164 considered to be the most common hydrocarbon in the human body and therefore would
1165 be expected to be found in faeces.
1166 Many alkenes/terpenoid compounds found are well documented as naturally occurring
1167 plant products [232]. Limonene has been reported as the most abundant of the terpenoid
1168 compounds and occurs in high concentration in citrus fruits. Most of the terpenes
1169 identified [9] are found in vegetable food stuffs and do not originate from animal
1170 products. For instance the following volatiles are present in carrots: pinene, limonene,
1171 terpinene (1-methyl-4-(1-methylethyl)-1,4-cyclohexadiene), p-cymene, terpinolene
1172 caryophyllene, and humulene [233]. Copaene is found in potato extracts [234].
1173 Many ether compounds have been reported in the headspace of faeces. Commonly, 2-
1174 ethoxyethanol occurs in manufactured products like soaps and cosmetics [235] and 1,3-
1175 dimethoxybenzene is a registered food additive in Europe [9]. Similarly, it is very unlikely
1176 that chlorinated compounds found are of biological origin. Consumption of contaminated
1177 food or water is the likely source of these compounds. Chloroform may arise as a faeces
1178 VOC component from several sources, it is an air contaminant and has been detected in
1179 foodstuffs [236]. Chlorination for disinfection of drinking water is another source
1180 resulting in the production of chloroform and halogenated methanes [237].

1181 Many nitrogen compounds have been reported (Tables 2a-2c) and are likely to arise from
1182 the diet; for instance, methylpyrazine, pyridine, and pyrrole are constituents of coffee.
1183 However, pyrrole readily polymerizes with acid and, therefore, its presence is unlikely to
1184 be dietary, as it would be unlikely to survive transit through the stomach. Ammonia
1185 results from microorganism activity. In addition, increasing the amount of protein in the
1186 diet from 63 g to 136 g/day was found to increase the amount of faecal ammonia from 15
1187 to 30 mmol l⁻¹. Interestingly, increasing the amount of fibre to the high protein diet was
1188 reported to not alter the ammonia concentration [203]. In a study of nitrogen containing
1189 compounds in the faeces of 30 healthy individuals indole was the only compound found
1190 ubiquitously [9], followed by 3-methylindole, in 73 % of individuals, these compounds
1191 are well known to be produced by microbial degradation of l-tryptophan in the gut. Many
1192 compounds are present in a minority of volunteers. Allyl isothiocyanate was found to be
1193 present in 23 % of cases; this compound is of particular interest due to its suspected anti-
1194 cancer properties. Its occurrence would be expected to be determined by a number of
1195 factors such as diet (cruciferous vegetables e.g. broccoli, cauliflower, and cabbage), the
1196 cooking of these vegetables, and the ability of the host's bacteria to break down sinigrin,
1197 the main glucosinolate of Brussel sprouts.

1198 A diverse range of sulfur compounds has been reported. For instance, methanethiol and
1199 dimethylsulfide have been commonly observed; the former is, at least in part, considered
1200 to be produced from methionine by *Clostridia* in the gut [219]. Methanethiol has a toxicity
1201 approaching cyanide and the factors controlling its concentration and biosynthesis might
1202 warrant further investigation. Methanethiol and dimethylsulfide may also be produced
1203 by methylation of hydrogen sulfide as a detoxification mechanism by mucosal thiol S-
1204 methyltransferase [238]. Dimethyldisulfide and dimethyltrisulfide have both been
1205 commonly reported in faeces [9,239,240]. Hydrogen sulphide is probably most likely to
1206 occur due to the metabolism of sulphate by sulphate-reducing bacteria [239]. Sulphate,
1207 which is poorly absorbed in the small bowel, is naturally present in cruciferous
1208 vegetables and nuts and as an additive in bread and beer [239]. The main sulfur-
1209 containing flatus components in healthy individuals have been quantified: hydrogen
1210 sulphide (1.06 μmol l⁻¹), followed by methanethiol (0.21 μmol l⁻¹) and dimethyl sulphide
1211 (0.08 μmol l⁻¹ [239]. The authors were concerned about the social aspect of pungent
1212 flatus and found in their study that hydrogen sulphide and methanethiol appeared to be
1213 principally responsible and not indole-based compounds as previously thought.

1214

1215 **5.8. Volatile organic compounds from semen**

1216 In semen, 196 compounds have been reported. To date, it appears only one research
1217 group has published on VOC profiles in semen, using an investigation of healthy subjects,
1218 using SPME in the headspace above the semen combined with GC-MS detection [241].

1219 Semen assessment is the key test for infertility problems with a seminogram being the
1220 gold standard. Recently, metabolomics research was proposed as a method supporting
1221 male fecundity. Changes in the pattern of metabolites in semen may reflect the metabolic
1222 status of the sperm cells and the composition of the seminal fluid, which could affect the
1223 reproduction capacity. Most of the metabolomic studies on semen have been conducted
1224 using NMR and LC-MS, focusing on the secondary metabolites [242–244]. On the other
1225 hand, the volatile pattern of semen which could contribute to the fast detection of fertility
1226 problems remains hardly explored [241]. The authors detected the presence of 196 VOCs
1227 in semen samples collected from 69 men. The number of VOCs in semen, from each man,
1228 ranged from 3-28 VOCs. Curiously, no compound was present in all samples and 126
1229 compounds was observed only once. Also, interestingly, 98 of the reported compounds
1230 were detected for the first time in biological fluids. The dominant group of compounds in
1231 semen were nitrogen-containing volatiles, comprising more than 30 % of all the
1232 compounds identified. The tetramine, spermine, a compound found in semen at about 3.3
1233 mg/g and responsible for the characteristic odour of semen [245] was not reported in the
1234 study of Longo *et al* [241].

1235 It is worthwhile to underline that the majority of the compounds were detected only in
1236 one of the analysed samples, and only 70 VOCs were detected at least twice. The most
1237 frequently observed compounds were pyrrole, ethanol and 2-methylbutanal. The
1238 majority of the compounds had an exogenous origin according to the Human Metabolome
1239 Database [246], with 57 compounds that could have both exogenous and endogenous
1240 origin. The authors found there was an association between the VOCs profile and the
1241 sperm motility. There surely are more volatile compounds to be discovered in semen,
1242 considering the number of VOCs reported from other bodily fluids. It is suggested that
1243 further research in this area to establish a better base of VOC composition in semen from
1244 healthy men, could be beneficial to aid diagnoses of certain urological diseases.

1245

1246 **6. Conclusion**

1247 A study of VOCs from healthy humans is presented for a variety of reasons. There are
1248 many more papers than ever before now comparing ill patients with controls, These
1249 publications more often than not, have a favourable conclusion, that there are promising
1250 differences in the VOC profiles between the diseased patients and the non-diseased
1251 volunteers. Furthermore, there are many published studies where presence and absence
1252 of VOCs is considered for correlations with disease and controls (some researchers, now
1253 avoid the term VOC biomarkers). The present review now shows many of these
1254 “absences” are being found in healthy subjects, which neutralizes to a degree, their use
1255 in disease diagnoses. Presence and absence is no longer good enough, concentration is
1256 key. Absence could be that the compound really is not there, such as in the case of
1257 detecting a microbial toxin, where a bacterium does or does not produce a toxin. It is
1258 appreciated there may still be a case for comparison if exactly the same conditions and
1259 equipment sensitivity is applied. Diet from weeks, months ago could affect breath
1260 volatiles. It is simply very hopeful to design methods for clean air breathing with the belief
1261 that this will permit standardised results. An important reason for justifying this, is
1262 expanded on. Diet from weeks/months ago affects the lipid composition of the body, our
1263 MUFAs and PUFAs are determined by genetics and diet. These lipids are continuously
1264 being oxidized, producing a wide range of VOCs. such as alcohols, alkenes, alcohols and
1265 carboxylic acids [10], which can then be further metabolized into daughter compounds,
1266 e.g. by further oxidation in the liver etc., also concomitantly there are many new
1267 compounds being reported. There is a huge difference, almost 1000 compounds, between
1268 the numbers reported in 2014 and in 2020. There is then more scope, considering the
1269 huge variety of compounds, for finding correlations for disease diagnoses.

1270 Limited studies have been undertaken on exercise/movement and VOCs in breath etc.
1271 One such study has shown isoprene for instance does fluctuate with exercise in healthy
1272 humans. This might simply be considered as a simple, interesting observation, however
1273 if this phenomenon occurs for isoprene, what about the thousands of VOCs now listed in
1274 this review, which have not been studied, maybe the same phenomenon occurs for many
1275 of these. It could very well be the case that ill people may be less active, they may even be
1276 horizontal in a hospital. If a range of VOCs are being used for disease diagnoses it may be
1277 somewhat compromised by this situation.

1278 When the 2014 review was published the tables showed there were many gaps in the sub
1279 tables i.e. there would be a homologous series with compounds missing here and there

1280 i.e. “gaps”), such as in the first years of the periodic table being constructed. The absence
1281 of a certain compound could be considered to be due to a lack of a metabolic route, or due
1282 to the inability of the detection equipment, or some other reason. Many of these “gaps”
1283 have been filled in this current review compared to 2014 highlighting that further studies
1284 are required to identify the extent of the human volatilome. Another important
1285 consideration is the lack of validation of the current reported compounds from the human
1286 volatilome with a small % validated by standards. Therefore, effort should also focus on
1287 proper validation of the already reported compounds adhering to the principles of
1288 identification outlined in the metabolomic standards initiative.

1289 This review, unlike the earlier 2014 review shows within the tables the publications
1290 where each compound was originally reported, this can add confidence to the data
1291 especially where several research groups have identified the same compounds.

1292 For discussion, one might think the healthy controls would have many similarities,
1293 although this review shows only 14 compounds were common to all the bodily fluids and
1294 breath. One might not have expected this, and it would be preferable for disease
1295 diagnoses if there was a greater core number of compounds that differ in concentration
1296 between disease states. As an example, a recent study, described herein, found 4941 GC-
1297 MS peaks in the sweat of a group of healthy humans and found very few peaks common
1298 to all samples.

1299 In an attempt to have more control over the jungle of compounds, one might consider
1300 controlling diet, between patients and volunteers however then there is the difficulty that
1301 there are different type and concentrations of bacteria, in our bodies. Gut transit time in
1302 healthy humans, varies between individuals. and this is known to affect gut chemistry.
1303 Then there are the VOCs in the environment – “the human exposome” which is highly
1304 individual, and furthermore these compounds can often be converted to other
1305 compounds in our bodies. The control group and patients are unlikely to individually be
1306 exposed to the same compound types at the same concentration levels.

1307 We are therefore assured that there will be a wide range of differences in the human
1308 volatilome, each of us could very well be unique, hopefully though with enough similarity
1309 so that quality correlations between control and disease states, will occur.

1310 This review now summarises many classes and sub-classes of compounds and hopefully
1311 now that they are easily visible will assist in deciding whether to target particular classes
1312 or sub-classes or combinations thereof, to aid disease diagnoses, and also to decide which

1313 is the appropriate bodily fluid or breath, which is the goal for many researchers in the
1314 VOC field.

1315

1316 **Acknowledgements**

1317

1318 **Funding**

1319 No funding was received for writing this paper

1320

1321 **Conflict of Interest**

1322 Authors declare no conflict of interest

1323

1324

1325

1326 **References**

1327 [1] De Lacy Costello B, Amann A, Al-Kateb H, Flynn C, Filipiak W, Khalid T, Osborne D
1328 and Ratcliffe N M 2014 A review of the volatiles from the healthy human body *J.*
1329 *Breath Res.* **8** 014001

1330 [2] Tangerman A 1997 Highly sensitive gas chromatographic analysis of ethanol in
1331 whole blood, serum, urine, and fecal supernatants by the direct injection method
1332 *Clin. Chem.* **43** 1003–9

1333 [3] Jones A W 1985 Excretion of Low-Molecular Weight Volatile Substances in Human
1334 Breath: Focus on Endogenous Ethanol *J. Anal. Toxicol.* **9** 246–50

1335 [4] Musshoff F 2000 ALCOHOL AND BIOLOGICAL MARKERS OF ALCOHOL ABUSE:
1336 GAS CHROMATOGRAPHY *Reference Module in Chemistry, Molecular Sciences and*
1337 *Chemical Engineering* ed I D B T-E of S S Wilson (Oxford: Academic Press) pp 1921–
1338 31

1339 [5] Hung C, Hung I, Yen J, Hwang B and Soong W 1998 Determination of benzene and
1340 alkylbenzenes in milk by purge and trap gas chromatography *Toxicol. Environ.*
1341 *Chem.* **67** 1–7

1342 [6] Filipiak W, Ruzsanyi V, Mochalski P, Filipiak A, Bajtarevic A, Ager C, Denz H, Hilbe
1343 W, Jamnig H, Hackl M, Dzien A and Amann D A 2012 Dependence of exhaled breath
1344 composition on exogenous factors, smoking habits and exposure to air pollutants
1345 *J. Breath Res.* **6** 036008

- 1346 [7] Chapman D E, Moore T J, Michener S R and Powis G 1990 Metabolism and covalent
1347 binding of [14C]toluene by human and rat liver microsomal fractions and liver
1348 slices. *Drug Metab. Dispos.* **18** 929 LP – 936
- 1349 [8] Raman M, Ahmed I, Gillevet P M, Probert C S, Ratcliffe N M, Smith S, Greenwood R,
1350 Sikaroodi M, Lam V, Crotty P, Bailey J, Myers R P and Rioux K P 2013 Fecal
1351 Microbiome and Volatile Organic Compound Metabolome in Obese Humans With
1352 Nonalcoholic Fatty Liver Disease *Clin. Gastroenterol. Hepatol.* **11** 868-875.e3
- 1353 [9] Garner C E, Smith S, de Lacy Costello B, White P, Spencer R, Probert C S J and
1354 Ratcliffe N M 2007 Volatile organic compounds from feces and their potential for
1355 diagnosis of gastrointestinal disease. *FASEB J.* **21** 1675–88
- 1356 [10] Ratcliffe N, Wieczorek T, Drabińska N, Gould O, Osborne A and De Lacy Costello B
1357 2020 A mechanistic study and review of volatile products from peroxidation of
1358 unsaturated fatty acids: an aid to understanding the origins of volatile organic
1359 compounds from the human body *J. Breath Res.* **14** 34001
- 1360 [11] Lundberg J O N, Farkas-Szallasi T, Weitzberg E, Rinder J, Lidholm J, Änggård A,
1361 Hökfelt T, Lundberg J M and Alving K 1995 High nitric oxide production in human
1362 paranasal sinuses *Nat. Med.* **1** 370–3
- 1363 [12] Luiking Y C, Engelen M P K J and Deutz N E P 2010 Regulation of nitric oxide
1364 production in health and disease *Curr. Opin. Clin. Nutr. Metab. Care* **13** 97–104
- 1365 [13] Harhangi H R, Le Roy M, van Alen T, Hu B, Groen J, Kartal B, Tringe S G, Quan Z-X,
1366 Jetten M S M and Op den Camp H J M 2012 Hydrazine Synthase, a Unique
1367 Phylomarker with Which To Study the Presence and Biodiversity of Anammox
1368 Bacteria *Appl. Environ. Microbiol.* **78** 752 LP – 758
- 1369 [14] (EFSA) E F S A 2019 Outcome of a public consultation on the draft scientific
1370 opinion on the health risks related to the presence of cyanogenic glycosides in
1371 foods other than raw apricot kernels *EFSA Support. Publ.* **16** 1601E
- 1372 [15] Maga J A 1981 Pyridines in foods *J. Agric. Food Chem.* **29** 895–8
- 1373 [16] Wieczorek M N and Jeleń H H 2019 Volatile Compounds of Selected Raw and
1374 Cooked Brassica Vegetables *Molecules* **24** 391
- 1375 [17] Ciska E, Drabińska N, Honke J and Narwojsz A 2015 Boiled Brussels sprouts: A rich
1376 source of glucosinolates and the corresponding nitriles *J. Funct. Foods* **19** 91-99
- 1377 [18] Voige W H 2000 Biochemical Pathways: An Atlas of Biochemistry and Molecular
1378 Biology (ed. Michal, Gerhard) *J. Chem. Educ.* **77** 163

- 1379 [19] Macfarlane S and Macfarlane G T 2003 Regulation of short-chain fatty acid
1380 production *Proc. Nutr. Soc.* **62** 67–72
- 1381 [20] Holtug K, Rasmussen H S and Mortensen P B 1988 Short chain fatty acids in
1382 inflammatory bowel disease. The effect of bacterial fermentation of blood *Scand. J.*
1383 *Clin. Lab. Invest.* **48** 667–71
- 1384 [21] Smith E A and Macfarlane G T 1998 Enumeration of amino acid fermenting
1385 bacteria in the human large intestine: effects of pH and starch on peptide
1386 metabolism and dissimilation of amino acids *FEMS Microbiol. Ecol.* **25** 355–68
- 1387 [22] Hijova E and Chmelarova A 2007 Short chain fatty acids and intestinal microflora
1388 *Bratisl. Lek. Listy* **108** 354–8
- 1389 [23] Gordon A H, Green D E and Subrahmanyam V 1940 Liver aldehyde oxidase *Biochem.*
1390 *J.* **34** 764–74
- 1391 [24] Larkin D R 1990 The Role of Catalysts in the Air Oxidation of Aliphatic Aldehydes
1392 *J. Org. Chem.* **55** 1563–8
- 1393 [25] Callol-Sanchez L, Munoz-Lucas M A, Gomez-Martin O, Maldonado-Sanz J A, Civera-
1394 Tejuca C, Gutierrez-Ortega C, Rodriguez-Trigo G and Jareno-Esteban J 2017
1395 Observation of nonanoic acid and aldehydes in exhaled breath of patients with lung
1396 cancer *J. Breath Res.* **11** 026004
- 1397 [26] García-Gómez D, Martínez-Lozano Sinues P, Barrios-Collado C, Vidal-De-Miguel G,
1398 Gaugg M and Zenobi R 2015 Identification of 2-alkenals, 4-hydroxy-2-alkenals, and
1399 4-hydroxy-2,6-alkadienals in exhaled breath condensate by UHPLC-HRMS and in
1400 breath by real-time HRMS *Anal. Chem.* **87** 3087–93
- 1401 [27] Belitz H-D, Grosch W and Schieberle P 2009 Milk and Dairy Products BT - Food
1402 Chemistry (Berlin, Heidelberg: Springer Berlin Heidelberg) pp 498–545
- 1403 [28] Yazdanpanah M, Luo X, Lau R, Greenberg M, Fisher L J and Lehotay D C 1997
1404 Cytotoxic aldehydes as possible markers for childhood cancer *Free Radic. Biol. Med.*
1405 **23** 870–8
- 1406 [29] Gaugg M T, Gomez D G, Barrios-Collado C, Vidal-De-Miguel G, Kohler M, Zenobi R
1407 and Martinez-Lozano Sinues P 2016 Expanding metabolite coverage of real-time
1408 breath analysis by coupling a universal secondary electrospray ionization source
1409 and high resolution mass spectrometry - A pilot study on tobacco smokers *J. Breath*
1410 *Res.* **10** 016010
- 1411 [30] De Lacy Costello B P J, Ledochowski M and Ratcliffe N M 2013 The importance of

- 1412 methane breath testing: A review *J. Breath Res.* **7** 024001
- 1413 [31] Horvat R J, Lane W G, Allan N and SHEPHERD D 1964 Saturated Hydrocarbons
1414 from Autoxidizing Methyl Linoleate *Nature* **203** 523–4
- 1415 [32] Ivin K J, Wijnen M H J and Steacie E W R 1952 Reactions of Ethyl Radicals *J. Phys.*
1416 *Chem.* **56** 967–72
- 1417 [33] Scheick C and Spiteller G 1996 Genesis and metabolisation of 1-pentene during
1418 lipid peroxidation of ω -6 unsaturated fatty acids: Metabolism of 1-pentene *Chem.*
1419 *Phys. Lipids* **81** 63–8
- 1420 [34] Mestrom L, Claessen J G R and Hanefeld U 2019 Enzyme-Catalyzed Synthesis of
1421 Esters in Water *ChemCatChem* **11** 2004–10
- 1422 [35] Meulenbelt J 1996 22 - Fumigants, fungicides and rodenticides *Human Toxicology*
1423 ed J B T-H T DESCOTES (Amsterdam: Elsevier Science B.V.) pp 561–76
- 1424 [36] Hu Q, Xie Z, Wang X, Yu J and Zhang Y 2016 Methyl iodine over oceans from the
1425 Arctic Ocean to the maritime Antarctic *Sci. Rep.* **6** 26007
- 1426 [37] Wang X, Mao Y, Tang S, Yang H and Xie Y F 2015 Disinfection byproducts in
1427 drinking water and regulatory compliance: A critical review *Front. Environ. Sci.*
1428 *Eng.* **9** 3–15
- 1429 [38] Phillips M, Herrera J, Krishnan S, Zain M, Greenberg J and Cataneo R N 1999
1430 Variation in volatile organic compounds in the breath of normal humans *J.*
1431 *Chromatogr. B Biomed. Sci. Appl.* **729** 75–88
- 1432 [39] Markar S R, Wiggins T, Antonowicz S, Chin S-T, Romano A, Nikolic K, Evans B,
1433 Cunningham D, Mughal M, Lagergren J and Hanna G B 2018 Assessment of a
1434 Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer
1435 *JAMA Oncol.* **4** 970–6
- 1436 [40] Singh K D, Tancev G, Decrue F, Usemann J, Appenzeller R, Barreiro P, Jaumà G,
1437 Macia Santiago M, Vidal de Miguel G, Frey U and Sinues P 2019 Standardization
1438 procedures for real-time breath analysis by secondary electrospray ionization
1439 high-resolution mass spectrometry *Anal. Bioanal. Chem.* **411** 4883–98
- 1440 [41] Gaugg M T, Engler A, Bregy L, Nussbaumer-Ochsner Y, Eiffert L, Bruderer T, Zenobi
1441 R, Sinues P and Kohler M 2019 Molecular breath analysis supports altered amino
1442 acid metabolism in idiopathic pulmonary fibrosis *Respirology* **24** 437–44
- 1443 [42] Tejero Rioseras A, Singh K D, Nowak N, Gaugg M T, Bruderer T, Zenobi R and Sinues
1444 P M-L 2018 Real-Time Monitoring of Tricarboxylic Acid Metabolites in Exhaled

1445 Breath *Anal. Chem.* **90** 6453–60

1446 [43] Gaisl T, Bregy L, Stebler N, Gaugg M T, Bruderer T, García-Gómez D, Moeller A,
1447 Singer F, Schwarz E I, Benden C, M-L Sinues P, Zenobi R and Kohler M 2018 Real-
1448 time exhaled breath analysis in patients with cystic fibrosis and controls *J. Breath*
1449 *Res.* **12** 36013

1450 [44] Gaugg M T, Bruderer T, Nowak N, Eiffert L, Martinez-Lozano Sinues P, Kohler M
1451 and Zenobi R 2017 Mass-Spectrometric Detection of Omega-Oxidation Products of
1452 Aliphatic Fatty Acids in Exhaled Breath *Anal. Chem.* **89** 10329-10334

1453 [45] García-Gómez D, Gaisl T, Bregy L, Martínez-Lozano Sinues P, Kohler M and Zenobi
1454 R 2016 Secondary electrospray ionization coupled to high-resolution mass
1455 spectrometry reveals tryptophan pathway metabolites in exhaled human breath
1456 *Chem. Commun.* **52** 8526–8

1457 [46] García-Gómez D, Gaisl T, Bregy L, Cremonesi A, Sinues P M L, Kohler M and Zenobi
1458 R 2016 Real-time quantification of amino acids in the exhalome by secondary
1459 electrospray ionization-mass spectrometry: A proof-of-principle study *Clin. Chem.*
1460 **62** 1230-1237

1461 [47] García-Gómez D, Bregy L, Nussbaumer-Ochsner Y, Gaisl T, Kohler M and Zenobi R
1462 2015 Detection and Quantification of Benzothiazoles in Exhaled Breath and
1463 Exhaled Breath Condensate by Real-Time Secondary Electrospray Ionization–
1464 High-Resolution Mass Spectrometry and Ultra-High Performance Liquid
1465 Chromatography *Environ. Sci. Technol.* **49** 12519–24

1466 [48] Martínez-Lozano P, Rus J, Fernández de la Mora G, Hernández M and Fernández de
1467 la Mora J 2009 Secondary Electrospray Ionization (SESI) of Ambient Vapors for
1468 Explosive Detection at Concentrations Below Parts Per Trillion *J. Am. Soc. Mass*
1469 *Spectrom.* **20** 287–94

1470 [49] Alonso M, Castellanos M and Sanchez J M 2010 Evaluation of potential breath
1471 biomarkers for active smoking: assessment of smoking habits *Anal. Bioanal. Chem.*
1472 **396** 2987–95

1473 [50] Jareño-Esteban J J, Muñoz-Lucas M Á, Carrillo-Aranda B, Maldonado-Sanz J Á, de
1474 Granda-Orive I, Aguilar-Ros A, Civera-Tejuca C, Gutiérrez-Ortega C and Callol-
1475 Sánchez L M 2013 Estudio de compuestos orgánicos volátiles en aire exhalado en
1476 una población clínicamente sana: efecto del tabaquismo *Arch. Bronconeumol.* **49**
1477 457–61

- 1478 [51] Abbott S M, Elder J B, Španěl P and Smith D 2003 Quantification of acetonitrile in
1479 exhaled breath and urinary headspace using selected ion flow tube mass
1480 spectrometry *Int. J. Mass Spectrom.* **228** 655–65
- 1481 [52] Bajtarevic A, Ager C, Pienz M, Klieber M, Schwarz K, Ligor M, Ligor T, Filipiak W,
1482 Denz H, Fiegl M, Hilbe W, Weiss W, Lukas P, Jamnig H, Hackl M, Haidenberger A,
1483 Buszewski B, Miekisch W, Schubert J and Amann A 2009 Noninvasive detection of
1484 lung cancer by analysis of exhaled breath *BMC Cancer* **9** 348
- 1485 [53] Prazeller P, Karl T, Jordan A, Holzinger R, Hansel A and Lindinger W 1998
1486 Quantification of passive smoking using proton-transfer-reaction mass
1487 spectrometry *Int. J. Mass Spectrom.* **178** L1–4
- 1488 [54] Kushch I, Schwarz K, Schwentner L, Baumann B, Dzien A, Schmid A, Unterkofler K,
1489 Gastl G, Španěl P, Smith D and Amann A 2008 Compounds enhanced in a mass
1490 spectrometric profile of smokers' exhaled breath versus non-smokers as
1491 determined in a pilot study using PTR-MS *J. Breath Res.* **2** 26002
- 1492 [55] Sakumura Y, Koyama Y, Tokutake H, Hida T, Sato K, Itoh T, Akamatsu T and Shin
1493 W 2017 Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung
1494 Cancer Patients Using Support Vector Machine Algorithm *Sensors (Basel)*. **17** 287
- 1495 [56] Allers M, Langejuergen J, Gaida A, Holz O, Schuchardt S, Hohlfeld J M and
1496 Zimmermann S 2016 Measurement of exhaled volatile organic compounds from
1497 patients with chronic obstructive pulmonary disease (COPD) using closed gas loop
1498 GC-IMS and GC-APCI-MS *J. Breath Res.* **10** 26004
- 1499 [57] Gaida A, Holz O, Nell C, Schuchardt S, Lavae-Mokhtari B, Kruse L, Boas U,
1500 Langejuergen J, Allers M, Zimmermann S, Vogelmeier C, Koczulla A R and Hohlfeld
1501 J M 2016 A dual center study to compare breath volatile organic compounds from
1502 smokers and non-smokers with and without COPD *J. Breath Res.* **10** 26006
- 1503 [58] Erhart S, Amann A, Haberlandt E, Edlinger G, Schmid A, Filipiak W, Schwarz K,
1504 Mochalski P, Rostasy K, Karall D and Scholl-Bürgi S 2009 3-Heptanone as a
1505 potential new marker for valproic acid therapy *J. Breath Res.* **3** 16004
- 1506 [59] Heaney L M, Ruszkiewicz D M, Arthur K L, Hadjithekli A, Aldcroft C, Lindley M R,
1507 Thomas C L P, Turner M A and Reynolds J C 2016 Real-time monitoring of exhaled
1508 volatiles using atmospheric pressure chemical ionization on a compact mass
1509 spectrometer *Bioanalysis* **8** 1325–36
- 1510 [60] Yang H-Y, Shie R-H, Chang C-J and Chen P-C 2017 Development of breath test for

- 1511 pneumoconiosis: a case-control study *Respir. Res.* **18** 178
- 1512 [61] Geer Wallace M A, Pleil J D, Mentese S, Oliver K D, Whitaker D A and Fent K W 2017
1513 Calibration and performance of synchronous SIM/scan mode for simultaneous
1514 targeted and discovery (non-targeted) analysis of exhaled breath samples from
1515 firefighters *J. Chromatogr. A* **1516** 114–24
- 1516 [62] Khalid T Y, Saad S, Greenman J, De Lacy Costello B, Probert C S J and Ratcliffe N M
1517 2013 Volatiles from oral anaerobes confounding breath biomarker discovery *J.*
1518 *Breath Res.* **7** 017114
- 1519 [63] Eisenmann A, Amann A, Said M, Datta B and Ledochowski M 2008 Implementation
1520 and interpretation of hydrogen breath tests *J. Breath Res.* **2** 46002
- 1521 [64] Pimentel M, Lin H C, Enayati P, van den Burg B, Lee H-R, Chen J H, Park S, Kong Y
1522 and Conklin J 2006 Methane, a gas produced by enteric bacteria, slows intestinal
1523 transit and augments small intestinal contractile activity *Am. J. Physiol. Liver*
1524 *Physiol.* **290** G1089–95
- 1525 [65] Arendacká B, Schwarz K, Štolc S, Wimmer G and Witkovský V 2008 Variability
1526 issues in determining the concentration of isoprene in human breath by PTR-MS *J.*
1527 *Breath Res.* **2** 37007
- 1528 [66] Kushch I, Arendacká B, Štolc S, Mochalski P, Filipiak W, Schwarz K, Schwentner L,
1529 Schmid A, Dzien A, Lechleitner M, Witkovský V, Miekisch W, Schubert J, Unterkofler
1530 K and Amann A Breath isoprene – aspects of normal physiology related to age,
1531 gender and cholesterol profile as determined in a proton transfer reaction mass
1532 spectrometry study *Clin. Chem. Lab. Med.* **46** 1011–8
- 1533 [67] Smith D, Španěl P, Enderby B, Lenney W, Turner C and Davies S J 2009 Isoprene
1534 levels in the exhaled breath of 200 healthy pupils within the age range 7–18 years
1535 studied using SIFT-MS *J. Breath Res.* **4** 17101
- 1536 [68] Turner C, Španěl P and Smith D 2005 A longitudinal study of breath isoprene in
1537 healthy volunteers using selected ion flow tube mass spectrometry (SIFT-MS)
1538 *Physiol. Meas.* **27** 13–22
- 1539 [69] Schwarz K, Pizzini A, Arendacká B, Zerlauth K, Filipiak W, Schmid A, Dzien A,
1540 Neuner S, Lechleitner M, Scholl-Bürgi S, Miekisch W, Schubert J, Unterkofler K,
1541 Witkovský V, Gastl G and Amann A 2009 Breath acetone—aspects of normal
1542 physiology related to age and gender as determined in a PTR-MS study *J. Breath*
1543 *Res.* **3** 27003

- 1544 [70] Turner C, Walton C, Hoashi S and Evans M 2009 Breath acetone concentration
1545 decreases with blood glucose concentration in type I diabetes mellitus patients
1546 during hypoglycaemic clamps *J. Breath Res.* **3** 46004
- 1547 [71] King J, Mochalski P, Unterkofler K, Teschl G, Klieber M, Stein M, Amann A and
1548 Baumann M 2012 Breath isoprene: Muscle dystrophy patients support the concept
1549 of a pool of isoprene in the periphery of the human body *Biochem. Biophys. Res.*
1550 *Commun.* **423** 526–30
- 1551 [72] Koc H, King J, Teschl G, Unterkofler K, Teschl S, Mochalski P, Hinterhuber H and
1552 Amann A 2011 The role of mathematical modeling in VOC analysis using isoprene
1553 as a prototypic example *J. Breath Res.* **5** 37102
- 1554 [73] King J, Kupferthaler A, Unterkofler K, Koc H, Teschl S, Teschl G, Miekisch W,
1555 Schubert J, Hinterhuber H and Amann A 2009 Isoprene and acetone concentration
1556 profiles during exercise on an ergometer *J. Breath Res.* **3** 27006
- 1557 [74] King J, Mochalski P, Kupferthaler A, Unterkofler K, Koc H, Filipiak W, Teschl S,
1558 Hinterhuber H and Amann A 2010 Dynamic profiles of volatile organic compounds
1559 in exhaled breath as determined by a coupled PTR-MS/GC-MS study *Physiol. Meas.*
1560 **31** 1169–84
- 1561 [75] King J, Koc H, Unterkofler K, Mochalski P, Kupferthaler A, Teschl G, Teschl S,
1562 Hinterhuber H and Amann A 2010 Physiological modeling of isoprene dynamics in
1563 exhaled breath *J. Theor. Biol.* **267** 626–37
- 1564 [76] Karl T, Prazeller P, Mayr D, Jordan A, Rieder J, Fall R and Lindinger W 2001 Human
1565 breath isoprene and its relation to blood cholesterol levels: new measurements and
1566 modeling *J. Appl. Physiol.* **91** 762–70
- 1567 [77] Farhi L E 1967 Elimination of inert gas by the lung *Respir. Physiol.* **3** 1–11
- 1568 [78] King J, Kupferthaler A, Frauscher B, Hackner H, Unterkofler K, Teschl G,
1569 Hinterhuber H, Amann A and Högl B 2012 Measurement of endogenous acetone
1570 and isoprene in exhaled breath during sleep *Physiol. Meas.* **33** 413–28
- 1571 [79] AMANN A, TELSERS S, HOFER L, SCHMID A and HINTERHUBER H 2005 EXHALED
1572 BREATH GAS AS A BIOCHEMICAL PROBE DURING SLEEP *Breath Analysis for*
1573 *Clinical Diagnosis and Therapeutic Monitoring* (WORLD SCIENTIFIC) pp 305–16
- 1574 [80] Amann A, Poupart G, Telsers S, Ledochowski M, Schmid A and Mechtcheriakov S
1575 2004 Applications of breath gas analysis in medicine *Int. J. Mass Spectrom.* **239**
1576 227–33

- 1577 [81] King J, Koc H, Unterkofler K, Teschl G, Teschl S, Mochalski P, Hinterhuber H and
1578 Amann A 2013 Chapter 3 - Physiological Modeling for Analysis of Exhaled Breath
1579 ed A Amann and D B T-V B Smith (Boston: Elsevier) pp 26–46
- 1580 [82] Herbig J, Müller M, Schallhart S, Titzmann T, Graus M and Hansel A 2009 On-line
1581 breath analysis with PTR-TOF *J. Breath Res.* **3** 27004
- 1582 [83] Agapiou A, Mochalski P, Schmid A and Amann A 2013 Chapter 24 - Potential
1583 Applications of Volatile Organic Compounds in Safety and Security ed A Amann and
1584 D B T-V B Smith (Boston: Elsevier) pp 514–58
- 1585 [84] Španěl P, Dryahina K, Rejšková A, Chippendale T W E and Smith D 2011 Breath
1586 acetone concentration; biological variability and the influence of diet *Physiol. Meas.*
1587 **32** N23–31
- 1588 [85] Španel P and Smith D 2011 Volatile compounds in health and disease *Curr. Opin.*
1589 *Clin. Nutr. Metab. Care* **14** 455-460
- 1590 [86] Španěl P and Smith D 2013 Chapter 4 - Recent SIFT-MS Studies of Volatile
1591 Compounds in Physiology, Medicine and Cell Biology ed A Amann and D B T-V B
1592 Smith (Boston: Elsevier) pp 48–76
- 1593 [87] Romano A, Doran S, Belluomo I and Hanna G B 2018 High-Throughput Breath
1594 Volatile Organic Compound Analysis Using Thermal Desorption Proton Transfer
1595 Reaction Time-of-Flight Mass Spectrometry *Anal. Chem.* **90** 10204–10
- 1596 [88] Pleil J D, Stiegel M A and Risby T H 2013 Clinical breath analysis: discriminating
1597 between human endogenous compounds and exogenous (environmental)
1598 chemical confounders *J. Breath Res.* **7** 17107
- 1599 [89] Pleil J D, Stiegel M A and Sobus J R 2011 Breath biomarkers in environmental
1600 health science: exploring patterns in the human exposome *J. Breath Res.* **5** 46005
- 1601 [90] Pleil J D, Stiegel M A, Sobus J R, Liu Q and Madden M C 2011 Observing the human
1602 exposome as reflected in breath biomarkers: heat map data interpretation for
1603 environmental and intelligence research *J. Breath Res.* **5** 37104
- 1604 [91] Sawyer K, Samet J M, Ghio A J, Pleil J D and Madden M C 2008 Responses measured
1605 in the exhaled breath of human volunteers acutely exposed to ozone and diesel
1606 exhaust *J. Breath Res.* **2** 37019
- 1607 [92] Pleil J D and Sobus J R 2013 Chapter 1 - Mathematical and Statistical Approaches
1608 for Interpreting Biomarker Compounds in Exhaled Human Breath ed A Amann and
1609 D B T-V B Smith (Boston: Elsevier) pp 2–18

- 1610 [93] Beauchamp J 2011 Inhaled today, not gone tomorrow: pharmacokinetics and
1611 environmental exposure of volatiles in exhaled breath *J. Breath Res.* **5** 37103
- 1612 [94] Filipiak W, Sponring A, Baur M M, Ager C, Filipiak A, Wiesenhofer H, Nagl M,
1613 Troppmair J and Amann A 2012 Characterization of volatile metabolites taken up
1614 by or released from *Streptococcus pneumoniae* and *Haemophilus influenzae* by
1615 using GC-MS *Microbiology* **158** 3044–53
- 1616 [95] Filipiak W, Sponring A, Baur M M, Filipiak A, Ager C, Wiesenhofer H, Nagl M,
1617 Troppmair J and Amann A 2012 Molecular analysis of volatile metabolites released
1618 specifically by *Staphylococcus aureus* and *Pseudomonas aeruginosa* *BMC Microbiol.*
1619 **12** 113
- 1620 [96] Pysanenko A, Španěl P and Smith D 2008 A study of sulfur-containing compounds
1621 in mouth- and nose-exhaled breath and in the oral cavity using selected ion flow
1622 tube mass spectrometry *J. Breath Res.* **2** 46004
- 1623 [97] Codipilly D and Kleinberg I 2008 Generation of indole/skatole during malodor
1624 formation in the salivary sediment model system and initial examination of the oral
1625 bacteria involved *J. Breath Res.* **2** 17017
- 1626 [98] Wang T, Pysanenko A, Dryahina K, Španěl P and Smith D 2008 Analysis of breath,
1627 exhaled via the mouth and nose, and the air in the oral cavity *J. Breath Res.* **2** 37013
- 1628 [99] Boyd T, Vazquez J and Williams M 2008 Reduction of VSC and salivary bacteria by
1629 a multibenefit mouthrinse *J. Breath Res.* **2** 17013
- 1630 [100] Nogueira-Filho G R, Peruzzo D and Sallum A W 2008 Relationship between the
1631 formation of volatile sulfur compounds (VSC) and the severity of the periodontal
1632 disease: a pilot study *J. Breath Res.* **2** 17005
- 1633 [101] Shin K, Horigome A, Wakabayashi H, Yamauchi K, Yaeshima T and Iwatsuki K 2008
1634 In vitro and in vivo effects of a composition containing lactoperoxidase on oral
1635 bacteria and breath odor *J. Breath Res.* **2** 17014
- 1636 [102] Di Francesco F, Loccioni C, Fioravanti M, Russo A, Pioggia G, Ferro M, Roehrer I,
1637 Tabucchi S and Onor M 2008 Implementation of Fowler's method for end-tidal air
1638 sampling *J. Breath Res.* **2** 37009
- 1639 [103] Herbig J, Titzmann T, Beauchamp J, Kohl I and Hansel A 2008 Buffered end-tidal
1640 (BET) sampling—a novel method for real-time breath-gas analysis *J. Breath Res.* **2**
1641 37008
- 1642 [104] Miekisch W, Kischkel S, Sawacki A, Liebau T, Mieth M and Schubert J K 2008 Impact

- 1643 of sampling procedures on the results of breath analysis *J. Breath Res.* **2** 26007
- 1644 [105] Filipiak W, Filipiak A, Ager C, Wiesenhofer H and Amann A 2012 Optimization of
1645 sampling parameters for collection and preconcentration of alveolar air by needle
1646 traps *J. Breath Res.* **6** 27107
- 1647 [106] Mochalski P, King J, Klieber M, Unterkofler K, Hinterhuber H, Baumann M and
1648 Amann A 2013 Blood and breath levels of selected volatile organic compounds in
1649 healthy volunteers *Analyst* **138** 2134–45
- 1650 [107] Mochalski P, King J, Kupferthaler A, Unterkofler K, Hinterhuber H and Amann A
1651 2011 Measurement of isoprene solubility in water, human blood and plasma by
1652 multiple headspace extraction gas chromatography coupled with solid phase
1653 microextraction *J. Breath Res.* **5** 46010
- 1654 [108] Mochalski P, King J, Kupferthaler A, Unterkofler K, Hinterhuber H and Amann A
1655 2012 Human Blood and Plasma Partition Coefficients for C4-C8 n-alkanes,
1656 Isoalkanes, and 1-alkenes *Int. J. Toxicol.* **31** 267–75
- 1657 [109] Lima D P, Diniz D G, Moimaz S A S, Sumida D H and Okamoto A C 2010 Saliva:
1658 reflection of the body *Int. J. Infect. Dis.* **14** e184–8
- 1659 [110] Al-Kateb H, De Lacy Costello B and Ratcliffe N 2013 An investigation of volatile
1660 organic compounds from the saliva of healthy individuals using headspace-
1661 trap/GC-MS *J. Breath Res.* **7** 036004
- 1662 [111] Monedeiro F, Milanowski M, Ratiu I-A, Zmysłowski H, Ligor T and Buszewski B
1663 2019 VOC Profiles of Saliva in Assessment of Halitosis and Submandibular
1664 Abscesses Using HS-SPME-GC/MS Technique *Molecules* **24** 2977
- 1665 [112] Brown J S, Prada P A, Curran A M and Furton K G 2013 Applicability of emanating
1666 volatile organic compounds from various forensic specimens for individual
1667 differentiation *Forensic Sci. Int.* **226** 173–82
- 1668 [113] Francavilla R, Ercolini D, Piccolo M, Vannini L, Siragusa S, De Filippis F, De Pasquale
1669 I, Di Cagno R, Di Toma M, Gozzi G, Serrazanetti D I, De Angelis M and Gobbetti M
1670 2014 Salivary microbiota and metabolome associated with celiac disease *Appl.*
1671 *Environ. Microbiol.* **80** 3416–25
- 1672 [114] Bessonneau V, Boyaci E, Maciazek-Jurczyk M and Pawliszyn J 2015 In vivo solid
1673 phase microextraction sampling of human saliva for non-invasive and on-site
1674 monitoring *Anal. Chim. Acta* **856** 35–45
- 1675 [115] Campanella B, Onor M, Lomonaco T, Benedetti E and Bramanti E 2019 HS-SPME-

- 1676 GC-MS approach for the analysis of volatile salivary metabolites and application in
1677 a case study for the indirect assessment of gut microbiota *Anal. Bioanal. Chem.* **411**
1678 7551–62
- 1679 [116] Shigeyama H, Wang T, Ichinose M, Ansai T and Lee S-W 2019 Identification of
1680 volatile metabolites in human saliva from patients with oral squamous cell
1681 carcinoma via zeolite-based thin-film microextraction coupled with GC-MS *J.*
1682 *Chromatogr. B* **1104** 49–58
- 1683 [117] Claus D, Geypens B, Ghooys Y, Rutgeerts P, Ghyselen J, Hoshi K and Delanghe G 1997
1684 Oral malodor, assessed by closed-loop, gas chromatography, and ion-trap
1685 technology *J. High Resolut. Chromatogr.* **20** 94–8
- 1686 [118] Kusano M, Mendez E and Furton K G 2013 Comparison of the Volatile Organic
1687 Compounds from Different Biological Specimens for Profiling Potential* *J. Forensic*
1688 *Sci.* **58** 29–39
- 1689 [119] Drabińska N, Młynarz P, de Lacy Costello B, Jones P, Mielko K, Mielnik J, Persad R
1690 and Ratcliffe N M 2020 An Optimization of Liquid-Liquid Extraction of Urinary
1691 Volatile and Semi-Volatile Compounds and Its Application for Gas
1692 Chromatography-Mass Spectrometry and Proton Nuclear Magnetic Resonance
1693 Spectroscopy *Molecules* **25** 3651
- 1694 [120] Shirasu M and Touhara K 2011 The scent of disease : volatile organic compounds
1695 of the human body related to disease and disorder *J. Biochem.* **150** 257–66
- 1696 [121] Cramer P H, Boggess K E, Hosenfeld J M, Remmers J C, Breen J J, Robinson P E and
1697 Stroup C 1988 Determination of organic chemicals in human whole blood:
1698 Preliminary method development for volatile organics *Bull. Environ. Contam.*
1699 *Toxicol.* **40** 612–8
- 1700 [122] Mather A and Assimos A 1965 Evaluation of Gas-Liquid Chromatography in Assays
1701 for Blood Volatiles *Clin. Chem.* **11** 1023–35
- 1702 [123] Ojanperä I, Pihlainen K and Vuori E 1998 Identification Limits for Volatile Organic
1703 Compounds in the Blood by Purge-and-Trap GC-FTIR *J. Anal. Toxicol.* **22** 290–5
- 1704 [124] Forbes S L, Rust L, Trebilcock K, Perrault K A and McGrath L T 2014 Effect of age
1705 and storage conditions on the volatile organic compound profile of blood *Forensic*
1706 *Sci. Med. Pathol.* **10** 570–82
- 1707 [125] Rust L, Nizio K D and Forbes S L 2016 The influence of ageing and surface type on
1708 the odour profile of blood-detection dog training aids *Anal. Bioanal. Chem.* **408**

1709 6349–60

1710 [126] Dubois L M, Perrault K A, Stefanuto P-H, Koschinski S, Edwards M, McGregor L and
1711 Focant J-F 2017 Thermal desorption comprehensive two-dimensional gas
1712 chromatography coupled to variable-energy electron ionization time-of-flight
1713 mass spectrometry for monitoring subtle changes in volatile organic compound
1714 profiles of human blood *J. Chromatogr. A* **1501** 117–27

1715 [127] Rendine M, Fiore C, Bertozzi G, De Carlo D, Filetti V, Fortarezza P and Riezzo I 2019
1716 Decomposing Human Blood: Canine Detection Odor Signature and Volatile Organic
1717 Compounds *J. Forensic Sci.* **64** 587–92

1718 [128] Zlatkis A, Lee K Y, Poole C F and Holzer G 1979 Capillary column gas
1719 chromatographic profile analysis of volatile compounds in sera of normal and
1720 virus-infected patients *J. Chromatogr. B Biomed. Sci. Appl.* **163** 125–33

1721 [129] Gould O, Ratcliffe N, Król E and de Lacy Costello B 2020 Breath analysis for
1722 detection of viral infection, the current position of the field *J. Breath Res.* **14** 41001

1723 [130] Xue R, Dong L, Zhang S, Deng C, Liu T, Wang J and Shen X 2008 Investigation of
1724 volatile biomarkers in liver cancer blood using solid-phase microextraction and gas
1725 chromatography/mass spectrometry *Rapid Commun. Mass Spectrom.* **22** 1181–6

1726 [131] Deng C, Zhang X and Li N 2004 Investigation of volatile biomarkers in lung cancer
1727 blood using solid-phase microextraction and capillary gas chromatography–mass
1728 spectrometry *J. Chromatogr. B* **808** 269–77

1729 [132] Horvath G, Andersson H and Paulsson G 2010 Characteristic odour in the blood
1730 reveals ovarian carcinoma *BMC Cancer* **10** 643

1731 [133] Wang C, Li P, Lian A, Sun B, Wang X, Guo L, Chi C, Liu S, Zhao W, Luo S, Guo Z, Zhang
1732 Y, Ke C, Ye G, Xu G, Zhang F and Li E 2014 Blood volatile compounds as biomarkers
1733 for colorectal cancer *Cancer Biol. Ther.* **15** 200–6

1734 [134] Ross B M and Babgi R 2017 Volatile compounds in blood headspace and nasal
1735 breath *J. Breath Res.* **11** 46001

1736 [135] Anon 2009 Centers for Disease Control and Prevention NHANES Fourth National
1737 Report on Human Exposure to Environmental Chemicals

1738 [136] Blount B C, Kobelski R J, McElprang D O, Ashley D L, Morrow J C, Chambers D M
1739 and Cardinali F L 2006 Quantification of 31 volatile organic compounds in whole
1740 blood using solid-phase microextraction and gas chromatography–mass
1741 spectrometry *J. Chromatogr. B* **832** 292–301

- 1742 [137] Ashley D L, Bonin M A, Cardinali F L, McCraw J M, Holler J S, Needham L L and
1743 Patterson D G 1992 Determining volatile organic compounds in human blood from
1744 a large sample population by using purge and trap gas chromatography/mass
1745 spectrometry *Anal. Chem.* **64** 1021–9
- 1746 [138] Ashley D L, Bonin M A, Cardinali F L, McCraw J M and Wooten J V. 1994 Blood
1747 concentrations of volatile organic compounds in a nonoccupationally exposed US
1748 population and in groups with suspected exposure *Clin. Chem.* **40** 1401–4
- 1749 [139] Ashley D L, Bonin M A, Cardinali F L, McCraw J M and Wooten J V 1996
1750 Measurement of volatile organic compounds in human blood *Environ. Health*
1751 *Perspect.* **104 Suppl** 871–7
- 1752 [140] Anon LEAN | Home Page
- 1753 [141] Kuhn E, Datta M and Ellis J 2001 Separation and identification of blood pollutants
1754 *Agil. Technol.* **B-0328**
- 1755 [142] Anon National Institute of Drug Abuse and & National Institute of Health 2013
1756 Inhalants 13549
- 1757 [143] Kimberley Molina D 2010 A Characterization of Sources of Isopropanol Detected
1758 on Postmortem Toxicologic Analysis *J. Forensic Sci.* **55** 998–1002
- 1759 [144] Kun E, Kearney E B 1974 Ammonia *Methods of enzymatic analysis* 1802-1806
- 1760 [145] Barsotti R J 2001 Measurement of ammonia in blood *J. Pediatr.* **138** S11–20
- 1761 [146] Spooner R J, Toseland P A and Goldberg D M 1975 The fluorimetric determination
1762 of ammonia in protein-free filtrates of human blood plasma *Clin. Chim. Acta* **65** 47–
1763 55
- 1764 [147] Cooke R J and Jensen R L 1983 Micromethod for determining plasma ammonia
1765 nitrogen with use of an ion-selective electrode. *Clin. Chem.* **29** 867–9
- 1766 [148] Müting D, Heinze J, Reikowski J, Betzien G, Schwarz M and Schmidt F H 1968
1767 Enzymatic ammonia determinations in the blood and cerebrospinal fluid of healthy
1768 persons *Clin. Chim. Acta* **19** 391–5
- 1769 [149] Romero-Gómez M, Ramos-Guerrero R, Grande L, de Terán L C, Corpas R, Camacho
1770 I and Bautista J D 2004 Intestinal glutaminase activity is increased in liver cirrhosis
1771 and correlates with minimal hepatic encephalopathy *J. Hepatol.* **41** 49–54
- 1772 [150] Ditisheim S, Giostra E, Burkhard P R, Goossens N, Mentha G, Hadengue A and Spahr
1773 L 2011 A capillary blood ammonia bedside test following glutamine load to
1774 improve the diagnosis of hepatic encephalopathy in cirrhosis *BMC Gastroenterol.*

1775 **11** 134

- 1776 [151] Jenness R 1979 The composition of human milk *Semin. Perinatol.* **3** 225–39
- 1777 [152] LaKind J S, Amina Wilkins A and Berlin C M 2004 Environmental chemicals in
1778 human milk: a review of levels, infant exposures and health, and guidance for
1779 future research *Toxicol. Appl. Pharmacol.* **198** 184–208
- 1780 [153] Sandgruber S, Much D, Amann-Gassner U, Hauner H and Buettner A 2011 Sensory
1781 and molecular characterisation of human milk odour profiles after maternal fish oil
1782 supplementation during pregnancy and breastfeeding *Food Chem.* **128** 485–94
- 1783 [154] Kirsch F, Horst K, Röhrig W, Rychlik M and Buettner A 2013 Tracing metabolite
1784 profiles in human milk: studies on the odorant 1,8-cineole transferred into breast
1785 milk after oral intake *Metabolomics* **9** 483–96
- 1786 [155] Pellizzari E D, Hartwell T D, Harris B S H, Waddell R D, Whitaker D A and Erickson
1787 M D 1982 Purgeable organic compounds in mother's milk *Bull. Environ. Contam.*
1788 *Toxicol.* **28** 322–8
- 1789 [156] Shimoda M, Yoshimura T, Ishikawa H, Hayakawa I and Osajima Y 2000 Volatile
1790 compounds of human milk. *J. Fac. Agric. Kyushu Univ.* **45** 199–206
- 1791 [157] Kim S R, Halden R U and Buckley T J 2007 Volatile Organic Compounds in Human
1792 Milk: Methods and Measurements *Environ. Sci. Technol.* **41** 1662–7
- 1793 [158] DeBruin L S, Pawliszyn J B and Josephy P D 1999 Detection of Monocyclic Aromatic
1794 Amines, Possible Mammary Carcinogens, in Human Milk *Chem. Res. Toxicol.* **12** 78–
1795 82
- 1796 [159] Zhu J, Phillips S P, Feng Y-L and Yang X 2006 Phthalate Esters in Human Milk:
1797 Concentration Variations over a 6-Month Postpartum Time *Environ. Sci. Technol.*
1798 **40** 5276–81
- 1799 [160] Fabietti F, Ambrozzi A, Delise M and Sprechini M R 2004 Monitoring of the benzene
1800 and toluene contents in human milk *Environ. Int.* **30** 397–401
- 1801 [161] Blount B C, McElprang D O, Chambers D M, Waterhouse M G, Squibb K S and LaKind
1802 J S 2010 Methodology for collecting, storing, and analyzing human milk for volatile
1803 organic compounds *J. Environ. Monit.* **12** 1265–73
- 1804 [162] Buettner A 2007 A selective and sensitive approach to characterize odour-active
1805 and volatile constituents in small-scale human milk samples *Flavour Fragr. J.* **22**
1806 465–73
- 1807 [163] Hausner H, Philipsen M, Skov T H, Petersen M A and Bredie W L P 2009

- 1808 Characterization of the Volatile Composition and Variations Between Infant
1809 Formulas and Mother's Milk *Chemosens. Percept.* **2** 79–93
- 1810 [164] Spitzer J and Buettner A 2010 Characterization of aroma changes in human milk
1811 during storage at -19°C *Food Chem.* **120** 240–6
- 1812 [165] Spitzer J, Klos K and Buettner A 2013 Monitoring aroma changes during human
1813 milk storage at $+4^{\circ}\text{C}$ by sensory and quantification experiments *Clin. Nutr.* **32**
1814 1036–42
- 1815 [166] Contreras C M, Gutiérrez-García A G, Mendoza-López R, Rodríguez-Landa J F,
1816 Bernal-Morales B and Díaz-Marte C 2013 Amniotic fluid elicits appetitive
1817 responses in human newborns: Fatty acids and appetitive responses *Dev.*
1818 *Psychobiol.* **55** 221–31
- 1819 [167] Garrido M, Contador R, García-Parra J, Delgado F J, Delgado-Adámez J and Ramírez
1820 R 2015 Volatile profile of human milk subjected to high-pressure thermal
1821 processing *Food Res. Int.* **78** 186–94
- 1822 [168] Scheffler L, Sauermann Y, Zeh G, Hauf K, Heinlein A, Sharapa C and Buettner A 2016
1823 Detection of Volatile Metabolites of Garlic in Human Breast Milk *Metabolites* **6** 18
- 1824 [169] Scheffler L, Sharapa C, Amar T and Buettner A 2018 Identification and
1825 Quantification of Volatile Ramson-Derived Metabolites in Humans *Front. Chem.* **6**
1826 410
- 1827 [170] Scheffler L, Sharapa C and Buettner A 2019 Quantification of volatile metabolites
1828 derived from garlic in human breast milk *Food Chem.* **274** 603–10
- 1829 [171] Hartmann C, Mayenzet F, Larcinese J-P, Haefliger O P, Buettner A and Starkenmann
1830 C 2013 Development of an analytical approach for identification and quantification
1831 of 5- α -androst-16-en-3-one in human milk *Steroids* **78** 156–60
- 1832 [172] Kirsch F and Buettner A 2013 Characterisation of the metabolites of 1,8-cineole
1833 transferred into human milk: concentrations and ratio of enantiomers *Metabolites*
1834 **3** 47–71
- 1835 [173] Buszewski B, Ligor T, Rudnicka J, Jezierski T, Walczak M and Wenda-Piesik A 2013
1836 Chapter 10 - Analysis of Cancer Biomarkers in Exhaled Breath and Comparison
1837 with Sensory Indications by Dogs *Volatile Biomarkers Non-Invasive Diagnosis in*
1838 *Physiology and Medicine* ed A Amann and D B T-V B Smith (Boston: Elsevier) pp
1839 177–92
- 1840 [174] Wallace P 1977 Individual discrimination of humans by odor *Physiol. Behav.* **19**

1841 577–9

1842 [175] Kuukasjärvi S, Eriksson C J P, Koskela E, Mappes T, Nissinen K and Rantala M J 2004

1843 Attractiveness of women’s body odors over the menstrual cycle: the role of oral

1844 contraceptives and receiver sex *Behav. Ecol.* **15** 579–84

1845 [176] Gallagher M, Wysocki C J, Leyden J J, Spielman A I, Sun X and Preti G 2008 Analyses

1846 of volatile organic compounds from human skin *Br. J. Dermatol.* **159** 780–91

1847 [177] Kuhn F and Natsch A 2009 Body odour of monozygotic human twins: a common

1848 pattern of odorant carboxylic acids released by a bacterial aminoacylase from axilla

1849 secretions contributing to an inherited body odour type *J. R. Soc. Interface* **6** 377–

1850 92

1851 [178] Bernier U R, Booth M M and Yost R A 1999 Analysis of Human Skin Emanations by

1852 Gas Chromatography/Mass Spectrometry. 1. Thermal Desorption of Attractants for

1853 the Yellow Fever Mosquito (*Aedes aegypti*) from Handled Glass Beads *Anal. Chem.*

1854 **71** 1–7

1855 [179] Zeng X, Leyden J J, Lawley H J, Sawano K, Nohara I and Preti G 1991 Analysis of

1856 characteristic odors from human male axillae *J. Chem. Ecol.* **17** 1469–92

1857 [180] Zeng X-N, Leyden J J, Spielman A I and Preti G 1996 Analysis of characteristic

1858 human female axillary odors: Qualitative comparison to males *J. Chem. Ecol.* **22**

1859 237–57

1860 [181] Hasegawa Y, Yabuki M and Matsukane M 2004 Identification of New Odoriferous

1861 Compounds in Human Axillary Sweat *Chem. Biodivers.* **1** 2042–50

1862 [182] Penn D J, Oberzaucher E, Grammer K, Fischer G, Soini H A, Wiesler D, Novotny M

1863 V., Dixon S J, Xu Y and Brereton R G 2007 Individual and gender fingerprints in

1864 human body odour *J. R. Soc. Interface* **4** 331–40

1865 [183] Haze S, Gozu Y, Nakamura S, Kohno Y, Sawano K, Ohta H and Yamazaki K 2001 2-

1866 Nonenal Newly Found in Human Body Odor Tends to Increase with Aging *J. Invest.*

1867 *Dermatol.* **116** 520–4

1868 [184] Zhang Z-M, Cai J-J, Ruan G-H and Li G-K 2005 The study of fingerprint

1869 characteristics of the emanations from human arm skin using the original sampling

1870 system by SPME-GC/MS *J. Chromatogr. B* **822** 244–52

1871 [185] Curran A M, Rabin S I, Prada P A and Furton K G 2005 Comparison of the Volatile

1872 Organic Compounds Present in Human Odor Using Spme-GC/MS *J. Chem. Ecol.* **31**

1873 1607–19

- 1874 [186] Vaglio S, Minicozzi P, Bonometti E, Mello G and Chiarelli B 2009 Volatile Signals
1875 During Pregnancy: A Possible Chemical Basis for Mother–Infant Recognition *J.*
1876 *Chem. Ecol.* **35** 131–9
- 1877 [187] Ruzsanyi V, Mochalski P, Schmid A, Wiesenhofer H, Klieber M, Hinterhuber H and
1878 Amann A 2012 Ion mobility spectrometry for detection of skin volatiles *J.*
1879 *Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* **911** 84–92
- 1880 [188] Prada P A, Curran A M and Furton K G 2011 The Evaluation of Human Hand Odor
1881 Volatiles on Various Textiles: A Comparison Between Contact and Noncontact
1882 Sampling Methods*,† *J. Forensic Sci.* **56** 866–81
- 1883 [189] Dormont L, Bessièrè J-M, McKey D and Cohuet A 2013 New methods for field
1884 collection of human skin volatiles and perspectives for their application in the
1885 chemical ecology of human–pathogen–vector interactions *J. Exp. Biol.* **216** 2783 LP
1886 – 2788
- 1887 [190] Dormont L, Bessièrè J-M and Cohuet A 2013 Human Skin Volatiles: A Review *J.*
1888 *Chem. Ecol.* **39** 569–78
- 1889 [191] Mochalski P, Wiesenhofer H, Allers M, Zimmermann S, Güntner A T, Pineau N J,
1890 Lederer W, Agapiou A, Mayhew C A and Ruzsanyi V 2018 Monitoring of selected
1891 skin- and breath-borne volatile organic compounds emitted from the human body
1892 using gas chromatography ion mobility spectrometry (GC-IMS) *J. Chromatogr. B*
1893 **1076** 29–34
- 1894 [192] Curran A M, Prada P A and Furton K G 2010 The Differentiation of the Volatile
1895 Organic Signatures of Individuals Through SPME-GC/MS of Characteristic Human
1896 Scent Compounds *J. Forensic Sci.* **55** 50–7
- 1897 [193] Mills G A and Walker V 2001 Headspace solid-phase microextraction profiling of
1898 volatile compounds in urine: Application to metabolic investigations *J. Chromatogr.*
1899 *B Biomed. Sci. Appl.* **753** 259–68
- 1900 [194] Smith S, Burden H, Persad R, Whittington K, De Lacy Costello B, Ratcliffe N M and
1901 Probert C S 2008 A comparative study of the analysis of human urine headspace
1902 using gas chromatography-mass spectrometry *J. Breath Res.* **2** 037022
- 1903 [195] Walker V and Mills G A 2001 Urine 4-heptanone: a β -oxidation product of 2-
1904 ethylhexanoic acid from plasticisers *Clin. Chim. Acta* **306** 51–61
- 1905 [196] Cozzolino R, De Giulio B, Marena P, Martignetti A, Günther K, Lauria F, Russo P,
1906 Stocchero M and Siani A 2017 Urinary volatile organic compounds in overweight

1907 compared to normal-weight children: results from the Italian I.Family cohort *Sci.*
1908 *Rep.* **7** 15636

1909 [197] Zou X, Lu Y, Xia L, Zhang Y, Li A, Wang H, Huang C, Shen C and Chu Y 2018 Detection
1910 of Volatile Organic Compounds in a Drop of Urine by Ultrasonic Nebulization
1911 Extraction Proton Transfer Reaction Mass Spectrometry *Anal. Chem.* **90** 2210–5

1912 [198] O’Lenick C R, Pleil J D, Stiegel M A, Sobus J R and Wallace M A G 2018 Detection and
1913 analysis of endogenous polar volatile organic compounds (PVOCs) in urine for
1914 human exposome research *Biomarkers* **24** 240–8

1915 [199] Penders J, Fiers T, Giri M, Wuyts B, Ysewyn L and Delanghe J R Quantitative
1916 measurement of ketone bodies in urine using reflectometry *Clin. Chem. Lab. Med.*
1917 **43** 724–9

1918 [200] Musa-Veloso K, Likhodii S S, Rarama E, Benoit S, Liu Y C, Chartrand D, Curtis R,
1919 Carmant L, Lortie A, Comeau F J E and Cunnane S C 2006 Breath acetone predicts
1920 plasma ketone bodies in children with epilepsy on a ketogenic diet *Nutrition* **22** 1–
1921 8

1922 [201] Musa-Veloso K, Likhodii S S and Cunnane S C 2002 Breath acetone is a reliable
1923 indicator of ketosis in adults consuming ketogenic meals *Am. J. Clin. Nutr.* **76** 65–
1924 70

1925 [202] Cozzolino R, De Magistris L, Saggese P, Stocchero M, Martignetti A, Di Stasio M,
1926 Malorni A, Marotta R, Boscaino F and Malorni L 2014 Use of solid-phase
1927 microextraction coupled to gas chromatography-mass spectrometry for
1928 determination of urinary volatile organic compounds in autistic children compared
1929 with healthy controls *Anal. Bioanal. Chem.* **406** 4649–62

1930 [203] Bone E, Tamm A and Hill M 1976 The production of urinary phenols by gut bacteria
1931 and their possible role in the causation of large bowel cancer *Am. J. Clin. Nutr.* **29**
1932 1448–54

1933 [204] Wahl H G, Hoffmann A, Luft D and Liebich H M 1999 Analysis of volatile organic
1934 compounds in human urine by headspace gas chromatography-mass
1935 spectrometry with a multipurpose sampler *J. Chromatogr. A* **847** 117–25

1936 [205] Mitchell S C and Zhang A Q 2001 Methylamine in human urine *Clin. Chim. Acta* **312**
1937 107–14

1938 [206] Zhang A Q, Mitchell S C and Smith R L 1995 Dimethylamine in human urine *Clin.*
1939 *Chim. Acta* **233** 81–8

- 1940 [207] Zhang A Q, Mitchell S C, Ayesch R and Smith R L 1992 Determination of
1941 trimethylamine and related aliphatic amines in human urine by head-space gas
1942 chromatography *J. Chromatogr. B Biomed. Sci. Appl.* **584** 141–5
- 1943 [208] Wagenstaller M and Buettner A 2013 Characterization of odorants in human urine
1944 using a combined chemo-analytical and human-sensory approach: a potential
1945 diagnostic strategy *Metabolomics* **9** 9–20
- 1946 [209] E R 1861 Beiträge zur Kenntnis der Darmgase *Sitzungsber Kaiserl Akad* **44** 738–62
- 1947 [210] Gibson G R, Macfarlane G T and Cummings J H 1993 Sulphate reducing bacteria
1948 and hydrogen metabolism in the human large intestine. *Gut* **34** 437 LP – 439
- 1949 [211] Cummings J H 1981 Short chain fatty acids in the human colon. *Gut* **22** 763 LP –
1950 779
- 1951 [212] Yokoyama M T and Carlson J R 1979 Microbial metabolites of tryptophan in the
1952 intestinal tract with special reference to skatole *Am. J. Clin. Nutr.* **32** 173–8
- 1953 [213] Gostner A, Blaut M, Schäffer V, Kozianowski G, Theis S, Klingenberg M, Dombrowski
1954 Y, Martin D, Ehrhardt S, Taras D, Schwiertz A, Kleessen B, Lühns H, Schaubert J,
1955 Dorbath D, Menzel T and Scheppach W 2006 Effect of isomalt consumption on
1956 faecal microflora and colonic metabolism in healthy volunteers *Br. J. Nutr.* **95** 40–
1957 50
- 1958 [214] Bäckhed F, Ley R E, Sonnenburg J L, Peterson D A and Gordon J I 2005 Host-
1959 Bacterial Mutualism in the Human Intestine *Science (80-.)*. **307** 1915 LP – 1920
- 1960 [215] Mortensen P B and Clausen M R 1996 Short-Chain Fatty Acids in the Human Colon:
1961 Relation to Gastrointestinal Health and Disease *Scand. J. Gastroenterol.* **31** 132–48
- 1962 [216] Gould O, de Lacy Costello B, Smart A, Jones P, Macmaster A, Ransley K and Ratcliffe
1963 N 2018 Gas Chromatography Mass Spectrometry (GC-MS) Quantification of
1964 Metabolites in Stool Using (13)C Labelled Compounds *Metabolites* **8** 75
- 1965 [217] Song E M, Byeon J-S, Lee S M, Yoo H J, Kim S J, Lee S-H, Chang K, Hwang S W, Yang
1966 D-H and Jeong J-Y 2018 Fecal Fatty Acid Profiling as a Potential New Screening
1967 Biomarker in Patients with Colorectal Cancer *Dig. Dis. Sci.* **63** 1229–36
- 1968 [218] Rice H B and Ismail A 2016 Chapter 6 - Fish Oils in Human Nutrition: History and
1969 Current Status ed S K Raatz and D M B T-F and F O in H and D P Bibus (San Diego:
1970 Academic Press) pp 75–84
- 1971 [219] Smith E A and Macfarlane G T 1997 Dissimilatory Amino Acid Metabolism in
1972 Human Colonic Bacteria *Anaerobe* **3** 327–37

- 1973 [220] Pitcher M C L, Beatty E R and Cummings J H 2000 The contribution of sulphate
1974 reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with
1975 ulcerative colitis *Gut* **46** 64 LP – 72
- 1976 [221] Olsen I and Yamazaki K 2019 Can oral bacteria affect the microbiome of the gut? *J.*
1977 *Oral Microbiol.* **11** 1586422
- 1978 [222] De Preter V, Van Staeyen G, Esser D, Rutgeerts P and Verbeke K 2009 Development
1979 of a screening method to determine the pattern of fermentation metabolites in
1980 faecal samples using on-line purge-and-trap gas chromatographic–mass
1981 spectrometric analysis *J. Chromatogr. A* **1216** 1476–83
- 1982 [223] Dixon E, Clubb C, Pittman S, Ammann L, Rasheed Z, Kazmi N, Keshavarzian A,
1983 Gillevet P, Rangwala H and Couch R D 2011 Solid-Phase Microextraction and the
1984 Human Fecal VOC Metabolome *PLoS One* **6** e18471
- 1985 [224] Lington A W and Bevan C 1994 Alcohols *Patty's Industrial Hygiene and Toxicology*
1986 ed G D Clayton pp 2585–2760
- 1987 [225] Seitz H K, Matsuzaki S, Yokoyama A, Homann N, Väkeväinen S and Wang X D 2001
1988 Alcohol and Cancer *Alcohol. Clin. Exp. Res.* **25** 137S-143S
- 1989 [226] Väkeväinen S, Tillonen J, Agarwal D P, Srivastava N and Salaspuro M 2000 High
1990 Salivary Acetaldehyde After a Moderate Dose of Alcohol in ALDH2-Deficient
1991 Subjects: Strong Evidence for the Local Carcinogenic Action of Acetaldehyde
1992 *Alcohol. Clin. Exp. Res.* **24** 873–7
- 1993 [227] Homann N 2001 Alcohol and upper gastrointestinal tract cancer: the role of local
1994 acetaldehyde production *Addict. Biol.* **6** 309–23
- 1995 [228] Décombaz J, Arnaud M-J, Milon H, Moesch H, Philipposian G, Thélin A-L and
1996 Howald H 1983 Energy metabolism of medium-chain triglycerides versus
1997 carbohydrates during exercise *Eur. J. Appl. Physiol. Occup. Physiol.* **52** 9–14
- 1998 [229] Ott A, Germond J-E and Chaintreau A 2000 Vicinal Diketone Formation in Yogurt:
1999 ¹³C Precursors and Effect of Branched-Chain Amino Acids *J. Agric. Food Chem.* **48**
2000 724–31
- 2001 [230] Salerno-Kennedy R and Cashman K D 2005 Potential applications of breath
2002 isoprene as a biomarker in modern medicine: a concise overview *Wien. Klin.*
2003 *Wochenschr.* **117** 180–6
- 2004 [231] Deneris E S, Stein R A and Mead J F 1985 Acid-catalyzed formation of isoprene from
2005 a mevalonate-derived product using a rat liver cytosolic fraction *J. Biol. Chem.* **260**

- 2006 1382–5
- 2007 [232] Kjeldsen F, Christensen L P and Edelenbos M 2003 Changes in Volatile Compounds
2008 of Carrots (*Daucus carota* L.) During Refrigerated and Frozen Storage *J. Agric. Food*
2009 *Chem.* **51** 5400–7
- 2010 [233] Tomlin J, Lowis C and Read N W 1991 Investigation of normal flatus production in
2011 healthy volunteers. *Gut* **32** 665 LP – 669
- 2012 [234] De Lacy Costello B P J, Evans P, Ewen R J, Gunson H E, Jones P R H, Ratcliffe N M
2013 and Spencer-Phillips P T N 2001 Gas chromatography–mass spectrometry analyses
2014 of volatile organic compounds from potato tubers inoculated with *Phytophthora*
2015 *infestans* or *Fusarium coeruleum* *Plant Pathol.* **50** 489–96
- 2016 [235] Anon 2002 Final Report on the Safety Assessment of Ethoxyethanol and
2017 Ethoxyethanol Acetate *Int. J. Toxicol.* **21** 9–62
- 2018 [236] Alloway B J and Ayres D C 1998 Chemical Principles of Environmental Pollution,
2019 B.J. Alloway and D.C. Ayres *Water. Air. Soil Pollut.* **102** 216–8
- 2020 [237] Herren-Freund S L and Pereira M A 1986 Carcinogenicity of by-products of
2021 disinfection in mouse and rat liver. *Environ. Health Perspect.* **69** 59–65
- 2022 [238] Weisiger R A, Pinkus L M and Jakoby W B 1980 Thiol S-methyltransferase:
2023 suggested role in detoxication of intestinal hydrogen sulfide *Biochem. Pharmacol.*
2024 **29** 2885–7
- 2025 [239] Suarez F, Furne J, Springfield J and Levitt M 1997 Insights into human colonic
2026 physiology obtained from the study of flatus composition *Am. J. Physiol. Liver*
2027 *Physiol.* **272** G1028–33
- 2028 [240] Moore J G, Jessop L D and Osborne D N 1987 Gas-chromatographic and mass-
2029 spectrometric analysis of the odor of human feces *Gastroenterology* **93** 1321–9
- 2030 [241] Longo V, Forleo A, Provenzano S P, Coppola L, Zara V, Ferramosca A, Siciliano P
2031 and Capone S 2018 HS-SPME-GC-MS metabolomics approach for sperm quality
2032 evaluation by semen volatile organic compounds (VOCs) analysis *Biomed. Phys.*
2033 *Eng. Express* **5** 15006
- 2034 [242] Mumcu A, Karaer A, Dogan B and Tuncay G 2020 Metabolomics analysis of seminal
2035 plasma in patients with idiopathic Oligoasthenoteratozoospermia using high-
2036 resolution NMR spectroscopy *Andrology* **8** 450–6
- 2037 [243] Murgia F, Corda V, Serrenti M, Usai V, Santoru M L, Hurt K J, Passaretti M, Monni M
2038 C, Atzori L and Monni G 2020 Seminal Fluid Metabolomic Markers of

2039 Oligozoospermic Infertility in Humans *Metabolites* **10** 64
2040 [244] Xu Y, Lu H, Wang Y, Zhang Z and Wu Q 2020 Comprehensive metabolic profiles of
2041 seminal plasma with different forms of male infertility and their correlation with
2042 sperm parameters *J. Pharm. Biomed. Anal.* **177** 112888
2043 [245] Khan A U, Mei Y H and Wilson T 1992 A proposed function for spermine and
2044 spermidine: protection of replicating DNA against damage by singlet oxygen *Proc.*
2045 *Natl. Acad. Sci. U. S. A.* **89** 11426–7
2046 [246] Wishart D S, Feunang Y D, Marcu A, Guo A C, Liang K, Vázquez-Fresno R, Sajed T,
2047 Johnson D, Li C, Karu N, Sayeeda Z, Lo E, Assempour N, Berjanskii M, Singhal S,
2048 Arndt D, Liang Y, Badran H, Grant J, Serra-Cayuela A, Liu Y, Mandal R, Neveu V, Pon
2049 A, Knox C, Wilson M, Manach C and Scalbert A 2018 HMDB 4.0: the human
2050 metabolome database for 2018 *Nucleic Acids Res.* **46** D608–17
2051

2052 **References included in the Tables, but not included in the manuscript:**

2053 [247] Ahmed I, Greenwood R, Costello B, Ratcliffe N and Probert C S 2016 Investigation
2054 of faecal volatile organic metabolites as novel diagnostic biomarkers in
2055 inflammatory bowel disease *Aliment. Pharmacol. Ther.* **43** 596–611
2056 [248] Gould O, Wiczorek T, de Lacy Costello B, Persad R and Ratcliffe N 2018 Assessment
2057 of a combined gas chromatography mass spectrometer sensor system for
2058 detecting biologically relevant volatile compounds *J. Breath Res.* **12** 16009
2059 [249] Wang X, Wang J, Rao B and Deng L 2017 Gut flora profiling and fecal metabolite
2060 composition of colorectal cancer patients and healthy individuals *Exp. Ther. Med.*
2061 **13** 2848–54
2062 [250] Silva C L, Passos M and Cmara J S 2011 Investigation of urinary volatile organic
2063 metabolites as potential cancer biomarkers by solid-phase microextraction in
2064 combination with gas chromatography-mass spectrometry *Br. J. Cancer* **105**
2065 1894–904
2066 [251] Hanai Y, Shimono K, Matsumura K, Vachani A, Albelda S, YAMAZAKI K, Beauchamp
2067 G K and Oka H 2012 Urinary Volatile Compounds as Biomarkers for Lung Cancer
2068 *Biosci. Biotechnol. Biochem.* **76** 679–84
2069 [252] Huang J, Kumar S, Abbassi-Ghadi N, Španěl P, Smith D and Hanna G B 2013 Selected
2070 Ion Flow Tube Mass Spectrometry Analysis of Volatile Metabolites in Urine
2071 Headspace for the Profiling of Gastro-Esophageal Cancer *Anal. Chem.* **85** 3409–16

- 2072 [253] Zhang S and Raftery D 2014 Headspace SPME-GC-MS Metabolomics Analysis of
2073 Urinary Volatile Organic Compounds (VOCs) BT - Mass Spectrometry in
2074 Metabolomics: Methods and Protocols ed D Raftery (New York, NY: Springer New
2075 York) pp 265–72
- 2076 [254] Bouatra S, Aziat F, Mandal R, Guo A C, Wilson M R, Knox C, Bjorndahl T C,
2077 Krishnamurthy R, Saleem F, Liu P, Dame Z T, Poelzer J, Huynh J, Yallou F S,
2078 Psychogios N, Dong E, Bogumil R, Roehring C and Wishart D S 2013 The Human
2079 Urine Metabolome *PLoS One* **8(9)** e73076
- 2080 [255] Zlatkis A, Lichtenstein H A and Tishbee A 1973 Concentration and analysis of trace
2081 volatile organics in gases and biological fluids with a new solid adsorbent
2082 *Chromatographia* **6** 67–70
- 2083 [256] Zlatkis A, Brazell R S and Poole C F 1981 The role of organic volatile profiles in
2084 clinical diagnosis. *Clin. Chem.* **27** 789–97
- 2085 [257] Wahl H G, Hoffmann A, Luft D and Liebich H M 1999 Analysis of volatile organic
2086 compounds in human urine by headspace gas chromatography–mass
2087 spectrometry with a multipurpose sampler *J. Chromatogr. A* **847** 117–25
- 2088 [258] Guernion N, Ratcliffe N M, Spencer-Phillips P T N and Howe R A 2001 Identifying
2089 bacteria in human urine: Current practice and the potential for rapid, near-patient
2090 diagnosis by sensing volatile organic compounds *Clin. Chem. Lab. Med.* **39** 893–906
- 2091 [259] Buszewski B, Ligor T, Jezierski T, Wenda-Piesik A, Walczak M and Rudnicka J 2012
2092 Identification of volatile lung cancer markers by gas chromatography-mass
2093 spectrometry: comparison with discrimination by canines *Anal. Bioanal. Chem.*
2094 **404** 141–6
- 2095 [260] Phillips C O, Syed Y, Parthaláin N Mac, Zwiiggelaar R, Claypole T C and Lewis K E
2096 2012 Machine learning methods on exhaled volatile organic compounds for
2097 distinguishing COPD patients from healthy controls *J. Breath Res.* **6** 36003
- 2098 [261] Altomare D F, Di Lena M, Porcelli F, Trizio L, Travaglio E, Tutino M, Dragonieri S,
2099 Memeo V and de Gennaro G 2013 Exhaled volatile organic compounds identify
2100 patients with colorectal cancer *BJS (British J. Surgery)* **100** 144–50
- 2101 [262] Baranska A, Tigchelaar E, Smolinska A, Dallinga J W, Moonen E J C, Dekens J A M,
2102 Wijmenga C, Zhernakova A and Van Schooten F J 2013 Profile of volatile organic
2103 compounds in exhaled breath changes as a result of gluten-free diet *J. Breath Res.*
2104 **7** 037104

- 2105 [263] Ghimenti S, Tabucchi S, Lomonaco T, Di Francesco F, Fuoco R, Onor M, Lenzi S and
2106 Trivella M G 2013 Monitoring breath during oral glucose tolerance tests *J. Breath*
2107 *Res.* **7** 17115
- 2108 [264] Grabowska-Polanowska B, Faber J, Skowron M, Miarka P, Pietrzycka A, Śliwka I and
2109 Amann A 2013 Detection of potential chronic kidney disease markers in breath
2110 using gas chromatography with mass-spectral detection coupled with thermal
2111 desorption method *J. Chromatogr. A* **1301** 179–89
- 2112 [265] Phillips M, Cataneo R N, Chaturvedi A, Kaplan P D, Libardoni M, Mundada M, Patel
2113 U and Zhang X 2013 Detection of an extended human volatome with
2114 comprehensive two-dimensional gas chromatography time-of-flight mass
2115 spectrometry *PLoS One* **8** e75274–e75274
- 2116 [266] Scott-Thomas A, Syhre M, Epton M, Murdoch D R and Chambers S T 2013
2117 Assessment of potential causes of falsely positive Mycobacterium tuberculosis
2118 breath test *Tuberculosis* **93** 312–7
- 2119 [267] Turner M A, Bandelow S, Edwards L, Patel P, Martin H J, Wilson I D and Thomas C L
2120 P 2013 The effect of a paced auditory serial addition test (PASAT) intervention on
2121 the profile of volatile organic compounds in human breath: a pilot study *J. Breath*
2122 *Res.* **7** 17102
- 2123 [268] Aprea E, Cappellin L, Gasperi F, Morisco F, Lembo V, Rispo A, Tortora R, Vitaglione
2124 P, Caporaso N and Biasioli F 2014 Application of PTR-TOF-MS to investigate
2125 metabolites in exhaled breath of patients affected by coeliac disease under gluten
2126 free diet *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **966** 208–13
- 2127 [269] Assady S, Marom O, Hemli M, Ionescu R, Jeries R, Tisch U, Abassi Z and Haick H 2013
2128 Impact of hemodialysis on exhaled volatile organic compounds in end-stage renal
2129 disease: a pilot study *Nanomedicine* **9** 1035–45
- 2130 [270] Biesterbos J W H, Beckmann G, Anzion R B M, Ragas A M J, Russel F G M and
2131 Scheepers P T J 2014 Sensitive Method for Quantification of
2132 Octamethylcyclotetrasiloxane (D4) and Decamethylcyclopentasiloxane (D5) in
2133 End-Exhaled Air by Thermal Desorption Gas Chromatography Mass Spectrometry
2134 *Anal. Chem.* **86** 5794–9
- 2135 [271] Bousamra M, Schumer E, Li M, Knipp R J, Nantz M H, van Berkel V and Fu X-A 2014
2136 Quantitative analysis of exhaled carbonyl compounds distinguishes benign from
2137 malignant pulmonary disease *J. Thorac. Cardiovasc. Surg.* **148** 1074–81

- 2138 [272] Bregy L, Sinues P M-L, Nudnova M M and Zenobi R 2014 Real-time breath analysis
2139 with active capillary plasma ionization-ambient mass spectrometry *J. Breath Res.*
2140 **8** 27102
- 2141 [273] Cikach Jr F S, Tonelli A R, Barnes J, Paschke K, Newman J, Grove D, Dababneh L,
2142 Wang S and Dweik R A 2014 Breath analysis in pulmonary arterial hypertension
2143 *Chest* **145** 551–8
- 2144 [274] Das M K, Bishwal S C, Das A, Dabral D, Varshney A, Badireddy V K and Nanda R 2014
2145 Investigation of Gender-Specific Exhaled Breath Volatome in Humans by GCxGC-
2146 TOF-MS *Anal. Chem.* **86** 1229–37
- 2147 [275] Filipiak W, Filipiak A, Sponring A, Schmid T, Zelger B, Ager C, Klodzinska E, Denz H,
2148 Pizzini A, Lucciarini P, Jamnig H, Troppmair J and Amann A 2014 Comparative
2149 analyses of volatile organic compounds (VOCs) from patients, tumors and
2150 transformed cell lines for the validation of lung cancer-derived breath markers *J.*
2151 *Breath Res.* **8** 27111
- 2152 [276] Fu X-A, Li M, Knipp R J, Nantz M H and Bousamra M 2014 Noninvasive detection of
2153 lung cancer using exhaled breath *Cancer Med.* **3** 174–81
- 2154 [277] Gruber M, Tisch U, Jeries R, Amal H, Hakim M, Ronen O, Marshak T, Zimmerman D,
2155 Israel O, Amiga E, Doweck I and Haick H 2014 Analysis of exhaled breath for
2156 diagnosing head and neck squamous cell carcinoma: a feasibility study *Br. J. Cancer*
2157 **111** 790–8
- 2158 [278] Hanouneh I A, Zein N N, Cikach F, Dababneh L, Grove D, Alkhouri N, Lopez R and
2159 Dweik R A 2014 The breathprints in patients with liver disease identify novel
2160 breath biomarkers in alcoholic hepatitis *Clin. Gastroenterol. Hepatol.* **12** 516–23
- 2161 [279] Huang J, Kumar S and Hanna G B 2014 Investigation of C3–C10 aldehydes in the
2162 exhaled breath of healthy subjects using selected ion flow tube-mass spectrometry
2163 (SIFT-MS) *J. Breath Res.* **8** 37104
- 2164 [280] Li J, Peng Y, Liu Y, Li W, Jin Y, Tang Z and Duan Y 2014 Investigation of potential
2165 breath biomarkers for the early diagnosis of breast cancer using gas
2166 chromatography–mass spectrometry *Clin. Chim. Acta* **436** 59–67
- 2167 [281]. Martinez-Lozano Sinues P, Tarokh L, Li X, Kohler M, Brown S A, Zenobi R and
2168 Dallmann R 2015 Circadian Variation of the Human Metabolome Captured by
2169 Real-Time Breath Analysis *PLoS One* **9** e114422

- 2170 [282] Meyer N, Dallinga J W, Nuss S J, Moonen E J C, van Berkel J J B N, Akdis C, van
2171 Schooten F J and Menz G 2014 Defining adult asthma endotypes by clinical features
2172 and patterns of volatile organic compounds in exhaled air *Respir. Res.* **15** 136
- 2173 [283] Munch R and Barringer S A 2014 Deodorization of Garlic Breath Volatiles by Food
2174 and Food Components *J. Food Sci.* **79** C526–33
- 2175 [284] Patel N, Alkhoury N, Eng K, Cikach F, Mahajan L, Yan C, Grove D, Rome E S, Lopez R
2176 and Dweik R A 2014 Metabolomic analysis of breath volatile organic compounds
2177 reveals unique breathprints in children with inflammatory bowel disease: A pilot
2178 study *Aliment. Pharmacol. Ther.* **40** 498–507
- 2179 [285] Pleil J D, Stiegel M A and Fent K W 2014 Exploratory breath analyses for assessing
2180 toxic dermal exposures of firefighters during suppression of structural burns *J.*
2181 *Breath Res.* **8** 37107
- 2182 [286] Reynolds J C, Jimoh M A, Guallar-Hoyas C, Creaser C S, Siddiqui S and Paul Thomas
2183 C L 2014 Analysis of human breath samples using a modified thermal desorption:
2184 gas chromatography electrospray ionization interface *J. Breath Res.* **8** 37105
- 2185 [287] Smolinska A, Klaassen E M M, Dallinga J W, van de Kant K D G, Jobsis Q, Moonen E J
2186 C, van Schayck O C P, Dompeling E and van Schooten F J 2014 Profiling of volatile
2187 organic compounds in exhaled breath as a strategy to find early predictive
2188 signatures of asthma in children *PLoS One* **9** e95668–e95668
- 2189 [288] Ueta I, Samsudin E L, Mizuguchi A, Takeuchi H, Shinki T, Kawakubo S and Saito Y
2190 2014 Double-bed-type extraction needle packed with activated-carbon-based
2191 sorbents for very volatile organic compounds *J. Pharm. Biomed. Anal.* **88** 423–8
- 2192 [289] van Ooij P J A M, van Hulst R A, Kulik W, Brinkman P, Houtkooper A and Sterk P J
2193 2014 Hyperbaric oxygen diving affects exhaled molecular profiles in men *Respir.*
2194 *Physiol. Neurobiol.* **198** 20–4
- 2195 [290] Walton C, Patel M, Pitts D, Knight P, Hoashi S, Evans M and Turner C 2014 The use
2196 of a portable breath analysis device in monitoring type 1 diabetes patients in a
2197 hypoglycaemic clamp: validation with SIFT-MS data *J. Breath Res.* **8** 37108
- 2198 [291] Wang C, Ke C, Wang X, Chi C, Guo L, Luo S, Guo Z, Xu G, Zhang F and Li E 2014
2199 Noninvasive detection of colorectal cancer by analysis of exhaled breath *Anal.*
2200 *Bioanal. Chem.* **406** 4757–63

- 2201 [292] Zou Y, Zhang X, Chen X, Hu Y, Ying K and Wang P 2014 Optimization of volatile
2202 markers of lung cancer to exclude interferences of non-malignant disease *Cancer*
2203 *Biomarkers* **14** 371–9
- 2204 [293] Alkhouri N, Eng K, Cikach F, Patel N, Yan C, Brindle A, Rome E, Hanouneh I, Grove
2205 D, Lopez R, Hazen S L and Dweik R A 2015 Breathprints of childhood obesity:
2206 changes in volatile organic compounds in obese children compared with lean
2207 controls *Pediatr. Obes.* **10** 23–9
- 2208 [294] Altomare D F, Di Lena M, Porcelli F, Travaglio E, Longobardi F, Tutino M, Depalma
2209 N, Tedesco G, Sardaro A, Memeo R and de Gennaro G 2015 Effects of Curative
2210 Colorectal Cancer Surgery on Exhaled Volatile Organic Compounds and Potential
2211 Implications in Clinical Follow-up *Ann. Surg.* **262** 862-867
- 2212 [295] Amal H, Shi D-Y, Ionescu R, Zhang W, Hua Q-L, Pan Y-Y, Tao L, Liu H and Haick H
2213 2015 Assessment of ovarian cancer conditions from exhaled breath *Int. J. Cancer*
2214 **136** E614–22
- 2215 [296] Barash O, Zhang W, Halpern J M, Hua Q-L, Pan Y-Y, Kayal H, Khoury K, Liu H, Davies
2216 M P A and Haick H 2015 Differentiation between genetic mutations of breast
2217 cancer by breath volatolomics *Oncotarget* **6** 44864–76
- 2218 [297] Biesterbos J W H, Beckmann G, van Wel L, Anzion R B M, von Goetz N, Dudzina T,
2219 Roeleveld N, Ragas A M J, Russel F G M and Scheepers P T J 2015 Aggregate dermal
2220 exposure to cyclic siloxanes in personal care products: Implications for risk
2221 assessment *Environ. Int.* **74** 231–9
- 2222 [298] Bodelier A G L, Smolinska A, Baranska A, Dallinga J W, Mujagic Z, Vanhees K, van
2223 den Heuvel T, Masclee A A M, Jonkers D, Pierik M J and van Schooten F J 2015
2224 Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity
2225 in Crohn’s Disease: A Metabolomic Approach *Inflamm. Bowel Dis.* **21** 1776–85
- 2226 [299] Dolch M E, Choukèr A, Hornuss C, Frey L, Irlbeck M, Praun S, Leidlmair C, Villinger
2227 J and Schelling G 2015 Quantification of propionaldehyde in breath of patients
2228 after lung transplantation *Free Radic. Biol. Med.* **85** 157–64
- 2229 [300] Dragonieri S, Porcelli F, Longobardi F, Carratù P, Aliani M, Ventura V A, Tutino M,
2230 Quaranta V N, Resta O and de Gennaro G 2015 An electronic nose in the
2231 discrimination of obese patients with and without obstructive sleep apnoea *J.*
2232 *Breath Res.* **9** 26005

- 2233 [301] Eng K, Alkhoury N, Cikach F, Patel N, Yan C, Grove D, Lopez R, Rome E and Dweik R
2234 A 2015 Analysis of breath volatile organic compounds in children with chronic
2235 liver disease compared to healthy controls *J. Breath Res.* **9** 26002
- 2236 [302] Fent K W, Evans D E, Booher D, Pleil J D, Stiegel M A, Horn G P and Dalton J 2015
2237 Volatile Organic Compounds Off-gassing from Firefighters' Personal Protective
2238 Equipment Ensembles after Use *J. Occup. Environ. Hyg.* **12** 404–14
- 2239 [303] Fernández Del Río R, O'Hara M E, Holt A, Pemberton P, Shah T, Whitehouse T and
2240 Mayhew C A 2015 Volatile Biomarkers in Breath Associated With Liver Cirrhosis -
2241 Comparisons of Pre- and Post-liver Transplant Breath Samples *EBioMedicine* **2**
2242 1243–50
- 2243 [304] Guo L, Wang C, Chi C, Wang X, Liu S, Zhao W, Ke C, Xu G and Li E 2015 Exhaled breath
2244 volatile biomarker analysis for thyroid cancer *Transl. Res.* **166** 188–95
- 2245 [305] Harshman S W, Geier B A, Fan M, Rinehardt S, Watts B S, Drummond L A, Preti G,
2246 Phillips J B, Ott D K and Grigsby C C 2015 The identification of hypoxia biomarkers
2247 from exhaled breath under normobaric conditions *J. Breath Res.* **9** 47103
- 2248 [306] Hengerics Szabó A, Podolec P, Ferenczy V, Kubinec R, Blaško J, Soják L, Górová R,
2249 Addová G, Ostrovský I, Višňovský J, Bierhanzl V, Čabala R and Amann A 2015 The
2250 analysis of linear and monomethylalkanes in exhaled breath samples by GC×GC-
2251 FID and GC–MS/MS *J. Chromatogr. B* **978–979** 62–9
- 2252 [307] Hicks L C, Huang J, Kumar S, Powles S T, Orchard T R, Hanna G B and Williams H R
2253 T 2015 Analysis of Exhaled Breath Volatile Organic Compounds in Inflammatory
2254 Bowel Disease: A Pilot Study *J. Crohns. Colitis* **9** 731–7
- 2255 [308] Kleeblatt J, Schubert J K and Zimmermann R 2015 Detection of Gaseous Compounds
2256 by Needle Trap Sampling and Direct Thermal-Desorption Photoionization Mass
2257 Spectrometry: Concept and Demonstrative Application to Breath Gas Analysis
2258 *Anal. Chem.* **87** 1773–81
- 2259 [309] Kumar S, Huang J, Abbassi-Ghadi N, Mackenzie H A, Veselkov K A, Hoare J M, Lovat
2260 L B, Španel P, Smith D and Hanna G B 2015 Mass Spectrometric Analysis of Exhaled
2261 Breath for the Identification of Volatile Organic Compound Biomarkers in
2262 Esophageal and Gastric Adenocarcinoma *Ann. Surg.* **262** 981-90
- 2263 [310] Li M, Yang D, Brock G, Knipp R J, Bousamra M, Nantz M H and Fu X-A 2015 Breath
2264 carbonyl compounds as biomarkers of lung cancer *Lung Cancer* **90** 92–7

- 2265 [311] Ligor T, Pater Ł and Buszewski B 2015 Application of an artificial neural network
2266 model for selection of potential lung cancer biomarkers *J. Breath Res.* **9** 27106
- 2267 [312] Rydosz A 2015 A Negative Correlation Between Blood Glucose and Acetone
2268 Measured in Healthy and Type 1 Diabetes Mellitus Patient Breath *J. Diabetes Sci.*
2269 *Technol.* **9** 881–4
- 2270 [313] Schumer E M, Trivedi J R, van Berkel V, Black M C, Li M, Fu X-A and Bousamra II M
2271 2015 High sensitivity for lung cancer detection using analysis of exhaled carbonyl
2272 compounds *J. Thorac. Cardiovasc. Surg.* **150** 1517–24
- 2273 [314] Španěl P, Dryahina K, Vicherková P and Smith D 2015 Increase of methanol in
2274 exhaled breath quantified by SIFT-MS following aspartame ingestion *J. Breath Res.*
2275 **9** 47104
- 2276 [315] Spesyvyi A, Smith D and Španěl P 2015 Selected Ion Flow-Drift Tube Mass
2277 Spectrometry: Quantification of Volatile Compounds in Air and Breath *Anal. Chem.*
2278 **87** 12151–60
- 2279 [316] Sukul P, Trefz P, Kamysek S, Schubert J K and Miekisch W 2015 Instant effects of
2280 changing body positions on compositions of exhaled breath *J. Breath Res.* **9** 47105
- 2281 [317] Allafchian A R, Majidian Z, Ielbeigi V and Tabrizchi M 2016 A novel method for the
2282 determination of three volatile organic compounds in exhaled breath by solid-
2283 phase microextraction–ion mobility spectrometry *Anal. Bioanal. Chem.* **408** 839–
2284 47
- 2285 [318] Amal H, Leja M, Funka K, Lasina I, Skapars R, Sivins A, Ancans G, Kikuste I, Vanags
2286 A, Tolmanis I, Kirsners A, Kupcinskis L and Haick H 2016 Breath testing as
2287 potential colorectal cancer screening tool *Int. J. Cancer* **138** 229–36
- 2288 [319] Bayrakli I, Öztürk Ö and Akman H 2016 Investigation of acetone, butanol and
2289 carbon dioxide as new breath biomarkers for convenient and noninvasive
2290 diagnosis of obstructive sleep apnea syndrome *Biomed. Chromatogr.* **30** 1890–9
- 2291 [320] Chen Y, Zhang Y, Pan F, Liu J, Wang K, Zhang C, Cheng S, Lu L, Zhang W, Zhang Z, Zhi
2292 X, Zhang Q, Alfranca G, de la Fuente J M, Chen D and Cui D 2016 Breath Analysis
2293 Based on Surface-Enhanced Raman Scattering Sensors Distinguishes Early and
2294 Advanced Gastric Cancer Patients from Healthy Persons *ACS Nano* **10** 8169–79
- 2295 [321] Gruber B, Keller S, Groeger T, Matuschek G, Szymczak W and Zimmermann R 2016
2296 Breath gas monitoring during a glucose challenge by a combined PTR-

2297 QMS/GC×GC-TOFMS approach for the verification of potential volatile biomarkers
2298 *J. Breath Res.* **10** 36003

2299 [322] Harshman S W, Mani N, Geier B A, Kwak J, Shepard P, Fan M, Sudberry G L, Mayes R
2300 S, Ott D K, Martin J A and Grigsby C C 2016 Storage stability of exhaled breath on
2301 Tenax TA *J. Breath Res.* **10** 46008

2302 [323] Huang Z, Zhang Y, Yan Q, Zhang Z and Wang X 2016 Real-time monitoring of
2303 respiratory absorption factors of volatile organic compounds in ambient air by
2304 proton transfer reaction time-of-flight mass spectrometry *J. Hazard. Mater.* **320**
2305 547–55

2306 [324] Jalali M, Zare Sakhvidi M J, Bahrami A, Berijani N and Mahjub H 2016 Oxidative
2307 Stress Biomarkers in Exhaled Breath of Workers Exposed to Crystalline Silica Dust
2308 by SPME-GC-MS *J. Res. Health Sci.* **16** 153–61

2309 [325] Jiang J, Wang Y, Hou K, Hua L, Chen P, Liu W, Xie Y and Li H 2016 Photoionization-
2310 Generated Dibromomethane Cation Chemical Ionization Source for Time-of-Flight
2311 Mass Spectrometry and Its Application on Sensitive Detection of Volatile Sulfur
2312 Compounds *Anal. Chem.* **88** 5028–32

2313 [326] Kang S and Paul Thomas C L 2016 How long may a breath sample be stored for
2314 at $-80\text{ }^{\circ}\text{C}$? A study of the stability of volatile organic compounds trapped onto a
2315 mixed Tenax:Carbograph trap adsorbent bed from exhaled breath *J. Breath Res.* **10**
2316 26011

2317 [327] Mirondo R and Barringer S 2016 Deodorization of Garlic Breath by Foods, and the
2318 Role of Polyphenol Oxidase and Phenolic Compounds *J. Food Sci.* **81** C2425–30

2319 [328] O'Hara M E, Fernández Del Río R, Holt A, Pemberton P, Shah T, Whitehouse T and
2320 Mayhew C A 2016 Limonene in exhaled breath is elevated in hepatic
2321 encephalopathy *J. Breath Res.* **10** 46010

2322 [329] Raninen K J, Lappi J E, Mukkala M L, Tuomainen T-P, Mykkänen H M, Poutanen K S
2323 and Raatikainen O J 2016 Fiber content of diet affects exhaled breath volatiles in
2324 fasting and postprandial state in a pilot crossover study *Nutr. Res.* **36** 612–9

2325 [330] Rieder F, Kurada S, Grove D, Cikach F, Lopez R, Patel N, Singh A, Alkhoury N, Shen B,
2326 Brzezinski A, Baker M, Fiocchi C and Dweik R A 2016 A Distinct Colon-Derived
2327 Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its
2328 Complications *Clin. Transl. Gastroenterol.* **7** e201–e201

- 2329 [331] Sánchez-López J A, Ziere A, Martins S I F S, Zimmermann R and Yeretdzian C 2016
2330 Persistence of aroma volatiles in the oral and nasal cavities: real-time monitoring
2331 of decay rate in air exhaled through the nose and mouth *J. Breath Res.* **10** 36005
- 2332 [332] Schallschmidt K, Becker R, Jung C, Bremser W, Walles T, Neudecker J, Leschber G,
2333 Frese S and Nehls I 2016 Comparison of volatile organic compounds from lung
2334 cancer patients and healthy controls—challenges and limitations of an
2335 observational study *J. Breath Res.* **10** 46007
- 2336 [333] Schönermarck U, Dengler C, Gmeinwieser A, Praun S, Schelling G, Fischereder M,
2337 Boulesteix A-L, and Dolch M E 2016 Exhaled breath volatile organic and inorganic
2338 compound composition in end-stage renal disease *Clin. Nephrol.* **86** 132-140
- 2339 [334] Schumer E M, Black M C, Bousamra 2nd M, Trivedi J R, Li M, Fu X-A and van Berkel
2340 V 2016 Normalization of Exhaled Carbonyl Compounds After Lung Cancer
2341 Resection *Ann. Thorac. Surg.* **102** 1095–100
- 2342 [335] Sukul P, Schubert J K, Oertel P, Kamysek S, Taunk K, Trefz P and Miekisch W 2016
2343 FEV manoeuvre induced changes in breath VOC compositions: an unconventional
2344 view on lung function tests *Sci. Rep.* **6** 28029
- 2345 [336] van Mastrigt E, Reyes-Reyes A, Brand K, Bhattacharya N, Urbach H P, Stubbs A P, de
2346 Jongste J C and Pijnenburg M W 2016 Exhaled breath profiling using broadband
2347 quantum cascade laser-based spectroscopy in healthy children and children with
2348 asthma and cystic fibrosis *J. Breath Res.* **10** 26003
- 2349 [337] Walton C, Montoya M P B, Fowler D P, Turner C, Jia W, Whitehead R N, Griffiths L,
2350 Waring R H, Ramsden D B, Cole J A, Cauchi M, Bessant C, Naylor S J and Hunter J O
2351 2016 Enteral feeding reduces metabolic activity of the intestinal microbiome in
2352 Crohn's disease: an observational study *Eur. J. Clin. Nutr.* **70** 1052–6
- 2353 [338] Wang Y, Jiang J, Hua L, Hou K, Xie Y, Chen P, Liu W, Li Q, Wang S and Li H 2016 High-
2354 Pressure Photon Ionization Source for TOFMS and Its Application for Online
2355 Breath Analysis *Anal. Chem.* **88** 9047–55
- 2356 [339] Zeng Q, Li P, Cai Y, Zhou W, Wang H, Luo J, Ding J and Chen H 2016 Detection of
2357 creatinine in exhaled breath of humans with chronic kidney disease by extractive
2358 electrospray ionization mass spectrometry *J. Breath Res.* **10** 16008
- 2359 [340] Aoki T, Nagaoka T, Kobayashi N, Kurahashi M, Tsuji C, Takiguchi H, Tomomatsu K,
2360 Oguma T, Kobayashi N, Magatani K, Takeda S, Asano K and Abe T 2017 Editor's

2361 Highlight: Prospective Analyses of Volatile Organic Compounds in Obstructive
2362 Sleep Apnea Patients *Toxicol. Sci.* **156** 362–74

2363 [341] Blanchet L, Smolinska A, Baranska A, Tigchelaar E, Swertz M, Zhernakova A,
2364 Dallinga J W, Wijmenga C and van Schooten F J 2017 Factors that influence the
2365 volatile organic compound content in human breath *J. Breath Res.* **11** 16013

2366 [342] Bouza M, Gonzalez-Soto J, Pereiro R, de Vicente J C and Sanz-Medel A 2017 Exhaled
2367 breath and oral cavity VOCs as potential biomarkers in oral cancer patients *J.*
2368 *Breath Res.* **11** 16015

2369 [343] Broza Y Y, Har-Shai L, Jeries R, Cancilla J C, Glass-Marmor L, Lejbkowitz I, Torrecilla
2370 J S, Yao X, Feng X, Narita A, Müllen K, Miller A and Haick H 2017 Exhaled Breath
2371 Markers for Nonimaging and Noninvasive Measures for Detection of Multiple
2372 Sclerosis *ACS Chem. Neurosci.* **8** 2402–13

2373 [344] Chen X, Wang F, Lin L, Dong H, Huang F, Ghulam Muhammad K, Chen L and Gorlova
2374 O Y 2017 Association of Smoking with Metabolic Volatile Organic Compounds in
2375 Exhaled Breath *Int. J. Mol. Sci.* **18** 2235

2376 [345] Demirjian S, Paschke K M, Wang X, Grove D, Heyka R J and Dweik R A 2017
2377 Molecular breath analysis identifies the breathprint of renal failure *J. Breath Res.*
2378 **11** 26009

2379 [346] Dias C M, Menezes H C and Cardeal Z L 2017 Environmental and biological
2380 determination of acrolein using new cold fiber solid phase microextraction with
2381 gas chromatography mass spectrometry *Anal. Bioanal. Chem.* **409** 2821–8

2382 [347] Dryahina K, Smith D, Bortlík M, Machková N, Lukáš M and Španěl P 2017 Pentane
2383 and other volatile organic compounds, including carboxylic acids, in the exhaled
2384 breath of patients with Crohn's disease and ulcerative colitis *J. Breath Res.* **12**
2385 16002

2386 [348] Gaugg M T, Engler A, Nussbaumer-Ochsner Y, Bregy L, Stöberl A S, Gaisl T, Bruderer
2387 T, Zenobi R, Kohler M and Martinez-Lozano Sinues P 2017 Metabolic effects of
2388 inhaled salbutamol determined by exhaled breath analysis *J. Breath Res.* **11** 46004

2389 [349] Gong X, Shi S and Gamez G 2017 Real-Time Quantitative Analysis of Valproic Acid
2390 in Exhaled Breath by Low Temperature Plasma Ionization Mass Spectrometry *J.*
2391 *Am. Soc. Mass Spectrom.* **28** 678–87

- 2392 [350] Güntner A T, Sievi N A, Theodore S J, Gulich T, Kohler M and Pratsinis S E 2017
2393 Noninvasive Body Fat Burn Monitoring from Exhaled Acetone with Si-doped WO₃-
2394 sensing Nanoparticles *Anal. Chem.* **89** 10578–84
- 2395 [351] Hartwig S, Raguse J D, Pfitzner D, Preissner R, Paris S and Preissner S 2017 Volatile
2396 Organic Compounds in the Breath of Oral Squamous Cell Carcinoma Patients: A
2397 Pilot Study *Otolaryngol. Neck Surg.* **157** 981–7
- 2398 [352] Jareño-Esteban J J, Muñoz-Lucas M Á, Gómez-Martín Ó, Utrilla-Trigo S, Gutiérrez-
2399 Ortega C, Aguilar-Ros A, Collado-Yurrita L and Callol-Sánchez L M 2017 Estudio de
2400 5 compuestos orgánicos volátiles en aire exhalado en la enfermedad pulmonar
2401 obstructiva crónica *Arch. Bronconeumol.* **53** 251–6
- 2402 [353] Lamote K, Brinkman P, Vandermeersch L, Vynck M, Sterk P J, Van Langenhove H,
2403 Thas O, Van Cleemput J, Nackaerts K and van Meerbeeck J P 2017 Breath analysis
2404 by gas chromatography-mass spectrometry and electronic nose to screen for
2405 pleural mesothelioma: a cross-sectional case-control study *Oncotarget* **8** 91593–
2406 602
- 2407 [354] Lau H-C, Yu J-B, Lee H-W, Huh J-S and Lim J-O 2017 Investigation of Exhaled Breath
2408 Samples from Patients with Alzheimer’s Disease Using Gas Chromatography-Mass
2409 Spectrometry and an Exhaled Breath Sensor System *Sensors (Basel)*. **17** 1783
- 2410 [355] Li X, Huang L, Zhu H and Zhou Z 2017 Direct human breath analysis by secondary
2411 nano-electrospray ionization ultrahigh-resolution mass spectrometry:
2412 Importance of high mass resolution and mass accuracy *Rapid Commun. Mass*
2413 *Spectrom.* **31** 301–8
- 2414 [356] Lu Y, Niu W, Zou X, Shen C, Xia L, Huang C, Wang H, Jiang H and Chu Y 2017 Glass
2415 bottle sampling solid phase microextraction gas chromatography mass
2416 spectrometry for breath analysis of drug metabolites *J. Chromatogr. A* **1496** 20–4
- 2417 [357] Obermeier J, Trefz P, Happ J, Schubert J K, Staude H, Fischer D-C and Miekisch W
2418 2017 Exhaled volatile substances mirror clinical conditions in pediatric chronic
2419 kidney disease *PLoS One* **12** e0178745
- 2420 [358] Oguma T, Nagaoka T, Kurahashi M, Kobayashi N, Yamamori S, Tsuji C, Takiguchi H,
2421 Niimi K, Tomomatsu H, Tomomatsu K, Hayama N, Aoki T, Urano T, Magatani K,
2422 Takeda S, Abe T and Asano K 2017 Clinical contributions of exhaled volatile
2423 organic compounds in the diagnosis of lung cancer *PLoS One* **12** e0174802–
2424 e0174802

- 2425 [359] Peters A L, Gerritsen M G, Brinkman P, Zwinderman K A H, Vlaar A P J and Bos L D
2426 2017 Volatile organic compounds in exhaled breath are independent of systemic
2427 inflammatory syndrome caused by intravenous lipopolysaccharide infusion in
2428 humans: results from an experiment in healthy volunteers *J. Breath Res.* **11** 26003
- 2429 [360] Tong H, Wang Y, Li Y, Liu S, Chi C, Liu D, Guo L, Li E and Wang C 2017 Volatile organic
2430 metabolites identify patients with gastric carcinoma, gastric ulcer, or gastritis and
2431 control patients *Cancer Cell Int.* **17** 108
- 2432 [361] van Oort P M P, de Bruin S, Weda H, Knobel H H, Schultz M J, Bos L D and Consortium
2433 O B O T M 2017 Exhaled Breath Metabolomics for the Diagnosis of Pneumonia in
2434 Intubated and Mechanically-Ventilated Intensive Care Unit (ICU)-Patients *Int. J.*
2435 *Mol. Sci.* **18** 449
- 2436 [362] Zhou W, Huang C, Zou X, Lu Y, Shen C, Ding X, Wang H, Jiang H and Chu Y 2017
2437 Exhaled breath online measurement for cervical cancer patients and healthy
2438 subjects by proton transfer reaction mass spectrometry *Anal. Bioanal. Chem.* **409**
2439 5603–12
- 2440 [363] Sukul P, Oertel P, Kamysek S and Trefz P 2017 Oral or nasal breathing? Real-time
2441 effects of switching sampling route onto exhaled VOC concentrations *J. Breath Res.*
2442 **11** 27101
- 2443 [364] Capone S, Tufariello M, Forleo A, Longo V, Giampetruzzi L, Radogna A V, Casino F
2444 and Siciliano P 2018 Chromatographic analysis of VOC patterns in exhaled breath
2445 from smokers and nonsmokers *Biomed. Chromatogr.* **32** e4132
- 2446 [365] Chappuis T H, Pham Ho B A, Ceillier M, Ricoul F, Alessio M, Beche J-F, Corne C,
2447 Besson G, Vial J, Thiébaud D and Bourlon B 2018 Miniaturization of breath
2448 sampling with silicon chip: application to volatile tobacco markers tracking *J.*
2449 *Breath Res.* **12** 46011
- 2450 [366] Durán-Acevedo C M, Jaimes-Mogollón A L, Gualdrón-Guerrero O E, Welearegay T G,
2451 Martínez-Marín J D, Cáceres-Tarazona J M, Sánchez-Acevedo Z C, Beleño-Saenz K
2452 de J, Cindemir U, Österlund L and Ionescu R 2018 Exhaled breath analysis for
2453 gastric cancer diagnosis in Colombian patients *Oncotarget* **9** 28805–17
- 2454 [367] Markar S R, Brodie B, Chin S-T, Romano A, Spalding D and Hanna G B 2018 Profile
2455 of exhaled-breath volatile organic compounds to diagnose pancreatic cancer *BJS*
2456 *(British J. Surgery)* **105** 1493–500
- 2457 [368] Princivalle A, Monasta L, Butturini G, Bassi C and Perbellini L 2018 Pancreatic

2458 ductal adenocarcinoma can be detected by analysis of volatile organic compounds
2459 (VOCs) in alveolar air *BMC Cancer* **18** 529

2460 [369] Schaber C L, Katta N, Bollinger L B, Mwale M, Mlotha-Mitole R, Trehan I, Raman B
2461 and Odom John A R 2018 Breathprinting Reveals Malaria-Associated Biomarkers
2462 and Mosquito Attractants *J. Infect. Dis.* **217** 1553–60

2463 [370] Stöner C, Edtbauer A and Williams J 2018 Real-world volatile organic compound
2464 emission rates from seated adults and children for use in indoor air studies *Indoor*
2465 *Air* **28** 164–72

2466 [371] Sukul P, Schubert J K, Trefz P and Miekisch W 2018 Natural menstrual rhythm and
2467 oral contraception diversely affect exhaled breath compositions *Sci. Rep.* **8** 10838

2468 [372] Trefz P, Schubert J K and Miekisch W 2018 Effects of humidity, CO₂ and O₂ on real-
2469 time quantitation of breath biomarkers by means of PTR-ToF-MS *J. Breath Res.* **12**
2470 26016

2471 [373] van Veldhoven K, Keski-Rahkonen P, Barupal D K, Villanueva C M, Font-Ribera L,
2472 Scalbert A, Bodinier B, Grimalt J O, Zwiener C, Vlaanderen J, Portengen L,
2473 Vermeulen R, Vineis P, Chadeau-Hyam M and Kogevinas M 2018 Effects of
2474 exposure to water disinfection by-products in a swimming pool: A metabolome-
2475 wide association study *Environ. Int.* **111** 60–70

2476 [374] Wang M, Sheng J, Wu Q, Zou Y, Hu Y, Ying K, Wan H and Wang P 2018 Confounding
2477 effect of benign pulmonary diseases in selecting volatile organic compounds as
2478 markers of lung cancer *J. Breath Res.* **12** 46013

2479 [375] Adam M E, Fehervari M, Boshier P R, Chin S-T, Lin G-P, Romano A, Kumar S and
2480 Hanna G B 2019 Mass-Spectrometry Analysis of Mixed-Breath, Isolated-Bronchial-
2481 Breath, and Gastric-Endoluminal-Air Volatile Fatty Acids in Esophagogastric
2482 Cancer *Anal. Chem.* **91** 3740–6

2483 [376] Berna A Z, DeBosch B, Stoll J and Odom John A R 2019 Breath Collection from
2484 Children for Disease Biomarker Discovery *J. Vis. Exp.* 10.3791/59217

2485 [377] Berna A Z, Schaber C L, Bollinger L B, Mwale M, Mlotha-Mitole R, Trehan I and Odom
2486 John A R 2019 Comparison of breath sampling methods: a post hoc analysis from
2487 observational cohort studies *Analyst* **144** 2026–33

2488 [378] Chandran D, Ooi E H, Watson D I, Kholmurodova F, Jaenisch S and Yazbeck R 2019
2489 The Use of Selected Ion Flow Tube-Mass Spectrometry Technology to Identify

2490 Breath Volatile Organic Compounds for the Detection of Head and Neck Squamous
2491 Cell Carcinoma: A Pilot Study *Medicina (Kaunas)*. **55** 306

2492 [379] De Vietro N, Aresta A, Rotelli M T, Zambonin C, Lippolis C, Picciariello A and
2493 Altomare D F 2020 Relationship between cancer tissue derived and exhaled
2494 volatile organic compound from colorectal cancer patients. Preliminary results *J.*
2495 *Pharm. Biomed. Anal.* **180** 113055

2496 [380] Geer Wallace M A, Pleil J D, Oliver K D, Whitaker D A, Mentese S, Fent K W and Horn
2497 G P 2019 Non-targeted GC/MS analysis of exhaled breath samples: Exploring
2498 human biomarkers of exogenous exposure and endogenous response from
2499 professional firefighting activity *J. Toxicol. Environ. Heal. Part A* **82** 244–60

2500 [381] Hamilton B K, Rybicki L A, Grove D, Ferraro C, Starn J, Hodgeman B, Elberson J,
2501 Winslow V, Corrigan D, Gerds A T, Hanna R, Kalaycio M E, Sobecks R M, Majhail N
2502 S and Dweik R A 2019 Breath analysis in gastrointestinal graft-versus-host disease
2503 after allogeneic hematopoietic cell transplantation *Blood Adv.* **3** 2732–7

2504 [382] Heaney L M, Kang S, Turner M A, Lindley M R and Thomas C L P 2020 Evidence for
2505 alternative exhaled elimination profiles of disinfection by-products and potential
2506 markers of airway responses to swimming in a chlorinated pool environment
2507 *Indoor Air* **30** 284–93

2508 [383] Ke M, Zhang H, Ding J, Xiong X, Li F, Chingin K, Kou W, Liu A, Zhu T, Fang X and Chen
2509 H 2019 Generating Supercharged Protein Ions for Breath Analysis by Extractive
2510 Electrospray Ionization Mass Spectrometry *Anal. Chem.* **91** 3215–20

2511 [384] Krilaviciute A, Leja M, Kopp-Schneider A, Barash O, Khatib S, Amal H, Broza Y Y,
2512 Polaka I, Parshutin S, Rudule A, Haick H and Brenner H 2019 Associations of diet
2513 and lifestyle factors with common volatile organic compounds in exhaled breath
2514 of average-risk individuals *J. Breath Res.* **13** 26006

2515 [385] Li B, Zou X, Wang H, Lu Y, Shen C and Chu Y 2019 Standardization study of
2516 expiratory conditions for on-line breath testing by proton transfer reaction mass
2517 spectrometry *Anal. Biochem.* **581** 113344

2518 [386] Malásková M, Henderson B, Chellayah P D, Ruzsanyi V, Mochalski P, Cristescu S M
2519 and Mayhew C A 2019 Proton transfer reaction time-of-flight mass spectrometric
2520 measurements of volatile compounds contained in peppermint oil capsules of
2521 relevance to real-time pharmacokinetic breath studies *J. Breath Res.* **13** 46009

- 2522 [387] Markar S R, Chin S-T, Romano A, Wiggins T, Antonowicz S, Paraskeva P, Ziprin P,
2523 Darzi A and Hanna G B 2019 Breath Volatile Organic Compound Profiling of
2524 Colorectal Cancer Using Selected Ion Flow-tube Mass Spectrometry *Ann. Surg.* **269**
2525 903-910
- 2526 [388] Sacks D, Baxter B, Campbell B C V, Carpenter J S, Cognard C, Dippel D, Eesa M,
2527 Fischer U, Hausegger K, Hirsch J A, Shazam Hussain M, Jansen O, Jayaraman M V,
2528 Khalessi A A, Kluck B W, Lavine S, Meyers P M, Ramee S, Rüfenacht D A, Schirmer
2529 C M and Vorwerk D 2018 Multisociety Consensus Quality Improvement Revised
2530 Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke *Int. J.*
2531 *Stroke* **13** 612-32
- 2532 [389] Pugliese G, Trefz P, Brock B, Schubert J K and Miekisch W 2019 Extending PTR
2533 based breath analysis to real-time monitoring of reactive volatile organic
2534 compounds *Analyst* **144** 7359-67
- 2535 [390] Saasa V, Beukes M, Lemmer Y and Mwakikunga B 2019 Blood Ketone Bodies and
2536 Breath Acetone Analysis and Their Correlations in Type 2 Diabetes Mellitus
2537 *Diagnostics (Basel, Switzerland)* **9** 224
- 2538 [391] Scheepers P T J, Graumans M H F, van Dael M, de Werdt L, Pinckaers N, Beckmann
2539 G and Anzion R 2019 Intrusion of chlorinated hydrocarbons and their degradation
2540 products from contaminated soil. Measurement of indoor air quality and
2541 biomonitoring by analysis of end-exhaled air *Sci. Total Environ.* **653** 223-30
- 2542 [392] Smolinska A, Baranska A, Dallinga J W, Mensink R P, Baumgartner S, van de Heijning
2543 B J M and van Schooten F J 2019 Comparing patterns of volatile organic
2544 compounds exhaled in breath after consumption of two infant formulae with a
2545 different lipid structure: a randomized trial *Sci. Rep.* **9** 554
- 2546 [393] Trefz P, Pugliese G, Brock B, Schubert J K and Miekisch W 2019 Effects of elevated
2547 oxygen levels on VOC analysis by means of PTR-ToF-MS *J. Breath Res.* **13** 46004
- 2548 [394] Vadhvana B, Belluomo I, Boshier P R, Pavlou C, Španěl P and Hanna G B 2020
2549 Impact of oral cleansing strategies on exhaled volatile organic compound levels
2550 *Rapid Commun. Mass Spectrom.* **34** e8706
- 2551 [395] Welearegay T G, Diouani M F, Österlund L, Borys S, Khaled S, Smadhi H, Ionescu F,
2552 Bouchekoua M, Aloui D, Laouini D, Cindemir U and Ionescu R 2019 Diagnosis of
2553 Human Echinococcosis via Exhaled Breath Analysis: A Promise for Rapid
2554 Diagnosis of Infectious Diseases Caused by Helminths *J. Infect. Dis.* **219** 101-9

- 2555 [396] Wingelaar T T, Brinkman P, van Ooij P J A M, Hoencamp R, Maitland-van der Zee A
2556 H, Hollmann M W and van Hulst R A 2019 Markers of Pulmonary Oxygen Toxicity
2557 in Hyperbaric Oxygen Therapy Using Exhaled Breath Analysis *Front. Physiol.* **10**
2558 475
- 2559 [397] Wingelaar T T, van Ooij P-J A M, Brinkman P and van Hulst R A 2019 Pulmonary
2560 Oxygen Toxicity in Navy Divers: A Crossover Study Using Exhaled Breath Analysis
2561 After a One-Hour Air or Oxygen Dive at Nine Meters of Sea Water *Front. Physiol.*
2562 **10** 10
- 2563 [398] Zhang Y, Zhao W, Wang D, Zhang H, Chai G, Zhang Q, Lu B, Sun S and Zhang J 2019
2564 Direct Analysis of Carbonyl Compounds by Mass Spectrometry with Double-
2565 Region Atmospheric Pressure Chemical Ionization *Anal. Chem.* **91** 5715–21
- 2566 [399] Zhou W, Hong Y, Zou X, Xia L, Lu Y, Shen C, Huang C and Chu Y 2019 Analysis of
2567 Nitrogen-containing Compounds in Mouth-exhaled Breath by Electrospray
2568 Ionization Quadrupole Time-of-Flight Mass Spectrometry *Anal. Sci.* **35** 1155–9
- 2569 [400] Zuo W, Bai W, Gan X, Xu F, Wen G and Zhang W Detection of Lung Cancer by Analysis
2570 of Exhaled Gas Utilizing Extractive Electrospray Ionization-Mass Spectroscopy *J.*
2571 *Biomed. Nanotechnol.* **15** 633–46
- 2572 [401] Sarbach C, Dugas B and Postaire E 2020 Evidence of variations of endogenous
2573 halogenated volatile organic compounds in alveolar breath after mental exercise-
2574 induced oxidative stress *Ann. Pharm. Françaises* **78** 34–41
- 2575 [402] Tabibpour M, Yamini Y, Ahmadi S H, Esrafil A and Salamat Q 2020 Carbon fibers
2576 modified with polypyrrole for headspace solid phase microextraction of trace
2577 amounts of 2-pentyl furan from breath samples *J. Chromatogr. A* **1609** 460497
- 2578 [403] Van Berkel J J B N, Dallinga J W, Möller G M, Godschalk R W L, Moonen E J, Wouters
2579 E F M and Van Schooten F J 2010 A profile of volatile organic compounds in breath
2580 discriminates COPD patients from controls *Respir. Med.* **104** 557–63
- 2581 [404] Kischkel S, Miekisch W, Sawacki A, Straker E M, Trefz P, Amann A and Schubert J K
2582 2010 Breath biomarkers for lung cancer detection and assessment of smoking
2583 related effects — confounding variables, influence of normalization and statistical
2584 algorithms *Clin. Chim. Acta* **411** 1637–44
- 2585 [405] Statheropoulos M, Sianos E, Agapiou A, Georgiadou A, Pappa A, Tzamtzis N, Giotaki
2586 H, Papageorgiou C and Kolostoumbis D 2005 Preliminary investigation of using

2587 volatile organic compounds from human expired air, blood and urine for locating
2588 entrapped people in earthquakes *J. Chromatogr. B* **822** 112–7

2589 [406] Rudnicka J, Kowalkowski T, Ligor T and Buszewski B 2011 Determination of
2590 volatile organic compounds as biomarkers of lung cancer by SPME–GC–TOF/MS
2591 and chemometrics *J. Chromatogr. B* **879** 3360–6

2592 [407] Ligor T, Ligor M, Amann A, Ager C, Bachler M, Dzien A and Buszewski B 2008 The
2593 analysis of healthy volunteers' exhaled breath by the use of solid-phase
2594 microextraction and GC-MS *J. Breath Res.* **2** 46006

2595 [408] Amann private communication.

2596 [409] Jiang R, Cudjoe E, Bojko B, Abaffy T and Pawliszyn J 2013 A non-invasive method
2597 for in vivo skin volatile compounds sampling *Anal. Chim. Acta* **804** 111–9

2598 [410] Mochalski P, King J, Unterkofler K, Hinterhuber H and Amann A 2014 Emission
2599 rates of selected volatile organic compounds from skin of healthy volunteers *J.*
2600 *Chromatogr. B. Analyt. Technol. Biomed. Life Sci.* **959** 62–70

2601 [411] Hartungen E von, Wisthaler A, Mikoviny T, Jaksch D, Boscaini E, Dunphy P J and
2602 Märk T D 2004 Proton-transfer-reaction mass spectrometry (PTR-MS) of
2603 carboxylic acids: Determination of Henry's law constants and axillary odour
2604 investigations *Int. J. Mass Spectrom.* **239** 243–8

2605 [412] Wisthaler A, Tamás G, Wyon D P, Strøm-Tejsten P, Space D, Beauchamp J, Hansel A,
2606 Märk T D and Weschler C J 2005 Products of Ozone-Initiated Chemistry in a
2607 Simulated Aircraft Environment *Environ. Sci. Technol.* **39** 4823–32

2608 [413] Natsch A, Emter R and Ellis G 2009 Filling the Concept with Data: Integrating Data
2609 from Different In Vitro and In Silico Assays on Skin Sensitizers to Explore the
2610 Battery Approach for Animal-Free Skin Sensitization Testing *Toxicol. Sci.* **107** 106–
2611 21

2612 [414] Echigo T, Hasegawa M, Shimada Y, Takehara K and Sato S 2004 Expression of
2613 fractalkine and its receptor, CX₃CR1, in atopic dermatitis: Possible contribution to
2614 skin inflammation *J. Allergy Clin. Immunol.* **113** 940–8

2615 [415] Hovander L, Malmberg T, Athanasiadou M, Athanassiadis I, Rahm S, Bergman and
2616 Wehler E K 2002 Identification of Hydroxylated PCB Metabolites and Other
2617 Phenolic Halogenated Pollutants in Human Blood Plasma *Arch. Environ. Contam.*
2618 *Toxicol.* **42** 105–17

- 2619 [416] Liebich H M and Wöll J 1977 Volatile substances in blood serum: Profile analysis
2620 and quantitative determination *J. Chromatogr. A* **142** 505–16
- 2621 [417] Miekisch W, Schubert J K, Vagts D A and Geiger K 2001 Analysis of Volatile Disease
2622 Markers in Blood *Clin. Chem.* **47** 1053–60
- 2623 [418] Kostelc J G, Preti G, Zelson P R, Tonzetich J and Huggins G R 1981 Volatiles of
2624 exogenous origin from the human oral cavity *J. Chromatogr. B Biomed. Sci. Appl.*
2625 **226** 315–23
- 2626 [419] Lochner A, Weisner S, Zlatkis A and Middleditch B S 1986 Gas chromatographic—
2627 mass spectrometric analysis of volatile constituents in saliva *J. Chromatogr. B*
2628 *Biomed. Sci. Appl.* **378** 267–82
- 2629 [420] Soini H A, Klouckova I, Wiesler D, Oberzaucher E, Grammer K, Dixon S J, Xu Y,
2630 Brereton R G, Penn D J and Novotny M V. 2010 Analysis of Volatile Organic
2631 Compounds in Human Saliva by a Static Sorptive Extraction Method and Gas
2632 Chromatography-Mass Spectrometry *J. Chem. Ecol.* **36** 1035–42
- 2633 [421] Alagendran S, Archunan G, Rameshkumar K, Kadalmani B, Rodriguez J A de L,
2634 Fernandez G, Martinez G and Guzman R G 2010 2-Nonenal-Ovulatory Specific
2635 Volatiles in Human Saliva throughout Menstrual Cycle by Gas Chromatography
2636 and Mass Spectrometry Analysis *Am. J. Biochem. Biotechnol.* **6** 187-94
- 2637 [422] Martin H J, Riazanskaia S and Thomas C L P 2012 Sampling and characterisation of
2638 volatile organic compound profiles in human saliva using a polydimethylsiloxane
2639 coupon placed within the oral cavity *Analyst* **137** 3627–34
- 2640 [423] Larsson B T 1965 Gas Chromatography of Organic Volatiles in Human Breath and
2641 Saliva. *Acta Chem. Scand.* **19** 159–64